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The objective of this research was to develop a supramolecular block building 
approach based on “Molecular LEGO®” strategy to construct and optimize efficient gene and 
drug delivery systems for cancer therapy. This supramolecular approach was based on the 
host-guest interaction between -cyclodxtrin and adamantyl moieties in the host and guest. 
Compared to traditional covalent conjugation block building approaches, this supramolecular 
approach, like the assembly of “LEGO® bricks”, is more convenient in building complicated 
architectures with multiple functionalities integrated within one system. 
Firstly, we applied this supramolecular approach for building a smart carrier system 
with the functions of reduction-responsiveness and biomimetic switchable shielding for DNA 
delivery. The system was composed of two LEGO
®
-like molecular building blocks: one host 
polymer and one guest polymer that can self-assemble to integrate multiple functions into one 
system, based on the host-guest interaction between β-cyclodextrin and adamantyl moieties 
in the host and guest. Results showed that the carrier CD-SS-P/Ad-pMPC possessed 
excellent protein stability, serum tolerance, cellular uptake and intracellular DNA release 
properties, and low cytotoxicity, which work collectively to result in a highly efficient gene 
delivery system. The novel carrier was successfully applied for delivering the therapeutic p53 
anti-cancer gene, showing great potential for cancer gene therapy. 
Secondly, with the aim of precise construction of multifunctional siRNA targeted 
delivery vehicle for cancer gene therapy, we applied this supramolecular block building 
“LEGO® bricks” concept to develop a “pegs into hole” screening platform to screen various 
architectures of siRNA targeting delivery system. The “hole” block is a cyclodextrin-
functionalized siRNA binding fixed host, and the “pegs” are a series of defined adamantyl-
bearing PEG or folate(s) conjugated PEG switchable guests, which could self-assemble into a 
supramolecule via host-guest interaction, like the “peg into hole” pattern, for siRNA targeted 
delivery screening. By using this platform, one formulation with 8 kDa comb-shaped PEG 
shielding and intermediated density of folate ligand (NP-8KFA6) showing minimum non-
specific binding and maximal folate receptor binding avidity was sorted out. NP-8KFA6 
could synergistically combine the following features to address the multiple challenges of 
siRNA targeted delivery, including serum tolerance, minimum non-specific binding, high 
folate receptor binding avidity, efficient targeted endocytosis, avoidance of acidic cellular 






to folate receptor overexpressing cell. The system successfully delivered Bcl-2 therapeutic 
siRNA to induce apoptosis of KB cells, indicating this smart multifunctional nanoparticles 
could be applied in targeted cancer therapy.         
Thirdly, with the objective of combining chemotherapy and gene therapy technology 
for the treatment of multidrug resistant cancer, we applied the supramolecular building block 
strategy in developing a dual-stimuli responsive vesicular carrier to accommodate 
combination of anticancer drug doxorubicin (DOX) and siRNA for reversal of drug 
sensitivity. The polymersome-based system was constructed by “pH-switch" method in 
aqueous solution from a supramolecular pseudo-triblock copolymer, which comprised of a 
host polymer consisting of multiple-arm pH sensitive diblock copolymers poly(2-
(diisopropyl-amino)ethyl methacrylate)-poly(2-(dimethyl-amino)ethyl methacrylate)  linked 
to a CD core with bioreducible disulfide linkers, and the guest polymer being adamantyl-
capped comb-shaped poly(ethylene glycol) methacrylate with conjugated folate ligands. This 
vesicular system was structurally flexible enough to integrate multiple functions into one 
carrier, including capabilities of co-encapsulation of hydrophobic anti-cancer drug and 
anionic siRNA, active targeting to folate receptor overexpressing cancer cells, pH and redox 
dual-stimuli responsive, facilitating nuclear accumulation of DOX. It showed a “fast-slow” 
two-phase DOX intracellular release kinetics, which mimic the clinic administratering pattern 
that initially medicating a high effective dose and followed by a low maintenance dose. Due 
to the synergistic effects of (1) folate receptor mediated transportation for DOX to bypass the 
drug efflux pump, (2) MDR1 gene silencing for inhibiting the expression of drug efflux pump, 
which led to increased  intracellular accumulation of DOX, and (3) nuclear distribution of 
DOX triggered by degradation of bioreducible disulfide linkers, this co-delivery 
vesicleplexes induced supreme effect on cell apoptosis and cell death. Collectively, this DOX 
and siRNA-MDR1 co-delivery vesicular system showed potential to be a promising nano-
chemotherapy for targeted treatment of multidrug resistant tumors. 
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CHAPTER 1. INTRODUCTION 
1.1 Background 
Cancer is the second leading cause of death worldwide. Therefore cancer therapy has 
recently attracted increasing interest among molecular biologists, medicinal chemists, and 
material scientists. Various strategies have been applied to counteract cancer disease. Up to 
date, cancer therapy can be broadly categorized into two types based on the therapeutic 
agents: cancer gene therapy and cancer drug therapy. 
Cancer is an acquired genetic disorder disease, which is mainly caused by multiple 
gene mutations. It is known that its progression involves multiple dynamic changes in the 
genome [1-3]. Up to date, genetic materials such as plasmid DNA, antisense oligonucleotides, 
small interfering RNA have demonstrated promise effects in cancer therapy [2, 4]. The 
progresses in cancer genetics and the expansion of therapeutic genes selectivity provide a 
promising platform of potential therapy of tumor suppression. Similar to gene therapy, the 
central idea of cancer gene therapy refers to the delivery of an anti-cancer genetic payload to 
target cancerous tissues or cells, achieving the anti-tumor therapeutic expression or silencing 
effect of the target gene [5]. The key components of gene therapy are therapeutic gene, gene 
delivery vehicle, and targeted therapeutic sites. Naked gene, with no protection from the 
carriers, is considered only be rarely applied due to rapid degradation by nucleases and too 
large for endocytosis. Therefore, development of gene delivery vector for specific, efficient, 
and safe genetic materials transfer to appropriate cells is crucial to the success of gene 
therapy. To date, viral and non-viral gene delivery carriers two different strategies under 
investigation for introducing genetic payload into cells or tissues. Virus vectors are regarded 
as the most efficient vehicles to transfer genes into cells. Up to now, most of the clinical trials 
of gene therapy use viral vectors as the gene delivery carriers. However, safety concerns have 
been the principal bottleneck in the clinical application of viral vector-based gene delivery [6]. 
Recombinant viral vectors exists the possibility to revert to a wild-type virus which would 
cause serious safety issues. Thus, it is an irreversible trend that relatively safe non-viral gene 
delivery carriers will eventually replace the viral carriers. 
Cationic polymer is a class of non-viral gene delivery systems, gaining an increasing 
interests and efforts to develop. Generally, cationic polymers possessing nucleic acids 
binding moieties like various types of amines, are able to condense DNA/RNA through 





electrostatic interactions to form nano-particles self-assembly. As the cationic polymers are 
easy to be designed, modified and engineered, constructing multiple-functional polymeric 
gene carriers for an efficient and safe gene delivery becomes possible [7]. Up to date, a large 
number of cationic based non-viral polymers were developed for gene delivery, such as pol-
L-lysine (PLL), polyethylimine (PEI), chitosan, poly(dimethylaminoethyl methacrylate) 
(pDMAEMA), cationic dendrimers and their derivatives. However, though polymeric gene 
delivery systems have developed for two decades, poor gene transfection efficiency and 
undesirable cytotoxicity limit their clinical applications.  It is known that polymeric gene 
carriers need to overcome a series of obstacles for a successful gene delivery, from 
preparation of the solution in vials to the release of the gene in cell nucleus/cytoplasm. 
Generally, the barriers for cationic polymers are the followings as shown in Figure 1.1: (1) 
Extracellular stability; (2) Targeted cell binding; (3) Cellular uptake; (4) Intracellular 
trafficking, (5) Protection vs release of genetic payload, and (6) Instinct cytotoxicity. The 
design of an efficient polymeric gene carriers should aim to meet the requirements that 
overcoming all the barriers. Although methodologies are existing or under development for 
solving individual barriers in polymeric gene delivery processes, it is eventually a big 
challenge to design a multi-functional or smart polymeric system with multiple features 
incorporated and optimized to overcome these hurdles collectively to achieve an efficient and 
safe gene delivery. Thus, the aim of this study is to develop an efficient non-viral delivery 
system to address multi-barriers of gene delivery for cancer therapy. 
 
Figure 1.1 Barriers to extracellular delivery, cellular uptake and intracellular trafficking of 
polyplexes [8].  
Cancer drug therapy, as known as chemotherapy, is defined as the use of 
chemotherapeutical agents to kill or control cancer cells, which was discovered in 1943. 





Despite significant progress in the invention of chemotherapeutic agents, there is still no cure 
for patients with malignant tumor. Due to lack of specificity and poor biodistribution, 
traditional cancer drug shows systemic toxicity and severe side effects e.g. tissue damage. To 
circumvent the problems associated with convential therapeutic agents, materials like 
liposomes [9], polymeric micelles [10], stimuli polymersomes [11] have been extensively 
developed in the last decades for cancer drug delivery, to improve the water solubility of drug, 
enhance anti-cancer efficacy and decrease the systemic toxicity. These particulate nano-size 
drug delivery systems successfully improve the biodistribution and pharmacokinetics of the 
associated chemotherapeutic agents. Till this date, several drug delivery systems have 
proceeded to clinical applications, including liposomal doxorubicin like Doxil, Myoocet, etc. 
However, despite the achievements that these reported drug delivery systems have made in 
improving cancer treatment, efficiency and biocompatibility of the reported drug delivery 
systems are still far from satisfactory.  
In addition, patients receiving chemotherapy treatment commonly generate resistance 
to drugs that are previously effective after several drug treatments. Multidrug resistance is a 
major barrier to the successful treatment of cancers and major cause of the re-occurrence of 
cancer. P-glycoprotein (P-gp) overexpression is the major mechanisms of MDR, and it can 
lead to an increase of effluxed anti-cancer drugs from cells, thus lowering the intracellular 
drug concentrations. P-glycoprotein is usually coded with MDR1 gene, thus RNA interferes 
technology could theoretically applied in overcoming the MDR obstacle of chemotherapy. 
Ideal approach to MDR tumor cancer therapy which is better accomodated for clinical 
application is a synergistic combination of chemotherapeutic drug and nucleic acid targeting 
to MDR protein. Thus, it is extraordinarily attractive to use nanoparticulate delivery systems 
for combinational therapy as these vehicles are able to co-deliver multiple drugs 
simultaneously in one single administration. With structural versatility of nanoparticulate 
delivery vehicles, the therapeutic agents that can be loaded into the carriers are not limited to 
hydrophobic anti-cancer drug with small molecular weight, macromolecules such as nucleic 
acids can also be co-delivered together using these vehicles. An ideal chemotherapeutic drug 
carrier for multidrug resistant cancer therapy should be (1) multifunctional, (2) co-
encapsulate chemotherapeutic drug and genetic materials, (3) highly selective, (4) low 
cytotoxicity to healthy tissues/cells, (5) stimuli release of payload, (6) capable to overcome 
the multidrug resistance. Therefore, it is necessary to develop a multifunctional targeting 
vehicles for anti-cancer drug and to overcome the obstacles of cancer drug therapy. 





It is difficult to develop multifunctional vectors, to establish a series of polymers for 
optimization by covalent conjugation method. Because it needs multiple steps, and it is time 
consuming. Things would become easier. If we can build polymers like the LEGO
®
 bricks, 
easy to assemble to together. The “Molecular LEGO®” block building method is produce 
functional components separately, and assemble them together using non-covalent 
conjugation method. It is more convenient and time saving, also easy to tune and optimize the 
properties, compared to the covalent conjugation method.  
Supramolecular chemistry, which combines the concepts of self assembly and 
molecular recognition, is a term describing the conjugation of two molecular entities via non-
covalent binding interactions [12]. Supramolecular chemistry has offered a powerful and 
convenient method for the fabrication of complicated nanostructures from individual tunable 
molecular building blocks [13]. -cyclodextrin (CD) is one of the most widely used 
supramolecular building blocks for a wide range of biomedical applications [12, 14]. CD is 
a natural cyclic oligosaccharides composed 7 D(+)-glucose units linked by -1,4-linkages 
[15], with hydrophobic inner cavity and hydrophilic exterior. The hydrophobic interior of 
CD is capable to form inclusion complexes with a wide range of guest molecules via 
molecular recognition mechanism [16]. -cyclodextrin (CD) and adamantane (Ad) is a host-
guest pair with high affinity. The formation of unique inclusion complex leads that the 
cyclodextrin could be functionalized with additional groups by non-covalent means with 
conjugation of functional groups to adamantyl-based moieties which capable of inclusion into 
the CD cavity.  
1.2 Objective and Scope of Study 
In this thesis, we aimed to develop a supramolecular building block approach based 
on the host-guest recognition between CD and adamantyl moiety, to design and construct a 
series of smart, stimuli-responsive, and multifunctional gene and drug delivery vehicles for 
overcoming multiple obstacles of cancer gene/drug therapy. The CD/Ad-based 
supramolecular building block strategy was similar to the concept of  construction of  
“LEGO® bricks” (Figure 1.2) which had a series advantages over traditional covalent 
conjugation methods.  






Figure 1.2 (a) Construction of “LEGO®-bricks”. (b) Formation of -cyclodextrin and 
adamantane host-guest inclusion complex. 
It is much more convenient and precise in building complicated architectures with 
multiple functionalities integrated within one system, as the respective components can be 
produced and modified separately, allowing the target system to be readily customized and 
fine-tuned to optimize the overall performance. The specific objectives of this research were: 
1. To incorporate multiple features in a system to overcome hurdles of cancer gene 
therapy collectively, we applied a prototype of “Molecular LEGO®” strategy for building a 
smart therapeutic p53 plasmid DNA carrier system with the functions of reduction-
responsiveness and biomimetic switchable shielding for DNA delivery with significantly 
enhanced gene transfection efficiency. This design is expected to provide the supramolecular 
polymer/p53 polyplex nanoparticles with high extracellular stability and protein resistance 
due to the shielding effect of biomimetic shell, as well as high efficiency of cellular 
internalization due to the membrane-mimic corona structure. Once internalized into the 
cytoplasm, the payload DNA can be readily released because the disulfide bonds can be 
cleaved by the intracellular reductive environment. The tumor apoptotic effect would be 
induced by the high transfection of p53 anti-cancer gene. 
2. In order to precisely construct siRNA-Bcl2 targeted delivery vehicle for the 
treatment of folate receptor positive cancer, we developed a “pegs into hole” multifunctional 
screening platform based on “LEGO® bricks” concepts to screen various architectures of 
siRNA system, including shape and size of the shielding corona of particle, and density of 
folate ligands. It is expected that by using this “LEGO®-like” platform, more concise control 
over the siRNA loaded NP shielding shell and ligand density could be gained. The optimized 
formulation is supposed to deliver siRNA cargo specifically to cancer cells with 
overexpressing folate receptors, follow by efficient folate receptor-mediated cellular uptake 
and folate-guided intracellular localization, and lastly the siRNA will be responsively 
released in cytosol for gene silencing. The intracellular released siRNA-Bcl2 would 
selectively induce apoptosis of FR+ cancer cells. 





3. To combine chemotherapy and gene therapy technology for the treatment of 
multidrug resistant cancer, we applied the “Molecular LEGO®” supramoclecular building 
block strategy to construct a dual-responsive asymmetric polymersome for doxorubicin and 
siRNA-MDR1 co-delivery. This vesicular carrier (polymersome-based) is structurally flexible 
enough to integrate multiple functions into one system, which is expected to be (i) recognized 
by folate receptors overexpressing mouth epidermal carcinoma cells (KB), and internalized 
selectively by cancer cells through receptor-mediated active endocytosis, (ii) provide redox-
trigger cytoplasmic release of DOX and siRNA, (iii) down-regulate the expression of drug 
efflux pump P-gp by siRNA-MDR1, (iv) reversal the drug sensitivity of doxorubicin- 
resistant cell (KB/DOX), (iv) increase DOX accumulation in the nucleic zone by 
resensitizaiton of multiple drug resistance cells to DOX, and induce apoptosis in MDR cancer 
cells.  
Results of this thesis served as examples of the applications of supramolecular 
chemistry on the constructions and modifications of nanoparticles to achieve precise 
structures and multifunctional qualitative controls of nano-particulate systems. This research 
should be helpful in the design of multifunctional biomaterials through the non-covalent host-
guest recognition for drug and gene delivery to overcome multiple obstacles of cancer 
therapy. This approach could be expanded to develop other nanoscale architectures with 
controlled function, size and shape. 
1.3 Organization of the Thesis 
Based on the objectives outlined previously, the detailed research works on the 
development of CD-based supramolecular architectures for gene and drug delivery will be 
reported in the following chapters.  
Chapter 2: Literature review on the topic of polymeric examples applied in cancer 
gene therapy and cancer drug therapy. Brief summary of strategies of overcoming multiple 
obstacles of gene delivery, reported nano structures of targeting gene and drug delivery, as 
well as the possibility of drug and gene co-delivery and reported nano particulate systems for 
combined delivery, followed by the design and advantages of cyclodextrin based 
supramolecular architectures as building blocks on nanoparticles. 
Chapter 3: Report on the construction of a smart therapeutic p53 plasmid DNA carrier 
system (CD-SS-P/Ad-pMPC) with the functions of reduction-responsiveness and 





biomimetic switchable shielding for plasmid DNA delivery. The properties of βCD-SS-P/Ad-
pMPC/DNA polyplex system was systematically investigated in comparison with control 
systems such as non-bioreducible, and non-shielding or PEG shielding DNA polyplexes, 
including extracellular colloidal stability, cytotoxicity, serum stability, cellular uptake kinetics, 
intracellular release of DNA, function of disulfide linkages, function of biomimetic pMPC 
shell, luciferase protein express and green fluorescence protein expression mediated by 
reporter gene, and cancerous apoptosis efficiency mediated by p53 anti-cancer gene. 
Chapter 4: Report on the development of a switchable platform based on the 
“Molecular LEGO®” supramoclecular building block approach for rapid screening and 
optimization of multifunctional siRNA targeting delivery system. To obtain minimum non-
specific binding and optimal ligand density of systems, various PEG with different 
architecture and number of conjugated folate was investigated. The optimized targeting 
formulation would be obtained under the selection criteria of minimum non-specific binding 
with highest FR binding avidity. Whether the optimal nanoparticles show ligand-selective 
internalization and gene silencing would be evaluated. The possible effects of the targeting 
FA on the intracellular trafficking/localization of the formulation would also be thoroughly 
investigated.  
Chapter 5: Report on the design of a dual-stimuli responsive polymeric carrier to 
accommodate combination of anticancer drug doxorubicin (DOX) and siRNA for selective 
treatment of multidrug resistant cancer. The capabilities of nanoparticles including co-
encapsulation of hydrophobic anti-cancer drug and anionic siRNA, active targeting to folate 
receptor overexpressing cancer cells, pH and redox dual-stimuli responsive, suppressing the 
expression of P-gp, reversing the drug sensitivity of dox-resistant cells, facilitating nuclear 
accumulation of DOX, as well as anti-tumor efficacy, would be systemically examined and 
compared with carefully chosen controls. 
Chapter 6: Conclusion of the work done with possible future endeavors. 
  





CHAPTER 2. LITERATURE REVIEW 
2.1 Cancer gene therapy 
Cancer belongs to the category of acquired genetic disorder disease, which is mainly 
caused by multiple gene mutations. It is known that its progression involves multiple 
dynamic changes in the genome [1-3]. Up to date, genetic materials such as plasmid DNA 
(pDNA), antisense oligonucleotides (AON), small interfering RNA (siRNA) etc. have 
demonstrated promise effects in cancer therapy [2, 4]. The progresses in cancer genetics and 
the expansion of therapeutic genes selectivity provide a promising platform of potential 
therapy of tumor suppression. 
Re-construction of tumor suppressor and re-regulation of molecular pathway is a new 
direction of anti-cancer gene therapy [17]. Therapeutic gene p53, which is a tumor suppressor 
gene, acts as an important in reverse the molecular pathway including activation of DNA 
damage, regulation of the cell cycle and induction of programmed apoptosis (cell death) [18-
20]. A series of in vitro and in vivo studies on the p53-based gene therapy p53 expression 
showed direct correction of the defects of p53-mutated cells, which demonstrated notable 
anti-cancer efficacy in various cancers, including ovarian, lung, head and neck, prostate, lung 
cancer [21-25]. However, lack of safe and promising gene delivery carriers are the major 
impediment towards cancer gene therapy. 
Besides plasmid DNA, siRNA is another strategy of cancer gene therapy. siRNA is 
capable to reverse the molecular pathway by suppression the expression of genes, which is a 
new treatments of cancer disease caused by gene mutant. Apoptosis is the process of 
programmed cell death, which is activated by a series of sub-cellular signals in which several 
proteins are involved. During cancer therapy, tumorous cells would activate the anti-
apoptosis pathway to avoid cell death [26]. This is the defense mechanism of cancer cells 
avoids from cell death [26].  
Bcl-2 is a protein encode by the gene Bcl-2, which plays a crucial role in preventing 
apoptosis in cancer cells. Overexpression of Bcl-2 protein will avoid cells to enter to 
apoptosis process [27, 28]. Thus, Bcl-2 protein appears to be an attractive target sites for 
siRNA-mediated gene therapy. After suppression the expression of Bcl-2 protein by siRNA-
Bcl-2, the apoptosis process would be re-activated, which induce the downstream cell death 
signal, and thereby promote cell apoptosis.  





2.1.1 Gene delivery vehicles  
As discussed in the introduction, similar to gene therapy, the central idea of gene 
therapy refers to the delivery of an anti-cancer genetic payload to targeted cancerous tissues 
or cells, achieving the anti-tumor therapeutic expression or silencing effect of the target gene 
[5]. Gene delivery vehicles are the key components of the success of cancer gene therapy. 
Due to the safety issue and facile to be engineered, non-viral gene delivery system would 
have potential to replace the viral-based system. Cationic polymer is a class of non-viral gene 
delivery systems, gaining an increasing interest and efforts to develop. Generally, cationic 
polymers possessing nucleic acids binding moieties like various types of amines, are able to 
condense DNA/RNA through electrostatic interactions to form nano-particles self-assembly. 
As the cationic polymers are easy to be designed, modified and engineered, constructing 
multiple-functional polymeric gene carriers for an efficient and safe gene delivery becomes 
possible [7]. Up to date, a large number of cationic based non-viral polymers were developed 
for gene delivery, such as pol-L-lysine (PLL), polyethylenimine (PEI), chitosan, 
poly(dimethylaminoethyl methacrylate) (pDMAEMA), cationic dendrimers and their 
derivatives. However, though polymeric gene delivery systems have developed for two 
decades, poor gene transfection efficiency and undesirable cytotoxicity limit their clinical 
applications.   
2.1.2 Gene delivery barriers 
 It is known that polymeric gene carriers need to overcome a series of obstacles for a 
successful gene delivery, from preparation of the solution in vials to the release of the gene in 
cell nucleus/cytoplasm. Different from virus vector, synthesized polymeric non-viral vectors 
generally fail to overcome all the barriers, as they lack one or several of perquisite functions, 
leading to unsatisfactory transfection efficiencies. To enhance the transfection ability of 
polymeric gene carriers and design multifunctional carriers, it is essential to understand each 
of the barrier and the limitations of cationic polymer in the corresponding barrier. Generally, 
the barriers for cationic polymers are the followings as: (1) Extracellular stability; (2) 
Targeted cell binding; (3) Cellular uptake; (4) Intracellular trafficking, (5) Protection vs 
release of genetic payload, and (6) Instinct cytotoxicity. The design of an efficient polymeric 
gene carriers should aim to meet the requirements that overcoming all the barriers. 
2.1.3 Strategies to enhance serum stability of gene delivery system 





Attach hydrophilic polymers to the polycations is the one of the most extensive way 
to maintain the stability of particles against serum.  Modification of polyplexes with 
hydrophilic polymers such as polyethylene glycol (PEG) [29], N-(2-hydroxypropyl) 
methacrylamide (HPMA) [30] and other hydrophilic polymers to form a ‘brush’ shell of the 
particles, could stabilize the polymer/DNA complexes against salt-, protein- and biological 
complement-induced non-specific interaction. Enhanced stability presumably results from 
steric effects and surface charge shielding effects that lead to decrease particle-particle and 
particle-protein interactions. The effects mainly rely on the length of the hydrophilic polymer, 
grafting density and the method of conjugation of the hydrophilic polymer to the cationic 
polymer. Thus, PEG modifications are widely employed to prevent aggregation induced by 
serum and protein adsorption to the polyplexes under in vitro and in vivo conditions [31]. 
However, various in vitro studies suggested that PEG-modification resulted in lower 
transfection efficiency and reduced internalization of untargeted polyplexes [32]. It was also 
reported that PEGlyation polyplexes dissociated too readily under the physiological 
environment, resulting in the degradation of the DNA by nucleases [33].  Additionally, 
attaching a PEG chain to a primary amine is the most common modification of polycation 
[34]. As primary amines are the DNA binding sites, the modifications would probably lower 
the DNA binding ability of the polycations.  
Recently, zwitterionic polymer poly(methacryloxyloxyethyl phosphorylcholine) 
(pMPC) is being proposed as an alternative moiety of PEG to ensure effective steric 
stabilization for polyplexes. pMPC is a phosphorylcholine(PC)-based polymer, the structure 
of which is similar to the polar head group of phospholipid comprising cell membrane. The 
biocompatibility of pMPC polymer has been clinically proven. It is not surprising that pMPC-
based modifications have been verified to effectively suppress any unfavorable interactions 
with biocompoents, which possess the similar function as PEG. M. Licciardi et.al [35] 
prepared folic acid-functionalized diblock copolymer micelle which consisted of a 
hydrophilic block comprising MPC residues for tamoxifen and paclitaxel drug delivery. They 
found that MPC coronas of the micelles suppress the unwanted interactions between 
tamoxifen (or paclitaxel) and plasma proteins.  Lam et.al reported that MPC block act as a 
steric stabilizer for the gene delivery system comprising DNA and cationic diblock 
copolymer 2-(dimethylamino)ethyl methacrylate-block-2-(methacryloyloxyethyl 
phosphorylcholine) (DMAEMA-MPC) [36]. More importantly, it is highly evident that 
pMPC polymer would not inhibit cellular uptake. In A. Blanazs et.al’s study [32], cellular 





uptake of rhodamine-loaded PMPC-PDPA polymersomes and Rhodamine-stained PEO-PBO 
polymersomes was compared. The results clearly showed that, compared to the PEO-PBO 
polymersomes, the PMPC-PDPA polymersomes were rapidly internalized. HDF cells were 
incubated for rhodamine-loaded PMPC-PDPA polymersomes for just 1 h, the cellular uptake 
had reached to a plateau value, with approximately 95% of the cells had taken up the 
polymersomes. By contrast, no uptake of Rhodamine-loaded PEO-PBO polymer was 
detected up to 5 hours incubation with HDF cells. They proposed this remarkable difference 
is owing to the favourable interactions of the biomimetic PMPC block, located in the corona 
of PMPC-PDPA polymersomes, with the cellular plasma membrane. As pMPC mimic the 
surface of natural phospholipid membrane bilayer, the pMPC–pDPA polymersomes are 
highly compatible with the cell surface, allowing their sufficient cell attachment and rapid 
internalisation via an endocytic pathway. However, polymersomes that contain PEG in their 
hydrophilic corona cannot interact as readily with the cell surface membrane and 
consequently exhibit a much slower rate of cellular internalisation.  
2.1.4 Strategies to facilitate intracellular release of DNA 
As we discussed before, one goal of carrier design should concentrate on achieving an 
optimal balance between DNA protection and DNA release to maximize transfection. The 
general strategies used for facilitation of DNA release are summarized in Figure 2.1. Several 
studies have presented that weakening the polymer/DNA binding strength by decreasing the 
polymer molecular mass or polymer length [37], reducing the positive charges density [38], 
change of structural rigidity [39], or conjugation of PEG chains [40], leads to increased gene 
expression. However, all the above strategies results in steady releases of DNA, indicating 
that control over temporal-spatio release of DNA is completely lacking.  Thus, the ideal 
design is to incorporate a mechanism for environmentally responsive release of DNA to the 
design of polycation [8].  






Figure 2.1 Vectors exhibiting both strong protection of DNA and efficient intracellular 
release mediate the highest level of transfection. Vectors capable of only one of these 
qualities typically do not perform as well. Vectors capable of neither are largely ineffective 
[8].  
It is clear that polyplexes capable of responding to environmental stimuli have the 
potential to circumvent barriers to delivery in ways that traditional carriers cannot. Many 
stimuli have been employed to balance gene protection and release, including thermo-
sensitive [41], pH-sensitive [42], and redox-responsive. As incorporation of chemical stimuli 
redox change to polycation is the design idea of our gene delivery system, we review this 
strategy in detail. 
 Introduction of bioreducible disulfide linkages in the polymer chain is one strategy to 
facilitate DNA release in the proper time and proper place. Disulfide bond is prone to rapid 
cleavage under a reductive environment through thiol-disulfide exchange reactions [43]. -
glutamyl-cysteinyl-glycine (Glutathione tripeptide; GSH) is the major redox in eukaryotic 
cells [44]. GSH maintains distinct, non-equilibrium level between intracellular space like 
cytoplasm and nuclei and the extracellular space [45]. In blood fluids or cell surface, the 
disulfide bonds are stable due to a low concentration of GSH (approximately 2-20 M). In 
contrast, disulfide bond is prone to be degraded owing to high concentration of GSH (0.5-10 





mM) inside the cell at minutes to hour time [46].  This rapid degradation can lead to polymer-
DNA dissociation and DNA release. M.A. Gosselin cross-linked low molecular weight PEI 
through formation of disulfide bond to form a 25k molecular weight PEI, which showed 
improved gene-carrier properties, like sufficient release of DNA, enhanced of transfection 
efficiency, and decrease in cytotoxicity when compared with the non-degradable analogue 
[47]. It is worthy to point out that in addition to bringing about better balance between DNA 
protection and DNA release, which results in enhanced transfection, bioreducible polycations 
in general present largely improved toxicity profiles owing to decreased cationic charge 
density upon intracellular degradation of disulfide linkages [48]. C. Lin et.al synthesized a 
group of bioreducible poly(amido amine)s containing multiple disulfide bonds in main chain 
and SS-PAOAs in side chains, which showed distinguish toxicity profile [49]. These findings 
suggest that the introduction of disulfide linkages into polymer chains could allow sufficient 
DNA protection extracellularly, fast intracellular degradation of polymer, efficient DNA 
release, decreased cytotoxicity and enhanced transfection. 
2.2 Cancer drug therapy 
Compared to cancer gene therapy, chemotherapy is a more developed anti-cancer 
treatment options. Chemotherapy is defined as the use of chemotherapeutic agents to kill or 
control cancer cells, which was discovered in 1943. Over a few decades, there have been 
more than a hundred anti-cancer drug available for clinical applications, including natural 
plant extracts and synthetic chemicals. Anti-cancer drugs are grouped into different 
categories based on mechanisms, including anthracyclines, antimitotic, alkylating and 
antimetablites. 
2.2.1 Traditional chemotherapeutic agents 
Doxorubicin is an anthracycline antibiotic, which mechanisms work by intercalating 
DNA. It is widely used in the treatment of carcinomas including lung, ovarian, breast 
carcinoma, hematological malignancies, and some soft tissue sarcomas, both in clinical used 
and research studies.. The chemical structure of doxorubicin was shown in Figure 2.2. It 
usually exists in the hydrochloride salt form. Doxorubicin is available in the forms of 
liposome-encapsulation with or with no PEGylation, as Doxil, Myocet, and Caelyx. 






Figure 2.2 Chemical structure of doxorubicin. 
However, chemotherapeutical agents like DOX still have several limitations that 
hinder the effectiveness of chemotherapy, including (1) poor aqueous solubility (most of the 
anti-cancer drug is hydrophobic and require carrier to increase its solubility in aqueous 
solutions) [50]; (2) non-specific distribution throughout blood circulation, which results in 
failure to penetrate to tumors sufficiently [51]; (3) toxicity/adverse effect to non-targeted and 
healthy cells and tissues, which limits the frequency and dosage of the treatment, and thereby 
affects the effectiveness of therapy [52]; (4) Cancer cell will generate drug resistance after 
multiple chemotherapeutical treatments [52]. 
2.2.2 Multidrug resistance  
Drug resistance is a primary and persistent hindrance towards the success of 
chemotherapeutic treatments. Resistance to chemotherapeutic drug is a major cause of 
treatment failure and reasons of re-occurrence of cancer. The main mechanism of cells 
becoming multidrug resistance is increasing the drug efflux pump. Drug effux pump would 
pump the intracellular drug out of the cells which leads to a decrease in intracellular 
distribution of drug and compromised of the anti-cancer treatment efficiency [53]. Strategies 
to overcome drug resistance include: (1) Using the drug efflux inhibitor; (2) Development of 
carrier for chemotherapeutic agents that evades the recognition by MDR efflux pumps, e.g. 
via targeting drug delivery and internalization by active endocytosis; (3) Silencing the MDR 
pump expression using RNA interference (RNAi) [54].  
2.2.2.1 Strategies of overcoming multidrug resistance 
In most of the cases, multidrug resistance is highly linked with multidrug resistance 
protein 1 (MDR1), also known as P-glycoprotein (P-gp). P-gp is a glycoprotein located on the 
cell membrane and responsible for transferring a wide variety of free intracellular drug across 





cellular membranes. Application of siRNA and RNA interfering have the potential to abolish 
MDR efflux expression and translation via mRNA silencing [55]. Yadav et al. reported that 
poly(ethylene oxide)-poly(beta-aminoester) (PEO-PbAE) transfer siRNA-MDR1 against the 
P-gp in paclitaxel (PTX) resistant human ovarian adenocarcinoma cells (SOKV3). The results 
showed the silencing increase the sensitivity of carcinoma cells to both paclitaxel and 
doxorubicin [56]. Gao et al. presented a RCPNs successfully inhibited P-gp expression and 
enhanced the cytotoxicity of adrymicin against MCF7/ADR cells [57]. 
2.2.3 Combined therapy via co-delivery of anti-cancer drug and nucleic acids 
Combined therapy via simultaneous delivery of anti-cancer drug and siRNA is a 
highly effective strategy to treat tumor. Generally, co-delivery of genetic payload and 
chemotherapeutic agents exhibits superior anti-cancer effect compared with application of the 
individual treatments, separately.  Based on mechanisms, combing chemotherapy with 
nucleic acids (siRNA-MDR1) to overcome multidrug resistance is a promising strategy that 
RNA interfere suppresses the drug efflux pump and re-sensitizes the cells against anti-cancer 
drug. In addition to mechanistic considerations, co-delivery of therapeutic nucleic acids and 
chemotherapeutics in a single carrier may show benefits in (1) convenience, (2) delivery of 
both therapeutic agents to the same populations, (3) synchronized pharmacokinetics, and (4) 
synchronized biodistribution. The mechanism of re-sensitization of cancer cells and 
suppression of drug resistance by co-delivering siRNA and chemotherapeutic agents was 
shown in Figure 2.3. 
 
Figure 2.3 Mechanism of drug resistance and sensitization of cancer cells by co-delivering 
siRNA and chemotherapeutic agents. Drugs encapsulated in nanoparticles evade the efflux 
pump, by suppression the , release siRNA and drug to the cytosol [26].  





2.2.3.1 Polymeric micelle as carrier for drug and gene co-delivery 
Polymeric micelles, self-assembles from amphiphilic block copolymers above critical 
micelle concentration, are promising nanocarrier for drug and gene delivery. It is well 
acknowledged that amphiphilic block copolymers is capable to spontaneously assemble to 
micelles with a unique core-shell structure. The inner hydrophobic core of micelle serves as a 
container for hydrophobic drugs. Besides hydrophobic core, cationic segments are required 
for the co-delivery of drug and gene. Electrostatic interaction between cationic charged 
polymer and the negatively charged nucleic acids (pDNA, siRNA, etc.) is allowed to form the 
inner layer of micelles. The hydrophilic corona acts as the outer shell of micelles. Commonly, 
the outer shell is composed of hydrophilic polymer such as poly(ethylene glycol) (PEG), 
which prolongs the circulation time and provide effectual tumor accumulation. The formation 
and the properties of polymeric micelles for gene and drug co-delivery are illustrated in 
Figure 2.4 [58]. 
 
Figure 2.4 Formation and properties of polymeric micelles for drug and gene delivery. 
In this section, the examples employed amphiphilic polymeric micelles for anti-cancer 
drug and nucleic acids co-delivery will be reviewed. Wiradharma et al. designed an 
amphiphilic three-block copolymers Ac-(AF)6-H5-K15-NH2 (FA32) as carriers for doxorubicin 
and p53-encoding plasmid gene co-delivery. The amphiphile spontaneously self-assembled 
into cationic core-shell micelles. The co-delivery of DOX and p53 gene by this nanostructure 
achieved a synergistic effect in inhibiting the growth of HepG2 cells, as compared to the 
individual treatments of micelle/p53 complexes and pure DOX [59]. Endres et al. synthesized 
a series of amphiphilic PEG-PCL-PEI triblock copolymers with raying 
hydrophilic/hydrophobic ratios, which were optimized for drug and gene co-delivery. The 





hydrophilic polymer in nature formed ~40 nm micelle-like carriers, whereas hydrophobic 
polymers assembled to larger particle-like aggregates ~100 nm. The results showed that this 
triblock amphiphilic copolymer was a promising carrier for co-delivery of nucleic acids and 
drugs [60]. Zheng et al. prepared polypeptide micelle nanoparticles (NPs) of a triblock 
copolymer poly(ethylene glycol)-b-poly(l-lysine)-b-poly(l-leucine) (PEG-PLL-PLLeu) to 
synergistically codeliver siRNA-Bcl-2 and docetaxel (DTX) for an effective drug and gene 
co-delivery vector.The anti-cancer drug DTX was entrapped into the hydrophobic PLLeu 
core, while the negatively charged siRNA was compacted by cationic backbone PLL via 
electrostatic interaction. The hydrophilic PEG segment acts as the outer shell of the system. 
The results showed that the co-delivery system DTX-siRNA-NPs down-regulated of the anti-
apoptotic Bcl-2 gene and enhanced antitumor therapeutic effect with a lower dosage of DTX, 
resulting in the inhibition of tumor growth of MCF-7 xenograft murine model. The anti-
tumor effects were significant pronounced compared to the individual siRNA and DTX 
treatments [61]. 
2.2.3.2 Polymeric micelle as carrier for drug and gene co-delivery 
In recent years, micellar self-assembly techniques have been extended to prepare 
polymeric vesicles. Scientists have advanced to study and utilize the self-assembly properties 
polymeric vesicles, as known as polymersomes. Polymersomes are self-assembled from a 
variety of high molecular weight amphiphilic block copolymers, which share similarities in 
construction and function with lipid-based liposomes [62]. Now the polymersomes have been 
recognized as ideal nanovectors for co-delivery of anticancer drug and therapeutic gene. 
Formation of micelle or vesicle is dependent on the hydrophilic block to hydrophobic block 
volume fractions [11]. When the ratio of hydrophilic bocks to total polymer weight is larger 
than 45%, it is preferred to form micelle. While the occurrence of polymersome membrane 
structure is favored in the hydrophilic block ratios of ~35%. The formations of micelle and 
polymersome are illustrated in Figure 2.5. Similar phenomena were observed and explained 
in other researches [63, 64]. 
 
Figure 2.5 Formation of micelle and vesicle, depended on the chemical structure and 
compositions of amphiphilic copolymer [11]. 





Compared to other similar delivery systems like liposomes, micelles, polymer-drug 
conjugates, polymersomes have several advantages over these systems. (1) One of the 
advantages vesicles in comparison to micelle is to encapsulate both therapeutic genetic 
material and hydrophobic drug in their aqueous inner part and lamellar membranes, 
respectively, while micelles only capable to encapsulate hydrophobic part in the core and 
compact nucleic acids in the shell, which indicates the protection of genetic payload is 
weaker than that of polymersome system. (2) The time of release payload could adjusted by 
optimizing the properties and length of hydrophobic block of copolymer [65]. Polymersomes 
have slow chain exchange dynamics, indicating that such copolymer assemblies have slow 
rates of dissociation. The therapeutic payload could achieve sustained release for a long 
period of time.  (3) Polymersomes have kinetically stable structures, which exhibit much 
higher stability than liposomes [66]. (4) Compared to liposomes, polymersomes have 
stronger mechanical and physical properties, including better stability and stability ascribed 
to the tougher and thicker membrane. (5) Last but least, molecularly dissolved amphiphilic 
copolymers in solution is absent which avoids cytotoxic interactions with biological 
phospholipid membranes. 
Examples of polymersomes for co-delivery of gene and drug to achieve anti-cancer 
therapeutic effects are limited. Kim et al. encapsulated doxorubicin and Bcl-xL siRNA into 
polymersomes self-assembled by methoxy-poly(ethylene glycol)-block-poly(D,L-lactic acid) 
(mPEG-b-PLA) [67]. The polymersomes showed synergistic anti-cancer effect of gene and 
drug. Pangburn et al. reported on the encapsulation and delivery of siRNA and doxorubicin 
inside of polymersomes composed of peptide-based poly(1,2-butadiene)-b-poly(ethylene 
oxide). The polymersomes showed multifunctionality including targeting, controlled release 
of payload, and synergistic delivery of both gene and drug [62]. 
2.3 Receptor mediated targeting delivery of therapeutic payloads 
Due to the systemic toxicity and a series of undesirable adverse effects of drug/gene 
delivery systems depending on passive targeting made it necessary to develop active targeted 
delivery vectors. The concept of targeted gene/drug delivery by using receptor targeting for 
specific binding and internalization has attracted attention, which is particularly valuable 
against cancer disease and the therapeutic agent with toxicity concerns. Targeted delivery of 
drug/gene to specific cells and tissues by recognition of surface markers of cells showed great 
promise with clear advantages. (1) Cellular specificity by surface modified recognition 





moieties of nanoparticles could facilitate elevated nanoparticles uptake by target cells and 
support the retention of therapeutics within the pathologic tissues. (2) Delivering therapeutic 
gene or drug specifically to pathologic tissues could avoid the collateral toxicity to normal 
cells.  
There are various targeting moieties for surface modifications of nano-carriers to 
deliver loaded agents to accumulate in target sites. The most widely used active targeting 
substances used for active targeted gene/drug delivery include peptides [68], monoclonal 
antibodies [69, 70], epidermal growth factor [71], galactose [72, 73] and folate [74-76]. Some 
of the researches utilized glycoprotein transferring (Tf) as the targeting ligand to bind to a 
transferring receptor (TfR), which is selectively enriched in rapidly proliferating tumor cells 
[77, 78]. Furthermore, it was found that tumor cells over express specific integrin receptors, 
v5 and v3, which would bind to the arginine-glycine-aspartic peptide sequence (RGD). 
Hence, RGD conjugation is used as a strategy to deliver nanoparticles to cancerous cells [79]. 
In 1985, since first example of low density lipoprotein (LDL) – mediated targeting 
nanocarriers to leukemic lymphocytes, LDL receptor (LDLR) has attracted continuous 
interests for design of targeting drug/gene vectors. In addition to the aforementioned 
receptors, owing to the rapid proliferation of cancerous cells, receptors over-expressed in 
tumor cells for enhancing the uptake nutrients, such as folic acids, glucose [80], vitamins, 
could be utilized for design of targeted delivery system. 
2.3.1 Folate receptor mediated targeting gene/drug delivery 
Among various cellular surface receptors potentially suitable for application in 
drug/gene targeting, folate receptor (FR) has emerged as one of the most promising and most 
investigated tumor markers. Human FR, a family of glycopolypeptides of Mr in the range of 
38 – 45 kDa [81], has three isoforms, FR-, FR-, and FR- [82-85]. FR- and FR-are two 
glycosyl phosphatidylinositol (GPI)-anchored isoforms, which are attached to the cell surface, 
whereas FR-is secreted constitutively [86-88] . The distribution of folate receptor are 
measured by different methods including reverse transcription-polymerase chain reaction 
(RT-PCR) analysis [89], western analysis, immunohistochemical staining [90], and 
3
H-folic 
acid binding [76]. FR was firstly knowledged that it was significantly up-regulated on cancer 
cells in early 1992 [91, 92]. After that, FR was frequently present in large numbers among 
human tumors and generally exhibit limited expression in most normal tissues. For example, 
elevated folate receptor  expression has been observed on epithelial cancers of ovary, ovarian 





endometrial colorectal, mammary gland, breast, colon, lung renal prostate, nose, and throat, 
as well as brain carcinomas [78, 87, 92-98]. Though folate receptors are also expressed in 
certain normal tissue like choroids plexus, fallopian, kidney, and placenta, their expressions 
are largely inaccessible to folate conjugates in the blood circulation, as their expressions are 
restricted in luminal surface of epithelial cells [99]. Consequently toxicities to normal healthy 
tissues which express folate receptor have not been observed [100]. In summary, the frequent 
up-regulated expression of FR in human tumors and FR normal tissues are highly 
inaccessible indicate that FR can potentially be employed as a cancerous selective cell 
surface biomarker that can be exploited in the cancer therapeutics targeted delivery.  
Folic acid is an aqueous soluble vitamin B, which has a high affinity to folate receptor 
(Kd = 10
-10
 M). The structure of folic acid was shown in Figure 2.6. The binding of folate 
conjugates to FR was shown in illustrative Figure 2.7.  
 
 
Figure 2.6 Chemical structure folic acid. 
 
 
Figure 2.7 Illustrative scheme showed the folate conjugates enter cells via high affinity folate 
receptors [101]. 





Compared with other ligands under investigations like antibodies and other 
polypeptide-based targeting ligands, folic acid owes a series of advantages which benefits its 
applications, like (1) Small size with low molecular weight Mw 441. The small size of folate 
ligand allows manufactured at an industrial scale. In addition, it is much easier to penetrate to 
tissue and be rapid clearance by the folate receptor negative tissues. (2) Facile conjugation 
chemistry, it is easy to conjugate to both diagnostic agents and therapeutic reagents; (3) 
Water solubility; (4) Stable in diverse pH, organic solvent, and heat; (5) Lack of 
immunogenicity and specificity to pathologic cells; (6) Higher affinity and more tumor 
specific (Kd = 10
-10
 M) than most other ligands under studied (e.g. peptide, monoclonal IgGs, 
etc.); (7) Less expensive; (8) Unlimited availability; (9) Not only able to target to FR 
overexpression tumors, but also target to a wide range of inflammatory diseases, which lead 
the applications of folic acid more diverse than most other targeting ligands. (10) Folate 
conjugate demonstrated favorable non-destructive cellular internalization pathway via FR-
mediated endocytosis [102-107]. In summary, all these features and merits render folic acid 
an attractive ligand for clinical application of folate-mediated targeting drug delivery in the 
foreseeable future. 
2.3.2 Polymeric nanostructures for folate receptor mediated targeting drug delivery 
Various types of chemotherapeutic drug carriers have been exploited to modify with 
folate, including polymers, amphiphilic micelles, lipid-based nanoparticles, and polymeric 
nanoparticles, to efficiently deliver anti-cancer drug to target tissues. Examples of types of 
FR-mediated polymeric drug delivery carriers would be summarized below in order to 
highlight the advances and strategies that had been made in the field of folate receptor 
mediated targeting. 
In one interesting report, Lu et al. reported the construction of poly-lactic acid (PLA)-
derived polymer based folate-functionalized nanoparticles, the in vivo distribution of which 
was investigated. The results showed that folate-drug-loaded nanoparticles showed strong 
signals in the xenograft tumors, indicating specific folate-targeting to FR overexpressed 
tumors, whereas the non-folate modified nanoparticles showed high nonspecific 
accumulation in the liver [108]. Kim et al. developed and optimized a targeted micelles 
which was comprised of poly(l-histidine-co-l-phenlyalanine) and poly(l-lactic acid)-b-PEG-
folate for doxorubicin delivery. The micelles showed FR+ tumor-selective accumulation in in 





vivo biodistribution study, indicating its capability to target to folate receptor [109]. Yoo et al. 
prepared a biodegradable polymeric micelles, which was self-assembled from a poly(D,L-
lactic-co-glycolic acid) – poly(ethylene glycol) – folate (PLGA-PEG-FOL), for folate 
receptor targeted doxorubicin delivery. Flow cytometry, confocal image, and in vivo animal 
studies demonstrated that the folate conjugated micelles exhibited far higher cellular uptake 
than non-folate conjugated micelles in FR overexpressed KB cells and tumor tissue of nude 
mice xenograft model [110]. Yu et al. developed a novel folic acid modified cholesterol-
conjugate glycol chitosan micelles (FCHGC). This doxorubicin-loaded targeted micelles 
showed markedly higher cytotxicity against folate receptor positive Hela cells, as compared 
to non-targeted DOX-encapsulated micelles and free DOX. These results indicated that folate 
functionalized micelles had potential to be drug carrier for targeted delivery [111]. Song et al. 
presented a new strategy to construct a versatile nanovesicles for targeted cancer therapy. The 
system was composed self-assembled from a tumor-cleavable and targeting clickable 
polyurethane poly(-caprolactone) and l-cystine-derivatized chain with a redox-responsive 
disulfide bond. The polymer was terminated by a folic acid conjugated methoxy-
poly(ethylene glycol) through a pH-sensitive benzoic-imine linkage. The FA decoration 
micelles showed improved cellular uptake and enhanced drug efficacy to FR-positive Hela 
cells in vitro [112]. Nair et al. synthesized a folic acid conjugated poly 
valerolactone/poly(ethylene glycol)/poly valerolactone (VEV-FOL) for doxorubicin delivery. 
The intracellular internalization test showed that the cellular uptake of folate-modified 
micelle was improved when compared to non-folate-functionalized micelles. In addition, the 
MTT assay and the apoptosis assay indicated that the micelles decorated with folate showed 
higher cytotoxicity and apoptosis rate. The results indicated that this system showed 
sustainable and controlled tumor targeting ability via the targeting ligand folate [113]. Our 
group also developed a multifunctional folate receptor targeted system for p53 gene and 
anticancer drug paclitaxel co-delivery. The co-delivery targeted system was derived from a 
supramolecular self-assembled inclusion complex, which was prepared from star-shaped 
cationic polymer containing multiple oligoethylenimine and gamma-cyclodextrin with folic 
acid conjugated to cyclodextrin via a bioreducible disulfide linker. The system showed folate 
receptor targeting and continuous FR-mediated endocytosis, which achieve enhanced gene 
transfection and anti-cancer therapeutic effects [114].  
From the above references, it was conceivable that folate-functionalized polymeric 
nanoparticles showed consequential improvements in cellular uptake in FR+ cells/tissues in 





comparison to non-targeted drug-loaded systems, indicating the tumor-targeting delivery 
could be enhanced by modification of folate to the corona of nanoparticles.  
2.3.3 Polymeric nanostructures for folate receptor mediated targeting gene delivery 
Interests in folate receptor (FR) mediated targeting for specific internalization of 
drugs delivered by folic acid-functionalized polymeric nanoparticles even further with the 
advent of nucleic acid including plasmid DNA and small interfere RNA (siRNA). Numerous 
investigations have been carried out to apply FR targeting to non-viral gene transfer vectors. 
In the following section, the applications of folic acid (FA) as targeting ligands would be 
summarized and the various examples being developed for delivery of nucleic acid to FR 
overexpressed cells or tissues would be highlighted. 
Several folate conjugated cationic polymers have been synthesized and evaluated for 
FR-mediated targeted gene delivery. These include folate-poly-L-lysine (folate-PLL) [115, 
116], folate-PEG-PLL [117], folate-PEG-pDMAEMA [118], folate-polyethylenimine (folate-
PEI) [119], folate-PEG-PEI [120], folate-chitosan [121], and other multifunctional folate 
conjugated cationic polymers. Gottschalk et al. conjugated folic acid to poly-L-lysine. It was 
found that the polymer was able to mediate folate dependent gene delivery to FR+ Hela cells 
[115]. Another report by Leamon et al. developed a folate-PEG-PLL conjugate and 
demonstrated it could facilitate FR-mediated targeting endocytosis and gene transfection 
[122]. In addition, Ward et al found that complexes formed by DNA and PLL with folate via 
a hydrophilic PEG linker exhibited long blood circulation time and selective cellular uptake 
by folate positive Hela cells. This study indicated that the length of PEG space was important 
to the FR targeting efficiency [117]. Another study repoted by Steenis et al. applied this 
strategy that post polyplex formation with conjugation of folate-PEG, to pDMAEMA, 
showing similar conclusions that systems targeted to FR+ ovarian carcinoma cells OVCAR-3 
[118]. Several studies including Guo et al. [123] and later, Benns et al. [124] prepared folate-
PEI and folate-PEG-PEI, showing FR-dependent delivery of GFP-reporter genes in folate 
receptor positive cells. It must be noted that the FR-specificity of folate-functionalized 
complexes was shown to be highest at neutral zeta potentials and non-specific transfection 
was found at high N/P ratios. Other FR-targeting cationic polymers were developed based on 
the pioneer researches. Li et al. reported a novel brush shaped copolymer poly[oligo(ethylene 
glycol) monomethyl ether methacrylate-co-folic acid methacrylate]-b-poly[2-(2-(2-(2-bromo-
2-methylpropanoyloxy)-ethyl) disulfanyl) ethyl methacrylate-g-2-dimethylaminoethyl 





methacrylate], P(OEGMA-co-FAMA)-b-P(BSSMA-g-PDMAEMA), which was synthesized 
by consecutive radical polymerizations. The tumor cell-targeting ligand folic acid was 
conjugated to the side chain of the brush block via disulfide linkages. This study showed 
tumor-targeted and relatively high gene transfection efficiency in FR+ cells [125]. Wang et al. 
developed a pH sensitive folic acid-PEG-chitosan-PAMAM/DNA complexes for targeted 
gene delivery (FPCPHDs). FPCPHDs exhibited improved gene transfection in KB cells, and 
the expressions were inhibited by free folic acid. In addition, FPCPHDs showed increased 
fluorescence protein expression at the targeting tumor sites of xenografted nude mice, 
indicating that FPCPHDS was potential to improve the transfection efficiency in most FR+ 
cancer cells [126]. In addition, a novel folated poly(ethylene glycol)-chitosan-graft-
polyethylenimine (FPCP) was investigated by Kim et al. as a non-viral gene carrier for 
potential folate receptor-overexpressed cancer cell targeting gene delivery. The FPCP 
targeting block copolymer showed supreme cancer cell specificity and reduced tumor 
numbers more effectively in H-ras 12V liver cancer mice model as compared to non-targeted 
PEI 25k [127]. Dong et al. developed a multifunctional delivery system that can targeted 
delivery siRNA to FR+ cancer cells. The system was developed by one step self-assemble of 
PEI-HZ and PEI-PEG-Folate. The study optimized the folate surface density. Results showed 
that the siRNA complexes can increase siRNA accumulation in the FR+ tumor cells and 
decrease non-specific binding in normal tissues [128]. Table 2.1 further summarized the 
examples of folate modified nanoparticles for both drug or gene delivery in FR+ cancerous 
cells. 
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doxorubicin Hela tumor [108] 
Cationic polymer siRNA KB tumor [134] 
 
From the above reported FR-targeted vector formulations, it was known that the folate 
was either directly conjugated to a cationic polymer, or in-directly grafted via a hydrophilic 
PEG linker. These folate functionalized vectors have shown impressive FR-specificity and 
selective transfer activity in both in vitro cell culture assays and in vivo models. It was 
indicated that folate receptor (FR) based targeting was a promising mechanism to promote 
tumor-specific gene delivery. Thus, targeted gene delivery via folate cellular receptors, by 
folate-based non-viral cationic polymer is emerged as a novel strategy to improve the gene 
transfer efficacy of cancer-selective gene delivery. 
2.3.3.1 Possible endocytosis pathway of folate receptor mediated targeting gene system 
From the literature review in the previous section, it was clear that folate modified 
drug or gene delivery nanoparticles were taken up by FR+ cells via the receptor-mediated 
endocytosis. However, the precise endocytosis pathway of folate conjugates remained 
unresolved. There have been several conflicting references regarding the pathways of the 
internalization and trafficking of folate-functionalized particles. 
Many early studies found that FR is not related to the clathrin-mediated pathway, as 
most of studies could not found clathrin-coated pits during the FR-mediated endocytosis of 
folate conjugates [135]. A series of reports proposed that folate receptor was endocytosis via 
potocytosis pathway via the pinching of caveolae compartment [135-138]. More recent 
results also indicated that the endocytosis of folate modified vehicles were in association with 
the flask-shaped membrane structure named caveolae [137, 139-143].  
Knowledge about the intracellular localization of vehicles is of great importance for 
further improvement of the system design [144]. Only the intracellular pathway of the 
drug/gene delivery systems was clear, further optimization could be performed to facilitate 





the carrier to overcome the corresponding barriers in the path of endocytosis. Thus, the 
endocytosis pathway of drug/gene delivery systems and their post-endocytotic distribution 
should be determined and evaluated in this study. 
2.3.3.2 Factors affecting targeting gene delivery  
Despite progresses were made in folate-functionalized polymeric nanoparticles for 
targeting gene/drug delivery, there were still several factors had the potential to negatively 
affect the gene transfer and drug delivery of folate-modified systems. Scientists believed that 
some factors, such as surface shielding e.g. hydrophilic polymer shielding, ligand densities, 
ligand orientation, multivalency, surface charge, pharmacokinetics, as well as biodistribution 
etc. may affect the cellular uptake and efficacy of FR-mediated targeting delivery. In order to 
get better understanding of the structure-property of folate targeting system and obtain the 
correct directions for further chemical structure modifications, the following sections would 
review the possible factors affecting the targeting efficacy of folate-based delivery system. 
(1) Surface shielding 
The prerequisite for successful targeting gene delivery is to achieve minimum non-
specific binding. Most of the gene delivery systems were positive charge, which would lead 
the nanoparticles non-specifically bind to most of the cells or tissues with negatively charged 
membranes. Thus, before endowing the targeting capacity to gene delivery system, 
eliminating most of the non-specific binding of nanoparticles is crucial to construction of 
targeting gene delivery system. PEGylation (modification of nanoparticles with poly(ethylene 
glycol) shell) was regarded as a useful tool to provide a steric barrier and charge shielding 
located [145]. For drug delivery system, PEGylation appeared to prolong the systemic 
circulation time of folate-functionalized nanoparticles, reduce the clearance and cellular 
internalization in non-targeted cells [141]. Thus, in our opinion, incorporation of a PEG 
spacer between folate ligands and polymer was necessary for reduction of non-specific 
delivery and improvement efficient targeting delivery. 
(2) Surface charge 
As mentioned before, particles with a high positive charge would promote non-
specific adhesion to all cells, which own abundantly negative charges owing to the presence 
of anionic phospholipid phosphatidylserin. Thus more effects should put to provide non-





specific binding to gene delivery systems compared to neutrally charged drug delivery system. 
Surface charge is another factor that affects the non-specific cellular binding of gene delivery 
particles which would influence the targeting efficiency. Zhao et al. summarized that high 
folate receptor selective gene delivery could only be obtained at neutral N/P ratios, where the 
in vitro non-selective transfection activity achieved to be minimum [76]. Pan et al. found that 
the FR specificity of the gene delivery complexes was superseded by non-selective at high 
surface charge with high N/P ratios, but the non-specific transfection was demonstrated to be 
minimized at approximate neutral surface charge with neutral N/P ratios. At the same time, 
the targeting selectivity could be obtained at a maximum [141]. Thus, for the design of gene 
and drug delivery targeting system, charge ratios (N/P) of targeting gene delivery system 
should be optimized in order to achieve reasonably low surface charge and minimum non-
specific binding. 
(3) Ligand structural features and homo/multi-valency 
Besides the surface shielding and charge of nanoparticles would affect the targeting 
efficiency, the structural features of folate ligand like the shape of folate, size, flexibility, 
orientation, density, and valence etc. also often dramatically influence the targeting binding 
efficiency. Because ligand bindings to receptor are linked for the sub-cellular signalling 
activity, careful optimization of ligand chemical features of the targeting nanoparticles is 
required. Receptors usually exist as “cluster” on the cell membrane, thus, multivalent ligands 
might be beneficial for the enhancement of NP targeting and downstream process [146]. As 
shown in Figure 2.8, on normal cells, as the density of folate receptors was low, in most of 
the case only one ligand–receptor interaction may occur. On contrary, on cancer cells, there 
would be a high surface density of the folate receptors, thus the folate-functionalized targeted 
nanoparticles can provide multivalency to engage enhanced binding and interactions over the 
one ligand–one receptor interaction (Figure 2.8). Theoretically, binding avidity between 
ligand and receptor clusters might substantially increase with valences. Vagner et al. found 
that multiple copies of folate via long and rigid spacer enhanced targeting cellular uptake as 
compared to single copy [147]. Multivalent ligands might obtain higher binding energy from 
binding to the receptor sites, which results in increased binding affinity [148]. Kessler et al. 
reported that ligands with multivalency showed 150 times increased affinity over the 
monovalency [149]. Nonetheless, from the molecular point of view, the interactions between 
ligand and receptor are strongly influenced by the number, size, and spatial organization of 





the recognition ligands [150]. Gillies et al. demonstrated that length, conformation, and 
structure of the hydrophilic linker, as well as the orientation of the recognition ligand 
presented impact on the binding affinity of particles to receptor [151].  Bulky multivalent 
ligands possibly act as inhibitors through steric stabilization, which lead to decrease of 
binding affinity. 
 
Figure 2.8 Nanoparticles with numerous targeting ligands can provide multivalent bindings to 
the surface of cells with high receptor density [152]. 
Overall, to achieve minimum non-specific binding and maximum targeting binding 
affinity, the optimized spacer length, density of ligand, and valency of binding should be 
screened. 
2.4 -Cyclodextrin-based supramolecular building block approaches 
2.4.1 -Cyclodextrin-based supramolecular chemistry 
Cyclodextrins (CDs) are macrocyclic oligosaccharides composed of 6, 7, or 8 D(+) 
and (+)-glucose units and dominated as -, -, and -CD, respectively [153, 154]. 
Cyclodextrin is aqueous soluble and non-immunogenic. The cytotoxicity of cyclodextrin is 
low on both animals and humans. Cyclodextrin has good pharmaceutical profiles and many 
practical applications in pharmacy. CDs are interesting core molecule with hydrophobic inner 
cavity and hydrophilic exterior. The hydrophobic interior of CD is capable to form inclusion 
complexes with a wide range of guest molecules via molecular recognition mechanism [16]. 
-cyclodextrin (CD) and adamantane (Ad) is a host-guest pair with high affinity, the 





formation of CD/Ad inclusion complexes was shown in Figure 2.9. Adamantane is able to 
form extremely strong complexes with CD core, as the size and structure of adamantane fits 




 at room temperature 
[155]. The inclusion complexation of adamantane (Ad) and its derivatives with -CD has 
been the subject of various studies [16].  
 
Figure 2.9 Formation of -cyclodextrin/adamantane host-guest inclusion complex. 
Supramolecular is a term describing a highly organized system ascribed to the 
association of two molecular entities via inter-molecular non-covalent binding interactions 
[156]. The researches on supramolecular structures with various properties from their 
subunits [157] are attractive because they hold promise for designing novel nanomaterials for 
biological or pharmaceutical applications [158-164].  The formation of unique inclusion 
complex leads that the cyclodextrin could be functionalized with additional groups by non-
covalent means with conjugation of functional groups to adamantyl-based moieties which 
capable of inclusion into the CD cavity. Recent progresses on the CD-based supramolecular 
structures included the construction of CD-based pseudo copolymer, creation of cationic 
CD-based as novel gene delivery vectors, CD-based supramolecular copolymers for 
controlled drug delivery, which will be reviewed in the following sections.  
2.4.2 -Cyclodextrin-based supramolecular system as carriers for gene/drug delivery 
Due to the chemical versatility, cyclodextrin can be modified with multifunctional 
groups such as cationic groups to achieve gene delivery functions. Cyclodextrin was firstly 
employed for nucleic acids delivery by Davis’s group [165]. The linear cationic polymers 
containing β-cyclodextrin (β-CD) were prepared and demonstrated low cytotoxicity and good 
gene transfection efficiency. After that, a series of similar CD-containing cationic polymers 
were synthesized and explored by attaching cationic polymers to the CD core [166-177]. 





Tang et al. demonstrated the conjugation of  CD and polyethylenimine (PEI) could be 
utilized as potential gene vectors with high efficiency low toxicity compared with 
corresponding PEIs [170, 176]. Further, application of CD in gene delivery is extended. 
CD not only served as backbone for designing the star-shaped polymers, but also the host 
moiety for building the supramolecular assembly structure. Researchers including us have 
demonstrated several supramolecular polymers formed through inclusion complexation based 
on non-covalent host-guest interaction between β-CD and adamantyl moieties, for soft 
materials and biomaterials applications [178-186]. Various self-assembly approaches such as 
multilayered assembly and complementary DNA strand self-assembly also have been 
reported for building multi-functional gene delivery systems [187-191].  
Here are several examples of supramolecular polymers formed through host-guest 
intearaction between -CD and Ad- moieties, developed by our group for biomedical 
applications, including gene and drug delivery. Zhang et. al developed a polymeric 
supramolecular host−guest system consisting of bis(adamantyl)-terminated poly(propylene 
glycol) (PPG) (the guest polymer) and star-shaped poly(N-isopropylacrylamide) (PNIPAAm) 
with a β-cyclodextrin (β-CD) core (the host polymer) in aqueous solution. It was found that 
the critical micelle temperature (CMT) for this thermoresponsive supramolecular polymer 
could be adjusted by the host-guest composition and concentration of the components. In 
addition, the size of supramolecular micelle could be tuned not only by adjusting by the ratio 
of host/guest and the length of the PPG block in the guest polymer. This study proved that the 
thermo-properties of this system could be easily tuned by simply adjusting the ratios of 
complexation ratios [179]. Ping et. al constructed supramolecular PEGylation polyplexes 
based on interactions between -CD and adamantyl moieties for plasmid DNA and siRNA 
delivery. Firstly, a water-soluble chitosan-graft-(polyethylenimine-β-cyclodextrin) cationic 
copolymer was synthesized via reductive amination between oxidized chitosan (CTS) and 
low molecular weight polyethylenimine-modified β-cyclodextrin (β-CD-PEI). After that, the 
pendent β-CD moieties of CPC copolymers allowed the supramolecular PEGylation though 
self-assembly of adamantyl-modified poly(ethylene glycol) with the β-CD moieties. The 
supramolecular PEGylation of the polyplexes exhibited significant improvement in stability, 
cytotoxicity profile, and transfection efficiency. Based on this study, it is expected that 
multifunctional gene delivery systems could be developed via inclusion complexation 
between β-CD unit and adamantyl guest molecules [180]. Zhao et al. developed a 
supramolecular self-assembled inclusion complex, which was prepared from star-shaped 





cationic polymer containing multiple oligoethylenimine and gamma-cyclodextrin with folic 
acid conjugated to cyclodextrin via a bioreducible disulfide linker. The system successfully 
co-delivered paclitaxel and p53 gene. The results indicated that this co-delivery targeted 
system showed folate receptor targeting and continuous FR-mediated endocytosis, which 
achieve enhanced gene transfection and anti-cancer therapeutic effects [114]. 
Compared to traditional covalent conjugation approaches, this supramolecular 
approach is much more convenient in building complicated architectures with multiple 
functionalities integrated within one system, as the respective components can be produced 
and modified separately, allowing the target system to be readily customized and fine-tuned 
to optimize the overall performance. Thus, it is expected this block building method based 
supramolecular non-covalent approach could be applied in design of multifunctional gene 
delivery system with complicated structures. 
2.5  Concluding comments on literature reviews 
Based on the literature review in 2.1, it is known that a successful gene delivery 
carrier for cancer gene therapy is required to overcome a series of gene delivery barriers. 
Although methodologies are existing or under development for solving individual barriers in 
polymeric gene delivery processes, it is eventually a big challenge to design a multi-
functional or smart polymeric system with multiple features incorporated and optimized to 
overcome these hurdles collectively to achieve an efficient and safe gene delivery. 
Based on the literature reviews in 2.2, it could be concluded that systemic cytotoxicity 
and multidrug resistance is the major obstacle of the application of chemotherapeutic agent 
like doxorubicin. Co-delivery of siRNA encoded MDR1 and anti-cancer drug doxorubicin is 
a promising strategy to conquer the multidrug resistance in chemotherapy.  In addition to 
mechanism considerations, spatially synergistic co-delivery of anticancer drug and siRNA in 
a single carrier may further benefit in synchronized pharmacokinetics and delivery of both 
therapeutic payload to the same population of cells. From the inherent property, it was 
acknowledged that polymersomes have supreme advantages as a gene and drug co-delivery 
system over other existed systems like liposomes. However, up to date, reports of 
polymersomes applied for co-delivery of hydrophobic compounds and genetic 
macromolecules were limited. Multifunctional polymersome carriers which targeting to 
deliver chemotherapeutic to multidrug resistant cancer cells, responsively release payload 
inside the cell, provide nucleus localization of anti-cancer drug are missing. Thus, in this 





thesis, a stimuli-responsive vesicular carrier would be designed to targeting co-deliver 
doxorubicin and siRNA-MDR1 for overcoming multidrug resistance in tumor. 
Based on the literature reviews in 2.3, it was confirmed that folate receptor mediated 
delivery is a promising strategy for treatment of FR overexpressed tumors. Over the last 
decades, considerable advances in drug and gene delivery have been made by folate-
functionalized polymeric systems. Clearly, folate modified drug/gene delivery nanoparticles 
showed high binding affinity to folate receptor and improved cellular uptake and therapeutic 
efficiency in FR+ cells, as compared to non-targeting counterpart. Nevertheless, despite all 
these progresses, the reported systems to date were still in the initial stages and far from ideal 
drug/gene carriers for clinical targeting applications. Before initial of clinical studies, 
additional improvements of the reported FR-selective targeting carriers were likely necessary.      
To reach the goal that obtaining the optimized targeting gene/drug delivery system 
with minimum non-specific binding and maximum targeting receptor attaching, as well as 
understanding the intracellular pathway and distribution of the targeted nanoparticles, the 
properties of hydrophilic shielding PEG including the length and shape, surface charge, 
ligand density, ligand binding valency should be screened and optimized. In addition, more 
comprehensive studies would have to be conducted to understand the mechanisms of 
trafficking pathways. PEGylation and multivalency are, with no doubt, important to the 
targeting nanoparticle construction. However, there are no clear guidelines for the precise 
ligand-polymer structure. Given the crucial role of the structure of nanoparticle itself, 
ultimate success of targeting polymer might come from the optimization of structures of 
targeting nanoparticles with parallel synthesis, resulting in a library of formulations that can 
be employed to screen the corresponding structural parameters for the desired targeting 
efficiency. Nevertheless, until now, no such a research was conducted. We reasoned that few 
previous attempts to address these issues were lack of reliable platform. Usually, construction 
of a library of nanoparticles for screening is time consuming and requires laborious covalent 
synthesis. The reproducibility and reliability is also a concern due to multiple steps of 
modifications. Thus, to precisely optimize and control over the ligands presentation on 
nanoparticles for targeted gene/drug delivery, a rapid and tunable optimization platform is 
urgently desired. 
Based on the literature review in 2.4, it was expected that CD-based supramolecular 
building block strategy could be employed in developing multifunctional nanocarriers with 
complicated structures for gene and drug delivery.  





CHAPTER 3. CD-BASED SUPRAMOLECULAR GENE 
DELIVERY SYSTEM WITH BIOMIMETIC SWITCHABLE 
SHIELDING FOR STIMULI-RESPONSIVE P53 GENE 
DELIVERY 
3.1  Introduction 
Gene delivery holds great promise as a therapeutic approach for cancer. Cationic 
polymers are a major type of non-viral gene vectors with an attractive feature that they can be 
tailored and synthesized to meet the requirements for different gene delivery processes [192, 
193]. However, low gene transfection efficiency is a common disadvantage of these 
polymeric systems due to the multiple hurdles in the gene delivery processes such as low 
stability during extracellular transport, inefficient cellular internalization, slow endosomal 
escape, unpacking and release of gene, poor nuclear translocation, and potential cytotoxicity.  
Although methodologies are existing or under development for solving individual 
barriers in polymeric gene delivery processes, it is eventually a big challenge to design a 
multi-functional or smart polymeric system with multiple features incorporated and 
optimized to overcome these hurdles collectively to achieve an efficient and safe gene 
delivery [194, 195]. For example, to conjugate poly(2-methacryloyloxyethyl 
phosphorylcholine) (pMPC) to a gene carrier can sterically inhibit protein adsorption and 
enhance serum tolerance of the gene vector [196, 197], while the zwitterionic pMPC mimics 
the surface of natural phospholipid bilayer membranes and may facilitate cellular association 
to enhance cellular uptake [198-200]. Another example is to incorporate bioreducible 
disulfide linkage in polymer chains to make the gene delivery system to respond to biological 
reductive environment, and then achieve a balance between the protection and release of 
genes. The disulfide bond is prone to rapid cleavage in the cytosol that is a reductive 
environment (glutathione level 0.5-10 mM), but remains stable in extracellular environment 
(glutathione level 2-20 M) [44-46, 201].   
Herein, we demonstrate a prototype of “Molecular LEGO®” strategy for building a 
smart DNA carrier system with the functions of reduction-responsiveness and biomimetic 
switchable shielding for DNA delivery with significantly enhanced gene transfection 
efficiency. This delivery system is composed of two modular molecular building blocks: one 





host polymer and one guest polymer that can self-assemble to integrate multiple functions 
into one carrier system, based on the host-guest interaction between β-cyclodextrin (β-CD) 
and adamantyl (Ad) moieties in the host and guest, respectively. The host polymer is a star-
shaped multiple-arm pDMAEMA with β-CD as a core and bioreducible disulfide bonds as 
linkers (βCD-SS-P). The guest polymer is an adamantyl-end capped pMPC (Ad-pMPC). Like 
the assembly of LEGO
®
 bricks, βCD-SS-P and Ad-pMPC could be assembled to form a 
supramolecular pseudo-diblock copolymer (βCD-SS-P/Ad-pMPC), which can further 
compact DNA to form polyplex nanoparticles with pMPC as the corona (Figure 3.1). This 
design is expected to provide the polyplex nanoparticles with high extracellular stability and 
protein resistance due to the shielding effect of pMPC, as well as high efficiency of cellular 
internalization due to the membrane-mimic structure of pMPC. Once internalized into the 
cytoplasm, the payload DNA can be readily released because the disulfide bonds can be 
cleaved by the intracellular reductive environment. In this study, the βCD-SS-P/Ad-
pMPC/DNA polyplex system was systematically investigated in comparison with control 
systems such as non-bioreducible, and non-shielding or PEG shielding DNA polyplexes. It 
was revealed that the protein stability, serum tolerance, cellular uptake, and intracellular 
release of DNA were all greatly enhanced by the novel design, resulting in a highly efficient 
gene delivery system. Furthermore, the excellent gene delivery ability of the βCD-SS-P/Ad-
pMPC “Molecular LEGO®” assembly was applied for delivering the therapeutic p53 anti-
cancer gene. 






Figure 3.1 Conceptual illustration of the βCD-SS-P/Ad-pMPC supramolecular gene delivery 
system. (A) Formation of βCD-SS-P/Ad-pMPC pseudo-diblock copolymer via host-guest 
interaction, followed by DNA compaction to form βCD-SS-P/Ad-pMPC/DNA polyplex. (B) 
The protein-repellent properties of pMPC imparting the extracellular stability of the polyplex. 
(C) Favorable cellular association and efficient cellular uptake due to the biomimetic 
structure of pMPC corona. (D) Rapid intracellular unpacking and release of DNA owing to 
the redox-sensitive disulfide linkages followed by efficient gene transfection. 
3.2 Materials and Methods 
3.2.1 Materials 





β-Cyclodextrin (≥98%) was from Sigma-Aldrich and dried at 100 °C for 24 h under 
vacuum before use. N,N’-dimethylaminoethyl methacrylate (DMAEMA) was purified by 
passing it through an inhibitor removal column (Scientific Polymer Products, Inc.) before use. 
Renilla luciferase assay system was from Promega Co. (Maidson, WI). Coomassie PlusTM 
Protein Assay Reagent was purchased from Thermo Scientific, USA. D,L-Buthionine 
sulfoximine (BSO) (>99%) was from Sigma-Aldrich. All other reagents were used as 
received without further purification. 
3.2.2 Methods 
Synthesis of 2-(aminoethyl)disulfanylethylcarbamoyl-β-CD (βCD-SS-NH2). 
Briefly, β-CD (0.50 g, 0.44 mmol) was dissolved in 50 mL of anhydrous DMF. After all β-
CD was dissolved, the DMF solution of β-CD was dropwise to a solution of 1,1-
carbonyldiimidazole (CDI) (5.67 g, 35 mmol) in anhydrous DMF for a period of 3 h under 
nitrogen, then the mixture was allowed to stir at room temperature (R.T.) overnight. 
Subsequently, the resulting solution was precipitated with the mixture solution of 250 mL 
THF and 750 mL diethyl ether. The precipitated was collected by centrifugation and washed 
with THF. Then the resulting white powder was dissolved in 50 mL of anhydrous DMF and 
this solution was added dropwise into cystamine dihydrochloride (7.88 g, 35.00 mmol) and 
triethylenediamine (11.78 g, 105 mmol) which was dissolved in 50 mL anhydrous DMF with 
stirring at room temperature. After this addition, the reaction mixture was stirred at room 
temperature for 24 h. The final reaction mixture was precipitated in diethyl ether. The crude 
product was purified by dialysis. Yield: 0.55 g, 55.6%, based on a substitution of 5. Yield: 
0.55 g, 55.6%, based on a substitution of 5.  
Synthesis of -bromoisobutyric amidoethyl disulfanylethylcarbamoyl-β-CD (β-
CD-SS-Br). Briefly, to a solution of β-CD-SS-NH2 (0.40 g, 0.2 mmol), EDC
.
HCl (0.28 g, 1.5 
mmol), NHS (0.17 g, 1.5 mmol) in anhydrous DMSO was added 2-bromo-2-methylpropionic 
acid (0.20 g, 1.2 mmol). After being stirred for 24 h at room temperature, the reaction 
solution was directly dialyzed against distilled water to remove the solvent DMSO and the 
product was obtained by freeze dried after dialysis (MWCO 1000). Yield: 0.26 g, 43.6%, 
based on a substitution of 4.  
Synthesis of βCD-SS-pDMAEMA (βCD-SS-P). Generally, βCD-SS-Br (104 mg, 
0.04 mmol) and DMAEMA (1.88 g, 6 mmol) were added into a dry flask. Me6-TREN (55 mg, 
0.24 mmol) in 3 mL of DMSO/methanol (V/V 1:2) was added with a syringe. After de-





gassing, CuBr (22 mg, 0.16 mmol) was added to the mixture. The [DMAEMA]:[CD-
Br]:[CuBr]:[Me6-TREN] relative molar ratios were 15:1:1:1.5. The mixture was then heated 
at 70 °C in an oil bath. After 24 h, final green mixture was passed through a short Al2O3 
column to remove copper catalyst. The resulting solution was precipitated with hexane. The 
light yellow product was collected by centrifugation and dried under vacuum. The product 
was further purified by dialysis against water for 7 days (MWCO 2000), follow by 
lyophilized. Yield: 853 mg, 44.8%.  
Synthesis of -bromoisobutyric amidoethyl methanyl adamantane (Ad-Br). 2-
bromo-2-methylpropionic acid (0.20 g, 1.2 mmol) was added to a solution of 1-adamantane-
methylamine (0.20 g, 1.2 mmol), EDC
.
HCl (0.28 g, 1.5 mmol), NHS (0.17 g, 1.5 mmol) in 
anhydrous DMSO. The mixture was stirred for 24 h at R.T.. The product was obtained by 
dialysis (MWCO 1000) against water, followed by freeze-dried. Finally, the product was 
further purified by column chromatography with silica gel (hexane : ethyl acetate 3/1 as 
eluent). Yield: 0.26 g, 65%.  
Synthesis of Ad-pMPC. In a typical ATRP procedure, Ad-Br (31.2 mg, 0.1 mmol), 
MPC (0.89 g, 3 mmol) and 2,2’-bypyridine ligand (31.1 mg, 0.2 mmol) was dissolved in 3 
mL of methanol. This solution was deoxygenated before adding CuBr (14.3 mg, 0.1 mmol) 
into the flask. The [MPC]:[Ad-Br]:[CuBr]:[bpy] molar ratios were 20:1:1:2. The mixture was 
reacted at 40 ºC for 24 h. The final green mixture was directly dialyzed (MWCO 2000) to 
remove the catalyst and unreacted monomer, followed by freeze-dried. Yield: 0.79 g, 86%.  





spectra were recorded at room temperature on a Bruker Avance DRX 400 MHz NMR 
spectrometer operating at 400.1 and 100.6 MHz, respectively. Elemental analysis of the 
samples was carried out using a Perkin-Elmer 2400 CHN/CHNS elemental analyzer.  
Formation and characterization of βCD-SS-P/Ad-pMPC supramolecular 
pseudo-diblock copolymer. Solution of βCD-SS-P in deionized water was prepared with a 
concentration of 10 mg/mL. Determined amount of Ad-pMPC in deionized water (10 mg/mL) 
(mole ratio of βCD-SS-P:Ad-pMPC 1:1) was added into βCD-SS-P solution with moderate 
stirring. The mixture solutions were stirred at room temperature for 24 h, followed by freeze 
drying. Gel permeation chromatography (GPC) analysis was carried out with a Shimadzu 
SCL-10A and LC-10AT system equipped with a Sephadex G-50 column (size: 2.5 × 32 cm), 
and a Shimadzu RID-10 A refractive index detector. PBS buffer solution (0.5 ×) was used as 
the eluent at a flow rate of 1.0 mL/min at 25 °C. Monodispersed poly(ethylene glycol) (PEG) 





standards were used to obtain a calibration curve. To confirm the formation of pseudo-block 
copolymer, two-dimensional nuclear overhauser effect spectroscopy nuclear magnetic 
resonance (2D-NOESY NMR) was performed at 500 MHz in D2O on a Bruker Avance DRX 
500 NMR spectrometer. 
DTT reduction of βCD-SS-P/Ad-pMPC/DNA tertiary complexes. The in vitro 
disintegration of particles under redox-environment were measured. Briefly, the freshly 
prepared βCD-SS-P/Ad-pMPC/DNA tertiary complexes (N/P 30) were mixed with 20 mM 
DTT solution or PBS. The average diameter or zeta potentials of particles in PBS before DTT 
treatment, to, was measured by dynamic light scattering. Then mixture was incubated at 37 °C 
and determined at  indicated time interval, defined as ti. The change ratio of particle size and 
change ratio of zeta potential was calculated as ti/to.  
To investigate whether DNA would be released under reductive conditions, Picogreen 
assay was performed. Generally, 50 L of polymer in HBS buffer solutions (25 mM HEPES, 
150 mM NaCl, pH 7.4) was mixed with 1.0 g DNA (in 50 L of PBS) and incubated at 
room temperature. After 30 min, tertiary polyplexes were treated with same volume of 20 
mM DTT solution or PBS. At various determined time intervals, 100 L of diluted 
PicoGreen dye (Molecular Probes) was added and incubated for 10 min. Fluorescence was 
measured on Fluostar optima microplate reader (BMG Labtech, UK) with the wavelength 
fixed at 485 nm for excitation (lex) and 526 nm for emission (lem). The relative fluorescence 
(RF) was calculated using the following relationship:  
        RF (%) = (Fsample - Fblank)/(FDNA - Fblank)                                  (1) 
Where Fsample is the fluorescence of the polymer-DNA-PicoGreen sample, Fblank is the 
fluorescence of a sample only with PicoGreen, and FDNA is the fluorescence of DNA-
PicoGreen (polymer free). 
Stability of βCD-SS-P/Ad-pMPC/DNA system. Polyplexes (N/P 20) in PBS 
containing 20 g/mL of DNA were mixed with an equal volume of 10 wt% BSA dissolving 
in PBS. The mixture was incubated at 37 °C and particle size of particles were determined by 
dynamic light scattering at various time intervals, defined as ti. The average diameter of 
particles in PBS before BSA treatment, to, was also measured. The ratio of particle size 
change was calculated as ti/to. 
Protein adsorption. Complexes solution was prepared at N/P ratios of 20 with 120 
ug/mL of DNA as the final concentration. Briefly, 250L of complexes solution was 
incubated with 750 L of 4% BSA solution at 37 °C for 24 h. At predetermined time 





intervals the solution was centrifuged at 15,000 rpm for 5 min. The concentration of 
unadsorbed albumin in the supernatant was analyzed by Braford method. The absorbance was 
measured at 595 nm using microplate reader (Fluostar OPTIMA, BMG Labtech). The 
adsorbed protein was calculated as follows, protein adsorbed % =  (BSAtotal – BSAunabsorbed) / 
BSAtotal × 100%. 
Cell culture. Breast cancer MCF-7 cell line was purchased from ATCC, and 
maintained in DMEM media supplemented with 10% heat-inactivated FBS in a humidified 
CO2 incubator at 37 °C. 
Polymer and DNA labeling. FITC was conjugated to the hydroxyl group 
cyclodextrin. Briefly, 200 mg of polymer βCD-SS-P was dissolved in 4 mL of anhydrous 
DMSO, and 25 mg of FITC was added to the solution. The reaction solution was allowed to 
stir for 24 h at room temperature. After that, the solution was directly dialyzed against water 
(MWCO 3500) to remove the unreacted FITC and the product was then obtained by freeze 
dried. All the experiments were conducted in the dark. Yield: 190 mg, 90.4%. Plasmid DNA 
pRL-CMV was covalently labeled with CX-rhodamine LabelIT nucleic acid labeling kits 
(Mirus, USA) according to the manufacture’s protocol. The CX-rhodamine labeled DNA was 
used for cellular uptake and colocalization studies analyzed by flow cytometry and confocal 
microscope. 
In vitro luciferase expression. MCF-7 cells were seeded onto 24-well plates at a 
density of 8×10
4
 cells per well, with 500 L of DMEM medium supplemented with 10% FBS. 
After the confluence of the cells reaching to 70-80%, the culture medium was replaced to 
serum free medium. polymer/DNA complexes containing 1 g luciferase-encoded plasmids 
were added to each well. The culture media were changed back to medium containing 10% 
FBS after 4 h incubation. After 44-48 h incubation, media was removed and the cells were 
washed with PBS for three times. The relative light units (RLU) were determined using a 
luminometer (Lumat Lb 9507, Berthold technologies), and normalized to protein content 
using coomassie plus protein assay. The experiments were expressed as g of luciferase per 
mg of protein. 
In vitro green fluorescence protein (GFP) expression. Plasmid pEGFP-N1 
(Clontech Laboratories Inc., USA), encoding a red shifted variant of wild type GFP, was used 
to examine the transgene ability of polymers. Transfection procedures were similar to the 
luciferase gene transfection described above. The transfection efficiency was quantified by 
the percentage of cells expressing GFP, analyzed by flow cytometry using a FACS Caliber 





System from Becton-Dickinson (San Joes, CA). The levels of GFP expression were also 
observed using fluorescence microscopy (Olympus, Japan). 
Cytotoxicity of βCD-SS-P/Ad-pMPC/DNA complexes. MCF-7 cell (2×104 
cells/well) were seeded in 96-well plates in 0.1 mL growth medium and incubated for 20-25 h 
prior to the addition of polyplexes. The cells were incubated with 0.1 mL fresh serum-free 
medium containing polymer/DNA complexes at various N/P ratios with 0.25 g of DNA. 
Medium containing complexes were replaced by complete medium after 4 h. After additional 
incubation for 44 h in complete medium, 20 L of MTT stock solution (5 g/mL in PBS) was 
added. After 4 h incubation, the formazan crystals were dissolved in DMSO (150 L/well), 
absorbance was measured at 595 nm. The cell viability (%) was calculated according to the 
following equation: cell viability (%) = OD595(sample)/OD595(control) × 100, where sample was 
the well treated with polymer and control represented the well treated with serum free 
medium only. For investigation of cell viability changed after treated with BSO, cells were 
pre-treated with 500 M of BSO for 18 h prior to adding complexes solution. The other 
procedures were the same as described above.  
Confocal microscope observation of intracellular release of DNA. MCF-7 cells 
were transfected by fluorescent polyplexes on MatTek 8 well chamber. After the transfection, 
the cells were fixed by 4% paraformaledhyde and the nuclear was stained using 2 g/mL of 
DAPI for 15 min. And the cells were visualized with an Olympus FV1000 confocal laser 
scanning microscope (CLSM) equipped with a 100× 1.6NA oil immersion objective lens.  
To evaluate the intracellular distributions of DNA and carrier polymer, the ratio of 
colocalization of FITC labeled polymer and CX-rhodamine labeled DNA was calculated 
from the obtained images using ImageJ software[202], as follows 
                                          
   -         -        -       
   -         -   
            (2) 
where FCX-rhodamine-DNA+FITC-polymer means pixels of CX-rhodamine-DNA co-localized 
with FITC-polymer, and FCX-rhodamine-DNA means the pixels of all intracellular rhodamine 
labeled DNA. The results were expressed as means and standard deviation obtained from 20 
cells at each specific time point.  
Quantitative evaluation of intracellular DNA release using PicoGreen assay. To 
determine the amount of DNA release from βCD-SS-P/Ad-pMPC/DNA polyplex inside the 
cells, PicoGreen dye exclusion assay was performed. Briefly, MCF-7 cells were seeded in 12-
well plates (15×10
4
) and incubated for 20 to 24 h. Polymer/DNA polyplexes were added and 





the cells were incubated at 37 ºC for 2 h. After determined incubation time, cells were 
washed with PBS twice and lysed in 200 L of lysis buffer (1% Triton X-100 in PBS) or 
lysis buffer (1% Triton X-100, 2% SDS in PBS) for 30 min. Lysates were centrifuged at 
15,000g for 15 min at 4 ºC. Then 100 L of supernatant was mixed with diluted PicoGreen 
for 10 min at room temperature and then transferred to a black 96-well plate for fluorescence 
measurement. The fluorescence was analyzed using an FITC setting (excitation 485 nm, 
emission 526 nm). The percentage of relative fluorescence (RF) was calculated using the 
following equation:  
       
 Fsample treate   it      riton  -    – Fblank
Fsample treated with 1% Triton X-100 and 2% SDS-Fblank
×100%                                (3) 
where Fsample treated with 1% Triton X-100) is the fluorescence induced by free DNA in the cell 
lysate, and Fsample treated with 1% Triton X-100 and 2% SDS is the fluorescence induced by whole DNA 
inside the cell (2% SDS could release DNA from polymer/DNA complexes), and Fblank is the 
fluorescence induced by untreated cells.  
Gene transfection of MCF-7 after D,L-buthionine sulfoxamine treatment. For 
investigation of transfection efficiency for cells after treatment with D,L-buthionine 
sulfoxamine (BSO), cells were pre-treated with 500 M of BSO solution (diluted by 20 mM 
stock solution in PBS) for 18 h prior to transfection. The rest procedures were the same as the 
transfection protocol depicted in supplementary methods.  
Cell viability of MCF-7 after BSO treatment. For investigation of cell viability 
after cells were treated with BSO, cells were pre-treated with 500 M BSO for 18 h prior to 
adding complexes solution. The other procedures were the same as the cell viability 
evaluation methods described in supplementary methods. 
Effects of serum concentration on transfection. The process of transfection 
experiments was similar to that described in supplementary methods, except that medium at 
the time of transfection was replaced with DMEM containing various serum concentrations 
(0, 5, 10, 20, 30, and 50%). 
Investigation of cellular uptake of polymer/DNA polyplexes. Briefly, MCF-7 cells 
were seeded in 12-well plates (15,000 cells per well) and allow to attach and grow for 20 to 
24 h. The cells were then incubated with the polymer/DNA polyplexes (2 g of DNA per 
well, optimal N/P ratio of each sample), prepared with fluorescence labeled DNA in various 
FBS concentrations of DMEM medium. At different determined time, polyplex solution was 
removed. After the cells were washed with PBS for three times, the cells were collected and 





fixed in 4% parafomaldehyde. The samples were assessed by flow cytometry and confocal 
microscope. 
Delivery of therapeutic p53 gene. MCF-7 cells were transfected with polyplexes 
containing p53-encoded plasmid. The transfection procedures were the same as those for 
luciferase and GFP plasmids. To measure the extent of p53 mRNA expression level upon 
transfection, quantitative real-time PCR technique was employed. To measure the p53 protein 
expression level after transfection, western blotting was performed. To monitor cell cycle 
arresting, MCF-7 cells were analyzed 48 h after transfection using propidium iodide staining 
methods. To investigate if p53 transfection induced cell apoptosis, the status of p53 
transfected cells were analyzed 72 h post transfection using FITC Annexin V/Dead Cell 
Apoptosis Kit by flow cytometry. 
p53 mRNA expression level. MCF-7 cells were seeded on 24-well plate at cell 
density of 80,000 cells/well. After 24 h incubations, cells were transfected with polymer/p53 
complexes for 4 h. 48 h post transfection, total RNA was extracted from cells by using 
Qiagen RNEasy Mini Kit. The RNA was reverse transcribed with Oligo(dT) (invitrogen) 
according to the manufacture’s protocol. Real-time PCR was performed on 1 L of cDNA 
with the SYBR Green PCR Kit (Qiagen) according to the manufacturer’s instructions. The 
p53 primers used for the RT-PCR experiment was as follows: Forward: 5’-
CCGCAGTCAGATCCTAGCG-3’; Reverse: 5’-AATCATCCATTGCTTGGGACG-3’. The 
actin primers were used as follows: Forward: 5’-TACCTCATGAAGATCCTCACC-3’; 
Reverse: 5’-TTTCGTGGATGCCACAGGAC-3’. Amplification conditions were shown as 
follows: 35 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s, and 
extension at 72 °C  for 30 s with a  iCycler (Bio-rad).  
Western-blotting. After transfection with polymer/p-53 complexes, cells were lysed 
with 50 L of RIPA lysis buffer (Thermo Scientific) containing protease inhibitor. Samples 
were mixed with western blot loading buffer and β-mercaptoethanol and boiled for 5 min at 
95 °C. The proteins were separated on a 14% SDS-PAGE gel. The proteins were transferred 
to a 0.2 m PVDF membrane by wet transfer cell (Bio-Rad). After electrophoresis, the 
membranes were blocked for 30 min with PBS-Tween containing 5% bovine serum albumin 
at room temperature. The p53 protein was detected by incubating the membranes with the 
primary antibody, a anti-rabbit p53 (1:500, Santa Cruz) 1 h at room temperature, followed 
with the secondary antibody, HRP-labeled goat anti-rabbit IgG (1:5000 dilution, life 
technology) for 1 h at room temperature. Proteins were detected by enhanced chem-





illuminescence (ECL, Pierce). Anti-β-actin (Cell Signal) was used as the protein loading 
control. 
Cell cycle analysis. To monitor cell cycle arresting, cells were transfected using 
polymer/p53 complexes for 4 h and detected 48 h after transfection. The cells were washed 
with PBS, trypsinized, centrifuged and fixed in 75% ethanol at -20 °C overnight. The fixed 
cells were centrifuged, washed with 0.01% Triton X-100 (Sigma)  containing PBS followed 
by 2× washing with PBS. Then the cells were re-suspended in PBS containing 50 g/mL 
propidium iodide (PI) and 200 g/mL RNaseA (Thermo Scientific). The cell suspension was 
incubated at 37 °C for 30 min and analyzed using flow cytometry. The histograms of number 
of cells versus PI intensity were analyzed quantitatively to determine the percentage of cells 
in each of the G0/G1, S and G2/M phases. 
Cell apoptosis analysis. MCF-7 cells were transfected by polymer/p53 complexes for 
4 h. After 72 h additional incubation, cells were trypsinized and collected in 1.5 mL 
microcentrifuge tubes, centrifuged an washed using 1× PBS. The cells were resuspended in 
1× annexin binding buffer containing FITC-annexin V and PI following the instruction of 
FITC Annexin V/Dead Cell Apoptosis Kit (Invitrogen). The cells were incubated for 15 min 
at room temperature in dark. The number of viable, apoptotic and dead cells were quantified 
by flow cytometer (Beckman Coulter), and analyzed for 10,000 cells using the FCS Express 4 
Flow Research software. 
Statistical analysis. Statistical analysis was conducted using variance tests (ANOVA) 
with Microsoft Excel 2007. Data sets were compared using two-tailed, unpaired t-test. p 
value of < 0.05 was regarded statistically significant. 
3.3 Results and Discussion 
3.3.1 Synthesis and characterization of host polymer βCD-SS-pDMAEMA (βCD-SS-P) 
The synthesis scheme of host cationic polymer CD-SS-P was shown in Figure 3.2 (A). 
To prepare bioresponsive star-shaped polymer using β-CD as a core via ATRP, the β-CD-
based macroinitiator was firstly prepared. Firstly, disulfide linkages were introduced to β-CD 
to form CD-SS-NH2 by activating the hydroxyl groups of β-CD with 1,1’-
carbonyldiimidazole (CDI), followed by reaction with large excess of cystamine. Secondly, 
the primary amine groups of CD-SS-NH2 were reacting with -bromoisobutyric acid, in the 





presence of EDC and NHS, producing CD-SS-Br as the ATRP macroinitiator. The well-
defined βCD-SS-P star shaped polymer, consisting of β-CD core and pDMAEMA arms with 
disulfide bond linkages, was subsequently prepared via ATRP of DMAEMA monomer using 
CD-SS-Br as the macroinitiator, in the presence of Cu(I) bromide as catalyst and Me6-TREN 
as ligand. According to references regarding ATRP methods[178, 179] and pre-experiments, 
it was found that the optimized reaction conditions were methanol/DMSO (V/V 2/1) as the 
reaction solution, and the initial molar ratio of [monomer]:[initiator]:[CuBr]:[Me6-TREN] 
was 15:1:1:1.5. 
 
Figure 3.2 (A) Synthesis scheme of host cationic polymer βCD-SS-P. (B) 1H NMR spectra 
(400 MHz) of β-CDβCD-SS, βCD-SS-Br, and βCD-SS-P. (C) 13C NMR spectrum of βCD-
SS-Br and βCD-SS-P.  





The representative structures of βCD, βCD-SS-NH2 and βCD-SS-Br were 
characterized by 
1
H NMR and 
13
C NMR as shown in Figure 3.2 (B) and Figure 3.2 (C). The 
assignments of the corresponding signals of compounds were shown in detail.  
βCD-SS-NH2, 
1H NMR (400 MHz, DMSO): δ 5.00 (brs, 7 H, H-1 of -CD), 3.30 – 
3.70 (m, 48 H, H-3, 5, 6a, 6b, 4, 2 of -CD), 2.56 – 3.05 (m, 16 H, -CH2- of cystamine). By 
comparing the integration of the signals for the methyl protons of cystamine (-SS-CH2CH2-, a, 
b-d, 2.56 – 3.05 ppm) to those for the 1 –positioned protons (-C(1)H) of -CD in the region 
of 5.00 ppm, the degree of substitution (DS) was estimated. The value was calculated to be 5 
for the purified CD-SS-NH2. 
βCD-SS-Br, 1H NMR (400 MHz, DMSO): δ 5.00 (brs, 7 H, H-1 of -CD), 3.30 – 3.70 
(m, 48 H, H-3, 5, 6a, 6b, 4, 2 of -CD), 2.56 – 3.05 (m, 16 H, -CH2- of cystamine), 1.86 (s, 
19 H, -CH3). By comparing the integration of the signals for the methyl protons (-
C(C(e)H3)2Br, 1.86 ppm) of the initiation group to those for the 1-positioned protons (-C(1)H) 
of -CD in the region of 5.00 ppm, the DS was estimated. The value was calculated to be 4 
for the purified macroinitiator CD-SS-Br.   
βCD-SS-P, 1H NMR (400 MHz, D2O): δ 4.10 (brs, 240 H, -OCH2- of PD), 2.66 (brs, 
240 H, -NCH2- of PD), 2.26 (brs, 360 H, -NCH3 of PD), 1.84 (brs, 360 H, -CBrCH3- of PD), 
0.62 – 1.20 (m, 240 H, -CBrCH2- of PD). As shown in the 
1H NMR spectrum of βCD-SS-P, 
the proton resonance signals corresponding to pDMAEMA arms and β-CD core were 
observed. By comparing the integration of the signals for the pDMAEMA (-N(CH3)2, around 
2.26 ppm) to those for the 1-positioned protons (-C(1)H) of -CD in the region of 5.00 ppm, 
the degree of polymerization (DP) was calculated. The value was determined to be 58, which 
was consistent with the results of elemental analysis shown in Table 3.1.  










N% C% H% S% N% C% H% S% 
βCD-SS CD1SS5 6.91 39.78 5.98 15.82 7.02 39.28 5.21 16.02 
βCD-SS-Br CD1SS5Br4 6.93 37.77 5.52 15.86 6.69 37.84 4.88 15.87 
βCD-SS-P CD1SS5Br4P58 9.20 53.80 8.33 3.98 9.18 53.67 8.31 4.09 
a
 The compounds are denoted CDxSSyPDn where x are number of cyclodextrin, y are 




 Theoretical elemental analysis calculated for the corresponding compound. 
c
 Elemental analysis found. 
 
CD-SS-P, 13C NMR (400 MHz, D2O): δ 63.3 (C-NMe and C-O of PDMAEMA), 
58.7 (C-CO of PDMAEMA), 46.0 (NCH3 of PDMAEMA). 





3.3.2 Synthesis and characterization of guest polymer Ad-pMPC 
The macromolecular guest adamantyl-based zwitterionic polymer Ad-pMPC was 
obtained according to the reaction sequence described in Figure 3.3 (A): (1) The ATRP 
initiator bromoisobutyryl-terminated adamantane (Ad-Br) was synthesized via the reaction of 
primary amino groups of 1-adamantanemethylamine with 2-bromo-2-methylpropionic acid 
using EDC as the crosslinker. (2) The well-defined Ad-pMPC zwitterionic polymer was 
subsequently prepared via ATRP of MPC monomer using Ad-Br as the macroinitiator.  
 
Figure 3.3 (A) Synthesis scheme of guest polymer Ad-pMPC. (B) 
1
H NMR spectra (400 
MHz) of d-NH2d-Br and Ad-pMPC. (C) 
13
C NMR spectrum of Ad-pMPC in D2O. 
The representative structures of Ad-Br, Ad-NH2 and Ad-pMPC were characterized by 
1
H NMR and 
13
C NMR as shown in Figure 3.3 (B) and Figure 3.3 (C). The DP of Ad-pMPC 
was calculated to be 18 by elemental analysis shown in Table 3.2. 
Ad-Br, 
1H NMR (400 MHz, DMSO): δ 3.51 (s, 2 H, -CH2NH2), 1.91 (s, 3 H, -CH-), 
1.88 (s, 6 H, -CH3), 1.52 – 1.70 (m, 6 H, -CH2-), 1.44 (brs, 6 H, -CH2-). 







H NMR (400 MHz, D2O): δ 3.95 – 4.32 (m, 180 H, -CH2PO2- and -
OCH2-), 3.64 (m, 60 H, -CH2N-), 3.20 (s, 270 H, -NCH3), 1.50 – 2.15 (m, 60 H, -CH2CBr-), 
0.70 – 1.15 (m, 90 H, -BrCCH3-).  
Ad-Br, 
13
C NMR (400 MHz, D2O) δ 54.6 (s, 270 H, –N
+
(CH3)3). 









N% C% H% N% C% H% 
Ad-Br Ad1Br1 4.50 56.52 7.64 7.02 39.28 5.21 
Ad-pMPC Ad1pMPC18 5.55 48.72 8.08 5.54 48.78 8.08 
a
 The compounds are denoted AdxPMPCn where x is number of Br and n is number of MPC 




 Theoretical elemental analysis calculated for the corresponding compound. 
c
 Elemental analysis found. 
 
3.3.3 Formation of βCD-SS-P/Ad-pMPC supramolecular pseudo-diblock copolymer.  
The βCD-SS-P/Ad-pMPC supramolecular pseudo-diblock copolymer was formed by 
mixing the host and guest polymers at 1:1 molar ratio in aqueous solution. The GPC analyses 
were performed for βCD-SS-P/Ad-pMPC supramolecular copolymer in comparison with 
βCD-SS-P, Ad-pMPC, and the βCD-SS-P/pMPC physical mixture, where pMPC is a control 
polymer without adamantyl end cap (Figure 3.4 (A)). The GPC diagram of the βCD-SS-
P/Ad-pMPC supramolecular copolymer showed one unimodal elution peak, while two peaks 
were observed for the βCD-SS-P/pMPC physical mixture. The βCD-SS-P/Ad-pMPC 
supramolecular copolymer gave higher MW (Mn = 12.9 kDa, Mw/Mn = 1.12) than either 
βCD-SS-P host star polymer (Mn = 9.1 kDa, Mw/Mn = 1.13) or Ad-pMPC guest polymer 
(Mn = 4.9 kDa, Mw/Mn   1.18), suggesting that βCD-SS-P and Ad-pMPC were self-
assembled through inclusion complexation between β-CD and Ad moieties. 
To further confirm the formation of βCD-SS-P/Ad-pMPC supramolecular copolymer, 
1:1 inclusion complex of βCD-SS-P and Ad-pMPC in D2O was studied by 2D-NOESY NMR 
spectroscopy (Figure. 3.4 (B)). A series of NOE cross peaks between the inner protons of 
C(3)H and C(5)H of β-CD and the methane (Hb) and methylene (Hc) protons of the Ad were 
observed. The results indicate that the adamantyl moiety entered into the hydrophobic cavity 
of β-CD to form the host-guest inclusion complex. No intermolecular NOE interaction 
between the Ha proton of Ad and the protons of the β-CD torus could be found in the 
spectrum, indicating that the adamantyl group entered β-CD core from the wide side of β-CD, 





but not from the narrow side. Thus, the NMR spectroscopic studies gave clear evidence that 
the supramolecular pseudo-diblock copolymer was formed via host-guest inclusion 
complexation between the β-CD core and the adamantyl unit. 
In order to test the biodegradation of the βCD-SS-P/Ad-pMPC supramolecular 
copolymer, the samples were incubated in PBS with and without the reducing agent 
dithiothereitol (DTT) that simulates the intracellular redox-potentials, and the degradation 
was monitored by GPC (Figure 3.4 (C)). After 4 h DTT treatment, a series of lower MW 
peaks were observed and the polydispersity increased significantly. In contrast, the MW of 
the supramolecular polymer did not change at all under the non-reducing environment in PBS. 
The results indicate that the βCD-SS-P/Ad-pMPC supramolecular copolymer is degradable 
under the reducing conditions, while physiological ionic strength will not affect its MW. This 
redox-sensitive biodegradation property is crucial to the in vivo application of the gene carrier. 
 
Figure 3.4 Formation of βCD-SS-P/Ad-pMPC supramolecular pseudo-diblock copolymer. (A) 
Representative GPC traces obtained for βCD-SS-P, Ad-pMPC, physical mixture of βCD-SS-
P and pMPC at 1:1 molar ratio (the degree of polymerization of pMPC was the same as Ad-
pMPC), and inclusion complex of βCD-SS-P/Ad-pMPC at 1:1 molar ratio. (B) 2D-NOESY 
NMR spectra of the 1:1 host-guest inclusion complex of βCD-SS-P and Ad-pMPC in D2O 
(300 MHz). Left, full scale; and right, selected scale. (C) GPC traces of CD-SS-P/Ad-pMPC 
supramolecular copolymer after incubation in PBS without and with DTT (20 mM) for 4 h at 
37 °C. 





Further, the βCD-SS-P/Ad-pMPC supramolecular copolymer had good DNA binding 
ability, forming DNA polyplex nanoparticles with size ranging from 110 to 150 nm and zeta 
potential ranging from 18 to 25 mV when N/P ratios were 10 to 40 (Figure 3.5).  
 





Figure 3.5 (A) DNA binding ability of polymers evaluated by gel retardation assay. (B) 
Particle size of polymer/DNA complexes at various N/P ratios. Data presented mean ± S.D. 
(n=3). (C) Zeta potentials of polymer/DNA complexes at various N/P ratios. Data present 
mean ± S.D. (n=3). (D) TEM images of particles Scale bar = 200 nm. 
3.3.4 Effect of disulfide bond on intracellular release, cytotoxicity, and gene 
transfection.  
Prior to investigating the effect of disulfide bond on intracellular release of DNA, we 
demonstrated that the βCD-SS-P/Ad-pMPC/DNA polyplex nanoparticles were stable and 
DNA was well protected in saline solution, while the deshielding, polyplex dissociation, and 
DNA release took place rapidly in a solution with DTT (20 mM) that simulates the reducing 
condition in the cytoplasm (Figure 3.6). 
 
Figure 3.6 Disintegration of βCD-SS-P/Ad-pMPC/DNA particles in reducing conditions. (A) 
Particle size changes kinetics of DNA complexes in the absence (dash line) or presence (solid 
line) of 20 mM DTT. (B) Zeta potential changes kinetics of DNA complexes in the absence 
(dash line) or presence (solid line) of 20 mM DTT. (C) Time-dependent DNA release of 
particles in the absence (dash line) and presence (solid line) of 20 mM DTT, determined by 
PicoGreen dye exclusion assay. The results were reported as a percentage of the PicoGreen 
fluorescence observed for DNA only. Data represent mean ± S.D., n=3. 
The intracellular degradation of βCD-SS-P/Ad-pMPC/DNA polyplexe and release of 
DNA were traced by observing the intracellular trafficking of fluorescence labeled βCD-SS-
P/Ad-pMPC/DNA nanoparticles using CLSM at various time points (Figure 3.7 (A)). The 
colocalization of FITC-labeled polymer βCD-SS-P/Ad-pMPC (green) and rhodamine-labeled 
DNA (red) would produce a yellow fluorescence in merged images. Otherwise, if the DNA is 
released from the polyplex, the green signals of FITC-polymer and the red signals of 
rhodamine-labeled DNA would appear separately. For non-degradable control system βCD-
P/Ad-pMPC, even after 12 h incubation, there were still a large number of yellow dots 
(marked by white arrows) distributed within the cytoplasm in the merged images, produced 
by the colocalization of FITC-βCD-P and rhodamine-DNA, indicating that the release of 





DNA was very slow. In contrast, for the redox-responsive system βCD-SS-P/Ad-pMPC, the 
number of red dots increased and the yellow dots decreased quickly in the merged images, 
indicating that DNA was rapidly released due to the dissociation of the polyplex with the 
cleavage of the disulfide linkages. Moreover, the area of green pixels decreased with time, 
which may be a result of the removing of the β-CD fragments (β-CD was FITC-labeled) from 
the cells after the degradation.  
The polymer-DNA colocalization ratio is plotted against incubation time (Figure 3.7 
(B)). For the non-degradable control system βCD-P/Ad-pMPC, the colocalization ratio 
remained very high after a long incubation time, being 86.8% at 12 h, and even 58.4% at 48 h. 
However, for the redox-responsive system βCD-SS-P/Ad-pMPC, the colocalization ratio 
decreased quickly to 43.5% at 12 h and 10.4% at 48 h, which was significantly lower than 
that of non-degradable system.
The kinetics of the intracellular release of DNA was further quantitatively studied by 
using PicoGreen assay. The percentage of released DNA of all internalized DNA at various 
time points is shown in Figure 3.7 (C). The unpacking and release of internalized DNA from 
all non-degradable carrier systems occurred in a slow manner over the course of 48 h. The 
cumulative release of DNA at 24 h was only 26.4%, 33.4%, and 37.5% for PEI 25k, βCD-P, 
and βCD-P/Ad-pMPC, respectively. In contrast, the release of DNA from both redox-
sensitive βCD-SS-P and βCD-SS-P/Ad-pMPC polyplexes was marked by a burst release 
within the first 12 h, due to the cleavage of the disulfide linkages within the cells. The 
cumulative release of DNA at 24 h was 81.2% and 84.9% for the two redox-sensitive carrier 
systems, respectively. The results suggest that the βCD-SS-P/Ad-pMPC/DNA polyplex 
exhibited not only rapid, but also complete release of internalized DNA within the cells.  
 






Figure 3.7 Effects of disulfide linkages of βCD-SS-P/Ad-pMPC/DNA polyplex system on 
intracellular DNA release, cytotoxicity, and gene transfection. (A) Confocal microscope 
images showing cellular distribution of FITC-labeled polymers (green) and CX-rhodamine-
labeled DNA (red) in MCF-7 cells at different time points post transfection. FITC 
fluorescence dye was labeled to the hydroxyl groups of β-CD of the host polymer. Cell nuclei 
were stained with DAPI (blue). Colocalization of DNA and polymer appeared yellow in 
merged images, indicating DNA was bound with cationic polymer. Scale bar is 10 m. (B) 
Ratio of colocalization of CX-rhodamine-labeled DNA and FITC-labeled polymer at various 
time points calculated from the number of pixels using ImageJ. Data represent means ± S.D. 
for 20 cells (*p < 0.05, **p < 0.01). (C) Cumulative intracellular release of DNA (the 
percentage of released DNA of all internalized DNA) at various time points measured by 
PicoGreen assay after cell lysis. Data represent means ± S.D. (n=3). (D) Cytotoxicity of 
βCD-SS-P/Ad-pMPC/DNA and other control polyplexes in MCF-7 cells pre-treated without 
and with BSO (500 M). BSO was used to deplete intracellular GSH. (E) GFP transfection 
using pEGFP-N1 mediated by (a) βCD-P/Ad-pMPC and (b) βCD-SS-P/Ad-pMPC complexes 
in MCF-7 cells pre-treated without and with BSO (Left panel: Flow cytometric histograms of 
GFP-transfected cells. Black line: cells without GFP transfection; Red line: cells with GFP 
transfection but without BSO pre-treatment; Blue line: cells with GFP transfection and BSO 





pre-treatment. Right panel: Fluorescence microscopy images of cells with GFP transfection; 
Scale bar is 100 m).  
The cytotoxicity of βCD-SS-P/Ad-pMPC on MCF-7 cells was significantly lower than that 
of non-degradable PEI 25k and βCD-P carriers in the forms of both DNA polyplexes (Figure 
3.8 (A)) and polymer alone (Figure 3.8 (B)). To examine whether the improved cytotoxicity 
profile of βCD-SS-P/Ad-pMPC was ascribed to the cleavage of the disulfide bonds that is 
associated with the intracellular glutathione (GSH) levels, the cytotoxicity of the polymers 
was further evaluated in the cells treated with and without D,L-buthionine sulfoxamine (BSO) 
[203]. BSO is known as GSH inhibitor, leading to depletion of intracellular GSH. It is 
believed that no intracellular cleavage of disulfide linkages will occur once the GSH is 
depleted. As shown in Figure 3.7 (D), it was clearly observed that the depletion of 
intracellular GSH by BSO led to significant elevation of cytotoxicity of the redox-responsive 
system βCD-SS-P/Ad-pMPC, approximately up to the level of its non-degradable analogue 
βCD-P/Ad-pMPC. As expected, both non-degradable PEI 25k and βCD-P/Ad-pMPC did not 
show such cytotoxicity dependence on the GSH level. Thus, it was proved that the 
intracellular degradation of the βCD-SS-P/Ad-pMPC pseudo-copolymer contributed to the 
low cytotoxicity. 
   
Figure 3.8 Cytotoxicity of CD-SS-P/Ad-pMPC carrier system in comparison with other 
systems in MCF-7 cells. (A) Cell viabilities of polymer/DNA polyplexes at different N/P 
ratios. Data were expressed as mean ± S.D. (n=3). (B) Cell viabilities of polymer alone at 
various concentrations. Data represent mean ± S.D. (n=3). 
The gene transfection efficiency of the gene carriers was evaluated by luciferase and 
green fluorescence protein expression using pRL-CMV plasmid. The luciferase gene 
transfection efficiency of βCD-SS-P was 4 to 30 folds higher than that of PEI 25k and βCD-P 
controls (Figure 3.9). Similarly, βCD-SS-P/Ad-pMPC showed much higher GFP gene 





transfection efficiency than βCD-P/Ad-pMPC (Figure 3.7 (E)). The gene transfection 
experiments were done in MCF-7 cells pre-treated without and with BSO, thereby the 
transfection efficiency under normal and low GSH levels was compared. For the non-
degradable βCD-P/Ad-pMPC, the GFP positive cell counts were 48% (without BSO 
treatment) and 44% (with BSO treatment). In such case, the gene transfection efficiency was 
not affected by the treatment of BSO. For βCD-SS-P/Ad-pMPC, the GFP positive cell counts 
were 78% (without BSO treatment) and 45% (with BSO treatment). As expected, the 
depletion of intracellular GSH led to much lower protein expression level. These results 
confirmed that the intracellular cleavage of disulfide linkages of βCD-SS-P/Ad-pMPC 
polyplexe and thereby rapid DNA release did play a crucial role in improving the gene 
transfection efficiency.  
 





Figure 3.9 (A) In vitro transfection efficiency of polymer/DNA polyplexes at various N/P 
ratios in the absence of fetal bovine serum in MCF-7 cell line. Transfection was performed at 
a dose of 0.5 g of pRL-CMV DNA per well. PEI 25k was used as positive controls. (B) 
Effect of BSO on luciferase expression mediated by polymer/DNA polyplexes. BSO was 
used to deplete the intracellular GSH. Data represent mean ± S.D. (n=3) ** p < 0.01. 
3.3.5 Serum stability of βCD-SS-P/Ad-pMPC/DNA polyplex nanoparticles.  
It is known that transfection efficiency is significantly reduced by the presence of 
serum for most of the cationic polymer gene delivery systems [204]. In this study, one of the 
purposes to introduce Ad-pMPC zwitterionic polymer block was to enhance the serum 
tolerance of the gene delivery system. The dynamic light scattering (DLS) and protein 
adsorption measurements showed that the shielding of pMPC block prevented the 
aggregation of the βCD-SS-P/Ad-pMPC/DNA polyplex nanoparticles and also greatly 
suppressed the protein adsorption of the polyplex nanoparticles (Figure 3.10).  
   
Figure 3.10 Stability of βCD-SS-P/Ad-pMPC/DNA polyplex in protein environment. (A) 
Change in nanoparticle size of polymer/DNA polyplexes in PBS containing 10 wt% BSA at 
37 °C, as determined by dynamic light scattering. (B) Protein adsorption by polymer/DNA 
nanoparticles at various time points. Data represent mean ± S.D. (n=3). 
Here, the effect of pMPC decoration on serum tolerance was investigated in MCF-7 
cell culture system (Figure 3.11). The presence of serum significantly reduced the luciferase 
expression of Lipofectamine 2000, PEI 25k, βCD-P, and βCD-SS-P (Figure 3.11 (A)). All 
these non-shielding vector systems suffered at least 10
3
 times reduction in transfection 
efficiency in the presence of 50% FBS as compared to the serum free condition. However, 
the βCD-SS-P/Ad-pMPC system exhibited very stable transfection levels at various FBS 
concentrations. At 50% serum concentration, it still maintained 35% transfection efficiency 
as compared to that under serum free condition. On the other hand, at 50% serum 





concentration, βCD-SS-P/Ad-pMPC system showed 103 times higher luciferase expression 
than βCD-SS-P alone, suggesting the zwitterionic Ad-pMPC shell greatly improved the 
serum tolerance of the gene delivery system. 
Flow cytometry and confocal microscope were employed to measure the cellular 
uptake of the polyplex nanoparticles formed by CX-rhodamine-labelled DNA and βCD-SS-
P/Ad-pMPC at different serum concentration levels, in comparison with the non-pMPC 
modified control. Figure 3.11 (B) displays the flow cytometry histograms, from which the 
fluorescence intensity of cells and the relative number of cells internalized with CX-
rhodamine labeled DNA were obtained at different serum concentration levels (Figure 3.11 
(C)). For non-pMPC modified βCD-SS-P, the presence of serum significant decreased the 
fluorescence intensity of the cells as well as the relative DNA-positive cell number, 
indicating a significant decrease in cellular uptake efficiency of the polyplex nanoparticles. 
However, the cellular uptake efficiency for βCD-SS-P/Ad-pMPC polyplex nanoparticles 
showed nearly no changes with the increase in serum concentration. In addition, similar 
trends were observed by confocal microscope (Figure 3.11 (D)). For the βCD-SS-P system, 
the increase in serum concentration caused significant decrease in red color dots, 
corresponding to the decrease in CX-rhodamine labeled DNA concentration in the cells. 
However, for the βCD-SS-P/Ad-pMPC system, the CX-rhodamine labeled DNA 
concentration in the cells showed no clear changes with increase in the serum concentration. 
Evidently, βCD-SS-P/Ad-pMPC polyplex nanoparticles showed significantly high cellular 
uptake efficiency at high serum concentrations, which was due to the pMPC shell that 
provided shielding and stability for the polyplex nanoparticles against serum.  






Figure 3.11 Evaluation of serum-tolerance of βCD-SS-P/Ad-pMPC/DNA system in MCF-7 
cell culture with various serum concentrations. (A) Gene transfection efficiency of βCD-SS-
P/Ad-pMPC/DNA polyplex. Non-pMPC systems were used as controls. Data represent mean 
± S.D. (n=3). (B) Flow cytometric analysis for cellular internalization of polyplex 
nanoparticles. CX-rhodamine labeled DNA was used. (C) Gated mean fluorescence intensity 
(MFI) of cells (solid dots + lines) and relative number of cells with CX-rhodamine labeled 
DNA internalized (empty dots without lines) measured by flow cytometry after 4 h of 
incubation with polyplex nanoparticles. Data represent mean ± S.D. (n=3). (D) Confocal 
microscopic images of MCF-7 cells after 4 h of incubation with polyplexes containing 0.5 g 
of CX-rhodamine-labeled DNA (N/P ratio = 20). Scale bar: 10 m. 
3.3.6 Biomimetic cellular uptake of βCD-SS-P/Ad-pMPC/DNA polyplex nanoparticles.  
In this study, biomimetic pMPC, instead of traditional PEG shielding shell, was 
introduced to the redox-sensitive supramolecular polyplex nanoparticles. We hypothesize that 
the phosphorylcholine-based pMPC could strongly associate with the cell surfaces due to its 
membrane-mimetic structure. 
The cellular uptake of DNA polyplexes formed by βCD-SS-P/Ad-pMPC and βCD-
SS-P/Ad-pEG was compared. It is noted that the βCD-SS-P/Ad-pEG pseudo-copolymer was 
prepared using the same βCD-SS-P host polymer, and the length of Ad-pEG was the same as 
Ad-pMPC. The zeta potential values of both polyplexes were also similar. The kinetics of 
cellular uptake of polyplexes of CX-rhodamine-labeled DNA with βCD-SS-P/Ad-pMPC and 
βCD-SS-P/Ad-pEG in MCF-7 cells was studied with flow cytometry (Figure 3.12 (A)). The 
relative DNA-positive cell number and the MFI per cell obtained from the flow cytometic 
histograms are plotted against incubation time (Figure 3.12 (B) and Figure 3.12 (C)). It is 





clear that the cellular uptake for βCD-SS-P/Ad-pMPC polyplex was much more rapid and 
efficient than βCD-SS-P/Ad-pEG. For βCD-SS-P/Ad-pMPC polyplex system, with only one 
hour incubation 80% of the MCF-7 cells had taken up the nanoparticles. In contrast, for βCD-
SS-P/Ad-pEG polyplex, it took up to 8 hour to achieve 80% cellular uptake. In addition, all 
the MFI values of βCD-SS-P/Ad-pMPC systems were significantly higher than those of 
βCD-SS-P/Ad-pEG (after 1 h incubation, p<0.01). The huge difference of the cellular uptake 
kinetics implied that the biomimetic pMPC corona exhibited favorable interactions with cell 
surface membranes. However, PEG could not interact with the cellular membranes and 
consequently displayed a much slower rate of cellular uptake [205]. The confocal microscope 
images also gave the same results (Figure 3.12 (D)). The βCD-SS-P/Ad-pMPC system 
showed rapid cellular uptake due to the biomimetic property of pMPC. 
 
 
Figure 3.12 Cellular uptake kinetics for CX-rhodamine-labeled DNA polyplexes formed with 
βCD-SS-P/Ad-pEG and βCD-SS-P/Ad-pMPC pseudo-copolymers in MCF-7 cells. (A) Flow 
cytometric histograms of MCF-7 cells after different times of incubation with the polyplexes. 
(B) Relative number of fluorescence positive cells as a function of incubation time. (C) Mean 
fluorescence intensity per cell as a function of incubation time. (D) Confocal microscopic 
images of MCF-7 cells that internalized polyplexes containing 0.5 g of CX-rhodamine-
labeled DNA (N/P ratio = 20) at various incubation times (Scale bar = 10 m). 
In polymeric gene delivery, positively charged polyplexes would electrostatically 
interact and aggregate with serum proteins and other negatively charged biomolecules in the 





blood, limiting the blood circulation retention time of the polyplexes. Surface modification of 
polycations with hydrophilic PEG has become a widely used strategy to sterically inhibit 
protein adsorption and then enhance serum tolerance of gene vectors. However, PEG 
shielding has been demonstrated to lower the gene transfection efficiency due to the reduced 
cell-surface association and cellular uptake [206-208], causing a “shielding dilemma”. In 
contrast, the biomimetic phosphorylcholine (PC) structure mimics the surface of natural 
phospholipid membrane bilayers, then can facilitate the cellular association and therefore 
enhance the cellular uptake [198-200]. Being bio-fouling [196, 197], which is similar to PEG, 
the PC-based polymer could replace PEGylation to be a shielding polymer for gene delivery 
systems. Thus, in this study, supramolecularly incorporating pMPC into the βCD-SS-P/Ad-
pMPC system could not only maintain the extracellular stability and serum tolerance, but also 
enhance the cellular uptake of the carrier/DNA polyplex nanoparticles, which smartly solve 
the “shielding dilemma” caused by the conventional PEGylation.  
Here the use of β-CD not only provided the backbone for designing the star-shaped 
polymers, but also the host moiety for building the supramolecular assembly structure. 
Researchers including us have demonstrated several supramolecular polymers formed 
through inclusion complexation based on non-covalent host-guest interaction between β-CD 
and adamantyl moieties, for soft materials and biomaterials applications [178-186]. Various 
self-assembly approaches such as multilayered assembly and complementary DNA strand 
self-assembly also have been reported for building multi-functional gene delivery systems 
[187-191].  
3.3.7 Delivery of therapeutic gene p53.  
The greatly enhanced overall gene transfection ability of the βCD-SS-P/Ad-pMPC 
pseudo-copolymer was demonstrated in delivering a therapeutic gene p53-encoding plasmid. 
The p53 gene is a tumor suppressor gene, which would inhibit cell proliferation through G1-
cell cycle arrest and induce cell apoptosis [209]. Here, the p53 mRNA and p53 protein 
expression levels, cell cycle arrest and cell status of MCF-7 cells were evaluated after 
transfection with polymer/p53 polyplexes (Figure. 3.13). The p53 mRNA levels of cells after 
transfection mediated by βCD-SS-P/Ad-pMPC were significantly higher than those of 
Lipofectamine, PEI 25k, βCD-P, and βCD-SS-P controls (Figure 3.13 (A)). In addition, the 
western blotting results demonstrated that the intensity of p53 protein band of the βCD-SS-
P/Ad-pMPC/p53 polyplex system was significantly higher than those of the controls, 





indicating that the p53 protein expressing amount was the highest for the βCD-SS-P/Ad-
pMPC/p53 polyplex system due to the rational design of the carrier (Figure 3.13 (B)). The 
cell cycle phase distributions of cells transfected by different polymer/p53 polyplexes were 
analyzed by flow cytometry with PI staining (Figure 3.13 (C) and Figure 3.13 (D)). For βCD-
SS-P/Ad-pMPC/p53 system, the G0/G1 phase cell population was as high as 81%. It is clear 
that much more cells were arrested in the G0/G1 phase and less cells were in the S phase for 
cells treated with the βCD-SS-P/Ad-pMPC/p53 system, as compared to all other control 
systems. Moreover, the percentage of apoptotic cells and dead cells induced by the 
polymer/p53 polyplexes were investigated by Annexin V-FITC and PI double staining 
(Figure 3.13 (E)). The flow cytometric results demonstrated that apoptosis was induced for 
32% of the MCF-7 cells treated with βCD-SS-P/Ad-pMPC/p53 system, which was 
significantly higher than those of control system (Figure 3.13 (F)). Thus, we could confirm 
that the βCD-SS-P/Ad-pMPC system possessed outstanding capacity in delivering p53 
therapeutic gene.  






Figure 3.13 Gene delivery of p53 therapeutic gene in MCF-7 cells. (A) mRNA expression 
levels of cells treated with polymer/p53 polyplexes. Data represent mean ± S.D. (B) Western 
blotting analysis for p53 protein expression in cells after transfection mediated by 
Lipofectamine, PEI 25k, βCD-P, βCD-SS-P, and βCD-SS-P/Ad-pMPC. β-actin was used as 
internal control. (C) Cell cycle analysis through propidium iodide (PI) staining of cells 
transfected with p53 polyplexes. (D) Quantified cell phase distribution of cells transfected by 
various polymer/p53 polyplexes. (E) Annexin V/PI double-staining assay of cells transfected 
by various polymer/p53 polyplexes. Y axis shows PI labeled population and X axis shows 
FITC-labeled Annexin V positive cells. Apoptotic cells showed a strong annexin V staining. 





Dead cells showed both membrane staining by annexin V and strong nuclear staining from PI. 
(F) Population of dead and apoptotic cells induced by polymer/p53 polyplexes.  
3.4 Conclusion 
We have prepared the star-shaped host polymer βCD-SS-P consisting of multiple-arm 
pDMAEMA linked to a β-CD core with bioreducible disulfide bonds, and the guest polymer 
Ad-pMPC being an adamantyl-end capped pMPC. The two LEGO
®
-like molecular building 
blocks self-assembled to form a supramolecular pseudo-diblock copolymer βCD-SS-P/Ad-
pMPC as a smart DNA carrier system with the functions of reduction-responsiveness and 
biomimetic switchable shielding for DNA delivery with significantly enhanced gene 
transfection efficiency. Our data showed that the supramolecular copolymer formation was 
based on the host-guest interaction between the β-CD core of the host polymer and the Ad 
moiety of the guest polymer. The βCD-SS-P/Ad-pMPC carrier had good DNA binding ability 
to form DNA polyplex nanoparticles with size ranging from 110 to 150 nm and zeta potential 
ranging from 18 to 25 mV at N/P ratio from 10 to 40. We systematically investigated the 
βCD-SS-P/Ad-pMPC/DNA polyplex system in various simulated environments and MCF-7 
cell culture systems under different conditions, in comparison with a number of carefully 
selected and designed control systems such as non-bioreducible, and non-shielding or PEG 
shielding polyplexes. The βCD-SS-P/Ad-pMPC/DNA polyplex nanoparticles have been 
proved to have excellent serum stability and protein resistance due to the shielding effect of 
pMPC, and in the meantime showed high cellular uptake efficiency due to the membrane-
mimic structure of pMPC. After the efficient cellular uptake into the cytoplasm, the polyplex 
nanoparticles readily released the DNA payload due to the cleavage of the disulfide bonds in 
the intracellular reductive environment. In addition, the βCD-SS-P/Ad-pMPC gene carrier 
also showed very low cytotoxicity. Therefore, the excellent protein stability, serum tolerance, 
cellular uptake and intracellular DNA release properties, and low cytotoxicity worked 
collectively to result in a highly efficient gene delivery system. Finally, the βCD-SS-P/Ad-
pMPC “Molecular LEGO®” assembly gene carrier was applied to deliver the therapeutic p53 
anti-cancer gene in MCF-7 cells, and have achieved high efficiency in cell apoptosis and 
death, showing great potential for cancer gene therapy. 
  





CHAPTER 4. A SUPRAMOLECULR SCREENING 
PLATFORM BASED ON A HOST-GUEST SELF-ASSEMBLY 
FOR PRECISE ARCHITECTURAL CONTROL OF SIRNA 
TARGETED DELIVERY  
4.1 Introduction 
Silencing of gene expression via RNA interfere (RNAi) is a promising novel 
treatment strategy for human diseases [210]. The main obstacle for RNAi application is the 
delivery of small interfering RNA (siRNA) [211]. An optimal siRNA delivery vehicle should 
be developed taking into accounts that the siRNA protection ability, serum stability, specific 
targeting, efficient cytoplasmic release, low cytotoxicity, etc. Thus, a delivery carrier 
synergistically combines above features to address the multiple challenges is highly desired. 
Targeting delivery of siRNA mediated by cell surface receptors to desired cells is an 
appealing strategy to achieve maximal therapeutic effects, avoid nonspecific silencing in 
bystander cells, and reduce the amount of siRNA required [212, 213]. There is increasing 
enthusiasm for developing polymer-based delivery vehicle for targeted siRNA delivery. In 
our opinion, a promising targeting nanocarriers design for siRNA delivery requires to address 
the followings: inhibit undesired biological process, promote efficient biological recognition, 
and comprehensive understanding of the subsequent intracellular localization after targeted 
cellular uptake. 
Surface shielding of nanoparticles (NP) has a significant effect on the targeting 
specificity of ligands. It is known that solely in the presence of proper shielding, targeting 
ligands would exhibit selective effects [214]. It must be noted, more efforts should be put to 
provide non-specific binding to gene delivery systems compared to neutrally charged drug 
delivery system, because particles with a high positive charge would tend to promote non-
specific adhesion to all cells, on the surface of which anionic phospholipid 
phosphatidylserines are abundantly located [145]. However, it is found that a few studies 
might ignore this point and fail to identify non-specific binding to specific binding [215, 216]. 
In our opinion, it is first necessary to establish a sufficient binding shells to ensure minimium 
non-specific binding before construction of the recognition moieties. PEGylation 
(modification of nanoparticles with PEG) is a most commonly used strategy to lower the 





cellular adsorption, as hydrophilic PEG provides steric barriers and charge shielding [217]. 
However, little work has been done to determine the effects of PEG surface density and 
architecture (length and shape) have on the shielding on the particles. Thus, optimization of 
the macromolecular structure and molecular weight of PEG should be performed to minimize 
the shielding. 
Optimal ligand-receptor interaction is crucial to the efficiency targeting system by 
obtaining the highest binding avidity and cellular uptake. Receptors usually exist as “cluster” 
on the cell membrane, thus, multivalent ligands might be beneficial for the enhancement of 
NP targeting and downstream process [146]. Theoretically, binding avidity between ligand 
and receptor clusters might substantially increase with valency. Nonetheless, from the 
molecular point of view, the interactions between ligand and receptor are strongly influenced 
by the number, size, and spatial organization of the recognition ligands [150]. Until now, a 
main topic whether an optimal ligand density exists remains largely unexplored and the 
effects of ligand density on NP binding has not been thoroughly investigated. We reason that 
few previous attempts to address these issues and to screen the cellular interactions with 
naonoscale-patterned ligands is lack of reliable platform. Usually, screening for the optimized 
ligand densities on NPs is time consuming and requires laborious covalent synthesis. The 
reproducibility and reliability is also a concern due to multiple steps of modifications. Thus, 
to precisely optimize and control over the ligands presentation on NPs for targeted siRNA 
delivery, a rapid and tunable optimization platform is urgently desired. 
Herein, we developed a switchable platform based on the “pegs-into-hole” LEGO® 
principle for rapid screening and optimization of siRNA targeting delivery system. This 
platform is constituted by two modular components, -cyclodextrin-based fixed host and 
adamantyl-functionalized guests. The host is a recently introduced cyclodextrin-based poly(2-
dimethylaminoethyl methacrylate) pDMAEMA, which has already been proven as an 
efficient DNA in Chapter 3 and siRNA carrier with responsive cytosolic gene payload release 
property as disulfide linkages were incorporated. The switchable guests are the screening 
candidates, a series of adamantyl-functionalized PEG-based shielding coronas and shielding 
shells with various densities of targeting ligands. By taking advantage of the molecular cavity 
of cyclodextrin that its exceptionally high binding affinity toward adamantane, the shells of 
siRNA-loaded nanoparticles could be judiciously varied in a modular and non-covalent 
manner. The schematic diagram in Figure 4.1 depicts idea of this platform for screening. To 
obtain minimum non-specific binding, total 8 adamantyl-ended PEGs with different 





architecture (linear and comb-shaped) and molecular weights (4k, 8k, 12k, and 20k) are 
screened (Figure 4.1 (A)). To gain the optimal ligand density of NP, we choose the well-
characterized ligand folate as the model ligand [218], targeting to the folate receptor (FR) 
which is expressed at high levels in numerous cancer cell [219]. The optimized targeting 
formulation would be obtained under the selection criteria of minimum non-specific binding 
with highest FR binding avidity (Figure 4.1 (B)). It is expected that by using this “LEGO®” 
platform, more concise control over the siRNA loaded NP shielding shell and ligand density 
could be gained. The optimized formulation is supposed to deliver siRNA cargo specifically 
to cancer cells with overexpressing folate receptors, follow by efficient folate receptor-
mediated cellular uptake and folate-guided intracellular localization, and lastly the siRNA 
will be responsive release in cytosol for gene silencing (Figure 4.1 (C)). Thus, whether the 
optimal nanoparticles show ligand-selective internalization and gene silencing would be 
evaluated. The possible effects of the targeting FA on the intracellular trafficking/localization 













Figure 4.1 (A) Preparation of PEG-based shielding shells of siRNA-loaded nanoparticles in a 
modular manner. The effects of architectures (linear and comb-shaped) and the length of PEG 





on shielding capacity were investigated the “LEGO®-like” screening platform. (B) Evaluation 
of the specific folate receptor targeting ability of nanoaprticles with various targeting ligand 
density and valencies. (C) Delivery of encapsulated siRNA to folate receptor overexpressing 
KB cells by the optimized targeted nanoparticles was achieved by the following successive 
steps. (1) Multivalent folate receptor binding of nanoparticles initiates receptor-mediated 
endocytosis. (2-3) different cellular localizations depended on the properties of nanoparticles. 
(4) Responsive release of siRNA in cytoplasm due to the degradation of disulfide linkages in 
the core of particles. (5) The siRNA in the cytosol would form RNA induced silencing 
complex and followed by (6) degradation of targeting mRNA. 
4.2 Materials and Methods 
Polymer synthesis. Star-shaped pDMAEMA with -cyclodextrin core and disulfide 
linkers (CD-SS-P, Host) as host polymer was synthesized using copper (I)-mediated ATRP 
based on our previous report. Two types of adamantly-terminated poly(ethylene glycol) with 
various molecular weights as guest polymers, linear pEG (PL) and combed-shaped pEGMA 
(PC), were synthesized. The synthesis methods were described supplementary methods. 
Folate was conjugated to Ad-pEG and Ad-pEGMA ends using DCC/NHS chemistry, which 
was described in supplementary methods in details. 
Synthesis of Ad-pEG-FA. The procedure for the preparation of Ad-pEG4.6k-FA 
from commercial PEG4.6k is given below as a typical example.  
Synthesis of pEG-SS-pEG. To a solution of PEG 4.6k (920 mg, 0.2 mmol) and 3,3'-
disulfanediyldipropanoic acid (21 mg, 0.1 mmol) in 10 mL of CH2Cl2 was added DCC (46 
mg, 0.11 mmol) and DMAP (4 mg 0.011 mmol). The mixture was stirred at room 
temperature for 24 h. The resulting solution was filtered to remove the white precipitants and 
then was precipitated in cold ether. The crude product was recrystallized three times from 
ether and dried in vacuum, and further purified by G50 column using H2O as the dilution. 
Yield: 460 mg, 48.8%.  
Synthesis of Ad-pEG-SS-pEG-Ad. To a solution of pEG-SS-pEG (135 mg, 0.015 
mmol) and 1-Adamantaneacetic (8.7 mg, 0.045 mmol) in 2 mL of CH2Cl2 was added DCC 
(10.31mg, 0.05 mmol) and DMAP (0.6 mg, 0.005 mmol). The mixture was stirred at room 
temperature for 24 h. The resulting solution was filtered to remove the white precipitants and 
then was precipitated in cold ether. The crude product was recrystallized three times from 
ether and dried in vacuum. Yield: 126 mg, 87.7%. 
Synthesis of Ad-pEG-SH. To a solution of Ad-pEG-SS-pEG-Ad (126 mg, 0.13 
mmol) in 1.6 mL of H2O was added DTT (19.98 mg, 1.3 mmol). The mixture was stirred at 





room temperature for 24 h. The resulting solution was dried and the crude was recrystallized 
three times from ether. Yield: 78mg, 61.9%. 
Synthesis of Ad-pEG-FA. To a solution of Ad-pEG-SH (48 mg, 0.01 mmol) and 
folic acid (6.6 mg, 0.015 mmol) in 1 mL of anhydrous was added EDCl (2.9 mg, 0.015 
mmol), HOBt (2.1 mg, 0.015 mmol), and triethylamine (1.5 mg, 0.015 mmol). The mixture 
was stirred at room temperature for 24 h under dark. The resulting solution was directly 
dialyzed against distilled water to remove the solvent DMSO and the product was obtained 
by freeze dried after dialysis (MWCO 1000). Yield: 52 mg, 98%. 
Synthesis of Ad-pEGMA. In a typical ATRP procedure, Ad-Br (31.2 mg, 0.1 mmol), 
determined amounts of monomer poly(ethylene glycol) monomethyl ether methacylate 
(EGMA) and 2,2’-bypyridine ligand (31.1 mg, 0.2 mmol) was dissolved in 3 mL of methanol. 
This solution was deoxygenated before adding CuBr (14.3 mg, 0.1 mmol) into the flask. The 
[Ad-Br]:[CuBr]:[bpy] molar ratios were 1:1:2. The mixture was reacted at 40 ºC for 24 h. The 
final green mixture was directly dialyzed (MWCO 2000) to remove the catalyst and 
unreacted monomer, followed by freeze-dried. Yield: 0.79 g, 86%.  
Synthesis of Ad-pEGMA-FA. To a solution of Ad-pEGMA and folic acid in a 
mixture of DMSO/pyridine (1:1) was added DCC (1.2 eq. to folic acid) and DMAP (0.1 eq. 
to folic acid). The mixture was stirred at R.T. for 1 d under dark. The crude was purified by 
recrystallization with ether. Products were further purified by dialysis (MWCO 2000).  
Polymer characterization. Proton nuclear magnetic resonance (
1
H NMR) spectra 
were recorded on a Bruker Avance DRX 400 MHz NMR spectrometer. Gel permeation 
chromatography (GPC) analysis was performed on a Shimadzu SCL-10A system equipped 
with a Shimadzu RID-10A refractive index detector. Tetrahydrofuran (THF) was used as 
eluent. Monodispersed poly(ethylene glycol) were used as standards to obtained a calibration 
curve. The degree of folate functionalization was determined using UV-Vis 
spectrophotometer (Shimadzu UV-2450). The absorbance of folate was detected at 290 nm. 
Polyplex formation. Polyplexes for cell binding, cellular uptake, knock down and 
endocytosis pathway investigations were prepared as follows, unless otherwise indicated: 20 
L of siRNA ore FITC-labeled siRNA (concentration: 20 g/mL) and the calculated amount 
of polymer at N/P ratio of 20 in PBS were mixed by rortexing and incubated for 30 minutes 
at room temperature  in order to form siRNA-loaded nanoparticles. 





Measurement of particle size and zeta potential. Particle size and zeta potential of 
siRNA-loaded polyplexes was measured  by (Malvern Instruments, UK). Polyplexes, 
containing 40 pmol siRNA, were prepared in 1 mL of PBS before measurement. 
Cell line and cell cultures. Folate receprtor (FR) overexpressed human nasopharynx 
carcinoma cells (KB, FR positive, FR+) (ATCC), and folate receptor deficient human 
adenocarcinomic cells (A549, FR negative, FR-) (ATCC), were used in our experiments. KB-
GFP and A549-GFP, which stably express green fluorescence protein (GFP), were 
constructed by Cell Biolabs, INC. RPMI 1640 Medium, no Folic Acid was from Life 
Technologies, supplemented with 10% fetal bovine serum (FBS). All cells were cultured in 
the folic free media for at least 7 days before use. The expression of folate receptors in KB 
and A549 cells were determined by western-blot using -FR goat polyclonal IgG (Santa Cruz 
Biotechnology) as the primary antibody and HRP-goat anti-rabbit (Life technologies) as the 
secondary antibody.  
Cell binding. For determination of the binding avidity, saturation binding experiment 
was performed. A range of FITC-siRNA-loaded targeted nanoparticles at N/P ratios of 20 
with different siRNA concentrations (from 10 to 250 mol/L) were incubated with FR+ KB 
cells on ice for 1 h. Following incubations, cells were washed with cold PBS and collected 
for FITC fluorescence analysis. The non-specific bindings were measured using the 
corresponding FITC-siRNA/polymer formulations without the targeting FA ligands. The 
degree of specific binding was determined by globally analyzing the total and non-specific 
binding. The apparent binding constant Kd values were calculated by fitting the experimental 
data to non-linear regression model, a built-in one sites – fit total and nonspecific binding 
model in GraphPad Prism. 
For determination of dissociation kinetics, a dissociation binding experiment was 
conducted. Generally, FR+ KB cells were firstly incubated with a very high concentrations 
FITC-siRNA-loaded targeted nanoparticles (concentration of siRNA was 20 mol/L) for 4 h 
allow equilibrium. After that, cells were collected by centrifugation and re-suspended in cold 
PBS. These cell suspensions were constantly stirred, spun down, washed, and tested at 
indicated time points to determine remaining bound FITC-siRNA-loaded nanoparticles on 
cells. The fluorescence intensities were measured by spectrofluorometer (TECAN, infinite 
200 pro) using FITC settings. The apparent rate of dissociation Koff value were calculated by 
fitting the experimental data to a one phase exponential decay model in GraphPad Prism 
(built in analysis model).   





Cellular uptake.  FR+ KB or FR- A549 cells were seeded into 24-well plates at a 
density of 8 × 10
4
 cells/well. Cell culture medium was replaced with fresh folic acid free 
medium after cell confluence reached 70%. Transfection complexes (N/P ratio of 20, 
containing 20 pmol FITC-labelled siRNA) were added to each well and incubated at 37 °C 
for 2 h. Subsequently, cells were then trypsinized, collected and fixed with 4% 
paraformaldehyde (PFA) in PBS, then proceed for flow cytometric analysis (Beckman 
Coulter). Cellular uptake was assayed by excitation of FITC at 495 nm and detection of 
emission at 530 nm. FCS express 4 flow research edition software was used to analyze the 
results and obtain mean fluorescence intensity (MFI) values. For competitive inhibition of 
cellular uptake by free folic acids, cells were preincubated with 300 M of folic acids for 1 h 
and the transfection medium were also containing 300 M of folic acids. For the cellular 
uptake after the a-folate receptor proteins were down-regulated, both KB and A549 cells were 
firstly transfected by Lipofectamine 2000/siRNA--FR complexes, cellular uptake 
measurements (same procedures as above) were conducted 24 h post folate receptor knocked 
down. Western blots of whole cell lysates were performed to verify the siRNA-mediated 
silencing of -folate receptor (-FR).  
For confocal microscopic observations, both KB and A549 cells were grown on glass 
coverslips to a ~50% - 70% confluency. Cells were incubated with FITC-siRNA loaded 
polyplexes for 2 h at 37 °C, and thereafter fixed with 4% of paraformaldehyde for 30 min. 
The cells were then washed and the nucleus was stained with DAPI (Sigma) at a 
concentration of 2 g/mL for 2 minutes. Cellular uptake was assayed by excitation of FITC at 
485 nm and detection of emission at 530 nm.  
Intracellular gene silencing efficiency. The siRNA induced silencing abilities of 
carriers were evaluated in both a folate receptor-overexpressing KB-GFP cell line and a 
folate receptor deficient A549-GFP cell line. Generally, 150,000 KB-GFP cells or A549-GFP 
cells were seeded into 6-well plates. When 50% - 70% confluence was reached, the cell 
culture media were replaced with fresh serum-free transfection media containing siRNA-GFP 
(Invitrogen) nanoparticles, at various dose of  siRNA per well. After 4 h incubations, the 
media were replaced with fresh complete cell growth media and the GFP expression of cells 
were detected 24 h post-transfection. Flow cytometry was performed on a FACScalibur 
(Beckman Coulter) to determine the GFP expression of every sample. Negative controls were 
cells treated with naked siRNA. The negative siRNA (containing a scrambled sequence that 





will not lead to the specific degradation of any known cellular mRNA) (Invitrogen) were also 
performed. 
To detect the mRNA transcription level of GFP after silencing, semi-quantitative RT-
PCR was performed. Transfection procedures were the same as above described. 24 h post-
knock down, total RNA extractions were carried out with the RNeasy mini kit (Qiagen). 
First-strand cDNA was synthesized using 0.5 mg of total RNA, SuperScript reverse 
transcriptase, and oligo d(T) primer (Invitrogen). RT-PCR was performed with 30 cycles. 
The intensities of PCR-generated fragments were analyzed by GBOX gel doc system 
(Syngene). 
Selection of endocytosis inhibitors. Caveolae-dependent uptake inhibitors (filipin, 
geinistein, and methyl--cyclodextrin) and clathrin-mediated endocytosis inhibitors 
(adamantine and chlorpromazine) were used to block the corresponding pathways. The 
functions of inhibitors were summarized below [220-223]. Filipin, which specifically binds to 
cholesterol rich in caveolae, blocks the caveolae dependent endocytosis pathway. Geinistein, 
which inhibits tyrosine kinase by preventing the phosphorylation of caveolin, inhibits the 
caveolae uptake. Methyl--cyclodextrin (mCD), which sequesteres the cholesterol on the 
surface of cells, prevents caveolae-mediated endocytosis. Amantadine, which blocks the 
formation of buds of clathrin-coated vesicles, inhibits clathrin-dependent uptake. 
Chlorpromazine, which prevents the association of clathrin-coated pits and the binding sites, 
blocks the clathrin-mediated cellular uptake.  Drug concentrations were selected based the 
ability of the inhibitors to prevent the internalization of endocytotic markers (transferring and 
toxin subnit B) of clathrin- and caveolae dependent pathway and ensuring minimum toxic 
effect inhibitors (data not shown). 
Endocytosis pathway investigations. For inhibition of endocytosis, cellular uptake 
of FITC-siRNA loaded polyplexes by KB cells were measured in the presence of endocytosis 
inhibitors by FACS analysis. Briefly, cells were first incubated with one of the following 
inhibitors fillipin (1 mg/mL), geneistein (200 mM), acetic acid (10 mM) or chlorpromazine 
(10 mg/mL0 for 60 min, or methyl--cyclodextrin (10 mM) for 15 min. Polyplexes 
containing FTIC-labeled siRNA were added and the cells were incubated for another 2 h. 
Subsequently, the cells were washed and collected. As positive control, FITC-siRNA 
polyplexes without inhibitors were used. The mean fluorescence intensity of 10,000 
individual cells was measured by flow cytometry and analyzed using cell quest software 
(FCS express 4).  





For knockdown studies with endocytosis inhibitors, KB-GFP cells were pretreated 
inhibitors as those mentioned above for indicated time. Then, KB-GFP cells were transfected 
with polyplexes containing 20 pmol of siRNA-GFP for 4 h with same concentrations of 
inhibitors. The knockdown efficiency was measured 24 h post-incubations. siRNA-GFP 
polyplexes without inhibitors were used as positive controls. 
To observe the siRNA polyplexes colocalization with endocytosis markers, FITC-
labeled siRNA nanoparticles were coinubated with either Texas Red-labeled transferring (50 
g/mL, Molecular Probes) or cholera toxin subunit B (10 g/mL) labeled with Alexa Fluor 
594 for 2 h. Further, the nuclei were stained with DAPI (2 g/mL) for 2 min after the cells 
were fixed with 4% PFA. Cells were analyzed by CLSM as described above. 
To observe the FITC-siRNA-loaded nanoparticles colocalization with specific 
intracellular compartment, the KB cells were washed with PBS 2 h post-transfections, 
permeabilized with 0.1% Triton X-100 in PBS, stained with rabbit anti-Caveolae-1 and rabbit 
anti-clathrin heavy chain IgG antibodies, and fixed with 4% formaldehyde in PBS. The cells 
were fluorescently labeled with Alexa Fluor 546 rabbit IgG secondary antibodies (Invitrogen).  
To assess lysosome colocalization of the nanoparticles, the KB cells were firstly 
incubated with FITC-siRNA-loaded polyplexes for 1.5 h, and then cells were incubated with 
lysotracker DND-99 (100 nM, Molecular Probe) for additional 0.5 h. Lysotracker DND-99 
was excited at 577nm  and detected at 590 nm. 
Delivery of Bcl-2 siRNA. Both KB and A549 cells were transfected with 
nanoparticles containing Bcl-2 siRNA. The transfection procedures were same as that of 
GFP-siRNA transfection. To measure the downregulation effect of Bcl-2 siRNA transfection, 
quantitative real-time PCR was performed. The Bcl-2 protein expression level after silencing 
was also determined by western blotting. The downstream effect of silencing cell apoptosis 
was analyzed by FITC Annexin V/Dead Cell Apoptosis Kit (Invitrogen) by flow cytometry. 
Reverse transcription polymerase (RT-PCR) analysis. 48 hours post transfection, 
total RNA was extracted from cells by using Qiagen RNEasy Mini Kit. The RNA was reverse 
transcribed with Oligo(dT) (Invitrogen) according to the manufacture’s protocol. Real-time 
PCR was performed on 1 L of cDNA with the SYBR Green PCR Kit (Qiagen) according to 
the manufacturer’s instructions. The Bcl-2 primers used for the RT-PCR experiment was as 
follows: Forward: 5′-TGTCCCTTTGACCTTGTTTCT-3′; Reverse: 5′-
TCATTTGCCATCTGGATTTT-3′. The actin primers were used as follows: Forward: 5’-
TACCTCATGAAGATCCTCACC-3’; Reverse: 5’-TTTCGTGGATGCCACAGGAC-3’. 





Amplification conditions were shown as follows: 40 cycles of denaturation at 95 °C for 30 s, 
annealing at 60 °C for 20 s, and extension at 72 °C  for 20 s with an  iCycler (Bio-rad).  
Western-blotting. After transfection with Bcl-2 siRNA loaded nanoparticles, cells 
were lysed with 50 L of RIPA lysis buffer (Thermo Scientific) containing protease inhibitor. 
Samples were mixed with western blot loading buffer and β-mercaptoethanol and boiled for 5 
min at 95 °C. The proteins were separated on a 12% SDS-PAGE gel. The proteins were 
transferred to a 0.2 m PVDF membrane by wet transfer cell (Bio-Rad). After electrophoresis, 
the membranes were blocked for 30 min with PBS-Tween containing 5% bovine serum 
albumin at room temperature. The Bcl-2  protein was detected by incubating the membranes 
with the primary antibody, an anti-rabbit Bcl-2  (1:500, Santa Cruz) 1 h at room temperature, 
followed with the secondary antibody, HRP-labeled goat anti-rabbit IgG (1:5000 dilution, life 
technology) for 1 h at room temperature. Proteins were detected by enhanced chem-
illuminescence (ECL, Pierce). Anti-β-actin (Cell Signal) was used as the protein loading 
control. 
Statistical analysis. Statistical analysis was performed using variance tests (ANOVA). 
Data sets were compared using two-tailed, unpaired t-test. p value of < 0.05 was regarded as 
statistically significant. 
4.3 Results and Discussion 
4.3.1 Fixed host for cytoplasmic siRNA delivery.  
The “LEGO®-like” screening system is composed of -CD based pDMAEMA fixed 
host for siRNA binding and switchable guests for particle shielding and targeting. The -
cyclodextrin-based disulfide linkages contained star-shaped pDMAEMA host (CD-SS-P) was 
prepared and characterized using the methods presented in our previous report in Chapter 3. 
There were 4 arms of pDMAEMA attached to the β-CD core, and the degree of 
polymerization (DP) of total 4 arms of pDMAEMA was 48, which was characterized by 
1
H 
NMR (data not shown). The host polymer was able to completely compact siRNA at N/P 
ratio of 3 (Figure 4.2 (A)). Moreover, it was confirmed that the redox-sensitive CD-SS-P 
could responsively release siRNA in cytoplasm (Figure 4.2 (B)). 






Figure 4.2 (A) siRNA binding ability of host polymer CD-SS-P, evaluated by gel retardation 
assay. (B) 3D (z-stack) confocal microscopic images cellular distribution of RITC-labeled 
polymer (red) and FITC-labeled DNA (green) in KB cells at 24 h post transfection. RITC dye 
was labeled to the hydroxyl groups of -CD of the host. Cell nucleus was stained by DAPI 
(blue). (a) Non-redox sensitive control nanoparticles RITC-CDP/FITC-siRNA. (b) Redox 
responsive nanoparticles RITC-CD-SS-P/FITC-siRNA. 
4.3.2 Optimization of PEG type and content to obtain minimum non-specific binding.  
The prerequisite for successful targeting siRNA delivery is to achieve minimum non-
specific binding, as positively charge gene delivery particles tend to bind to most of the cell 
surfaces non-specifically [224-226]. Thus, before endowing the targeting capacity to gene 
delivery system, PEG-based shielding shells were constructed and optimized to eliminate 
most of the non-specific binding of nanoparticles using the switchable “LEGO®-like” 
strategy. In this study, two types of adamantyl-terminated PEGs, linear and comb-shaped, 
with various lengths (PL4.3k, PL8k, PL12k, PL20k, PC4k, PC8k, PC 12k and PC20k) (PL: 
linear PEG, PC, comb-shaped PEG) were synthesized and screened as the corona of siRNA 
particles for shielding the non-specific binding (Figure 4.3 (A)). Adamantyl-ended linear 
PEG (Ad-pEG, PL) was synthesized by conjugating thiol-terminated pEG with adamantane 
acetic acid in the presence of DCC and DMAP. Comb-shaped Ad-pEGMA was prepared by 
ATRP methods using Ad-Br as the initiator. Detailed synthesis methods, schemes and 
1
H 
NMR characterizations of linear Ad-pEG and comb-shaped Ad-pEGMA were shown in 





Figure 4.4 and Figure 4.5. The chemical composition of the final adamantyl containing PEGs 
was determined by GPC and elemental analysis (Figure 4.3 (B) and Figure 4.3 (C)).   
Specifically, nonspecific binding of NPs have been shown greatly influenced by 
particle size and surface charge [150]. Here, the particle size and zeta potentials of a series 
siRNA-loaded NPs with various PEGyation were analyzed. The NPs were prepared by self-
assembling of the above discussed adamantyl terminated PEGs guest and fixed host polymer 
cyclodextrin-based pDMAEMA (CD-SS-P, Host), follow by complexation with siRNA. 
Formulations NP-PL20k (siRNA/CD-SS-P/PL20k nanoparticles), NP-PC8k, NP-PC12k and 
NP-PC20k showed low zeta potentials (< 10 mV) at N/P ratios of 20, which were desired for 
low non-specific binding [227] (Figure 4.3 (D)).  
To directly evaluate the non-specific binding of NPs, two cell lines KB (folate 
receptor overexpressing, FR+) and A549 (folate receptor deficient, FR-) were employed to 
determine the shielding effect of PEG shell of FITC-siRNA polyplexes. Cell associated mean 
fluorescence intensity (MFI), suggesting non-specific binding generated by non-specific 
electrostatic interactions between particles and cell surface, were shown in Figure 4.3 (E). 
NP-PL20k, NP-PC8k and NP-PC20k exhibited significant lower MFI value than other tested 
formulations with smaller PEG chain contents in both cell lines (p<0.01).  It was observed 
that arms with longer length showed a stronger shielding effect than that with shorter one. As 
compared to linear PEG, the comb-like pEGMA with equivalent molecular weights displayed 
greater steric hindrance, thus potentially enhancing the shielding from non-specific binding. 
However, it must be noted that longer spacer arms for ligand attachment might lead to an 
increase in particle size (Figure 4.3 (D)), which could also affect pharmacokinetics [150]. As 
no major differences were noted on the effect of preventing non-specific binding, comb-
shaped PC8k was selected instead of PC12k and PC20k. Based on the above results, linear 
shaped Ad-pEG-20k (PL20K) and comb-shaped Ad-pEGMA-8k (PC8K) were chosen for 
further targeting ligand folate conjugation. 






Figure 4.3 Preparation and evaluation of the shielding shell of siRNA-loaded particles. (A) 
Schematic diagram showed the optimization of pEG shape and length as the shielding shell of 
siRNA-loaded particles by the “LEGO®-like” strategy. (B) Characterization results of 
adamantyl-terminated linear pEGs. 
a 
The synthesis scheme and 
1
H NMR spectrum were 
shown in supporting information; 
b 
Measured by GPC, THF as the eluent; 
c
 Estimated by 
GPC, PDI = Mw/Mn. (C) Polymerization conditions and characterization results for 
adamantyl-ended comb-shaped pEGMAs polymer.
 a
 Ad-pEMGA polymer was synthesized 
by ATRP of poly(ethylene glycol) methacrylate, the synthesis scheme and 
1
H NMR spectrum 
were shown in supporting information; 
b




 The predicted Mn was calculated based on monomer conversion and [M]0/[I]0; 
d
 
Calculated from elemental analysis-derived [N]/[C] ratio. (D) Particle size and zeta potentials 
of linear pEG and combed-shaped pEGMA shielded polymer/siRNA particles. Particles 
formed by host polymer CD-SS-P and siRNA (NP-Host)was used as the positive controls 
(with no shielding shell). All polymer/siRNA particles were prepared at N/P ratios of 20 in 
PBS. Data was presented as mean ± S.D. (n=3). (E) Evaluation of the non-specific binding of 
FITC-siRNA-loaded particles in both FR+ KB and FR- A549 cells. The mean fluorescence 
intensity indicating non-specific binding of particles was measured by flow cytometry. Data 
was presented as mean ± S.D. (n=3). **p<0.01, when compared to NP-Host,.  






Figure 4.4 (A) Synthesis scheme of Ad-pEG-FA. (B) 
1
H NMR spectrum of Ad-pEG-FA and 
its synthetic intermediates in D2O.  
 
Figure 4.5 (A) Synthesis scheme of Ad-pEGMA-FA. (B) 
1
H NMR spectrum of Ad-pEGMA-
FA and its synthetic intermediates in D2O.  





4.3.3 Effect of folate ligand density on receptor binding.  
Based on the above PEG screening results, we further constructed the targeting shell 
by conjugating various numbers of folic acids (1, 3, 6, 9, and 12) to modify adamantyl-
terminated PEG (PL20k and PC8k) through EDCl/HOBt coupling chemistries (Figure 4.7 
(A)). Synthesis procedures and schemes were shown in Figure 4.4 (A) and Figure 4.5 (A). 
Successful conjugation of folate to PEG and pseudo-polymer was confirmed by the 
appearance of the absorption at 290 nm of UV-Vis spectrum (Figure 4.6). The number of 
folic acids conjugating to PEG were also calculated by 
1
H NMR (Figure 4.4 (B) an Figure 4.5 
(B)), by comparing the integration signals in the region of 6.5 - 9.0 ppm corresponding to 
hydrogen of aromatic groups of folate to those in the region of 3.4 - 3.7 ppm assigned to 
ethylene protons adjacent to ester bond on PEG. The compositions of Ad-pEG-FA 
(PL20kFA1) and Ad-pEGMA-FAs (PC8kFAn) were shown in Figure 4.7 (B). 
 
Figure 4.6 UV-vis spectroscopic data for (A) FA-modified guest polymer PL20kFA1 and 
PC8kFAn, and (B) FA-modified host/guest self-assembly. Folate was detected at 290 nm. 






Figure 4.7 Preparation and evaluation the folate targeted shells of siRNA-loaded particles. (A) 
Schematic diagram presented the optimization of targeted ligands (folic acid) number and 
density for the siRNA-loaded particles using “LEGO®-like” platform. (B) Characterization of 
adamantly-terminated pEG20k-FA1 (PL20kFA1) and pEGMA8k-FAn (PC8kFAn). 
a
 Various 
amounts of folic acids were conjugated to Ad-pEG and Ad-pEGMA using DCC as coupling 
reagent in anhydrous pyridine/DMSO (v/v 1:1). The 
1
H NMR spectrum were shown in 
supporting information. 
b
 The feeding ratio of folic acid and AdpEGMA. 
c
 The actual ratio of 
folate conjugated to Ad-pEGMA was calculated based on based on the 
1
H NMR (in D2O) 
result of the Ad-pEGMA-FA by comparing the integration of the signals in the region of 6.5 - 
9.0 ppm corresponding to hydrogen of aromatic groups of folic acid to those at the region of 
3.45 – 3.65 ppm assigned to ethylene protons adjacent to ester bond on pEG. (C) The binding 
constants (Kd) of various FITC-siRNA-loaded targeted nanoparticles in FR+ KB cells were 





measured by a saturation binding experiment. The data were fitted to the one site – total and 
nonspecific binding model. (D) The rate of decrease in FITC-siRNA-loaded targeted 
nanoparticles fluorescence was measured after FR+ KB cells pre-incubated to equilibrium 
with nanoparticles, followed by re-suspended in PBS. The data were analyzed using a 
dissociation – one-phase exponential decay model. All data shown were given in mean ± S.D. 
(n=3). (E) Apparent binding constant (Kd) and dissociation rate constant (Koff) values for the 
targeted formulations, based on the above fitting model.   
KB cells, which overexpress folate receptors on the cell surface (FR+), were used to 
evaluate the specific binding affinity of NPs to folate receptors and obtain the optimal 
number of folate ligands on the particle surface. Dissociation constant (Kd) and dissociation 
rate constant (Koff), where Kd and Koff are inversely associated to affinity, were used to 
quantify surface of binding. The equilibrium dissociation constant Kd was approximated by 
fitting the experimental data, which were determined by saturation binding experiment with 
various concentrations of FITC-siRNA loaded NPs with targeting ligand (specific binding) 
and corresponding polyplexes without targeting ligand (non-specific binding) to a model of 
one site –total and nonspecific binding (built-in model of GraphPad Prism) via non-linear 
regression. The measured EC50 (concentration producing 50% binding) was observed to be 
the lowest for CD-SS-P/PC8kFA6/siRNA formulation (NP-PC8kFA6) (Figure 4.7 (C)). NP-
PC8kFA6 functionalized with multivalent FA ligands had a highest specific affinity for KB 
cells with a lowest Kd value. Its Kd value was approximately 7-fold lower than the 
monovalent ligand formulation (NP-PL20kFA1 and NP-PC8kFA1. In addition, the cell 
associated fluorescences were measured at various times after saturation binding to determine 
how rapidly the FITC-siRNA-loaded NPs falls off the receptors (Figure 4.7 (D)). The 
dissociation kinetics rate constants (Koff) of targeted NPs were approximated by fitting a one-
phase exponential decay model  to the experimental data with nonlinear regression analysis. 
The Koff showed that NP-PC8kFA6 also had the longest dissociation time (Figure 4.7 (E)).  
Folate receptors has been reported that exist as “receptor clusters” in the cell 
membrane, with an average cluster size of 85 nm [228, 229]. Our results demonstrated that 
targeting to these clusters with low folate densities (monovalent interaction, NP-PL20kFA1 
and NP-PC8kFA1) may fail to provide a high enough affinity to promote strong and stable 
binding. Cell binding generally increased with ligand densities. When FA density was 
increased beyond optimal values, decreases in cell binding were observed (binding avidity: 
NP-PC8kFA6 > NP-PC8kFA9 >NP-PC8kFA12). Intermediate targeting ligand density seems 
to have the most optimal cell specific binding. It is known that the targeting efficiency 
depends on the density, size, orientations of the targeting ligands [150]. Overcrowding is 





highly possible to prevent ligands from obtaining the correct orientation for binding. Also, 
competitions might occur between multiple ligands for a single receptor, which tends to limit 
the access of ligands to receptor. Several recent publications also shared similar observations 
with ours [150, 224, 226, 230].  
The above observations indicated that the optimal FA density of NP-PC8kFA6 
attributed it having more NPs bind for longer times on the KB cell surface with strong 
binding affinity. Moreover, it was also confirmed that the cytotoxicity of this folate decorated 
particle was undetectable up to N/P ratio of 50 (Figure 4.8), and it showed supreme protein 
resistant capacity (Figure 4.9). Thus, this formulation was selected for further cellular uptake 
and silencing investigations. 
 
Figure 4.8 Cell viability of the PEG shielding or/and folate conjugated nanoparticles with 
siRNA at various N/P ratios were measured on KB cells. The non-shielding controls PEI 25k 
and CD-SS-P nanoparticles were used as the positive controls. (n=4) 
 
 
Figure 4.9 Protein adsorption of nanoparticles with various formulations at N/P 20. (n=3) 





4.3.4 NP-PC8kFA6 delivered siRNA only to FR+ cells.  
To demonstrate whether selective folate receptor-mediated endocytosis of NP-PC8kFA6 
occurs after the strong-avidity receptor binding, the cellular uptake of NP-PC8kFA6 on both 
KB (FR+) and A549 (FR-) were evaluated.  To validate the use of KB and A549 cells, folate 
receptor expression levels of these two cell lines were firstly investigated. Immunoblotting 
analysis (Figure 4.10 (A)) revealed that KB showed high expression of -FR (KB, I) while 
neglect expression of -FR(A549, I) was observed for A549. Expression of -FR in KB 
decreased after cells were knocked down by Lipofectamine 2k/siRNA--FR (KB, II). In 
Figure 4.10 (B), whether NP-PC8kFA6 can deliver siRNA to FR+ cells selectively was tested. 
Both KB and A549 were harvested with FITC-siRNA loaded NPs for 4 h, and then the cells 
were stained with -FR antibody. Flow cytometry results revealed that uptake of FITC-
siRNA delivered by NP-PC8kFA6 was seen mostly in FR+ KB cells, but few in FR- A549 
cells. However, no selectivity was observed for NP-host positive controls which contained no 
FR targeted corona. Figure 4.10 (C) further confirmed that cellular uptake of NP-PC8kFA6 
was directed by folate receptor mediated endocytosis. Depression of FR expression (line II) 
and competitive blocking of folate receptors by free folic acids (line III) reduced the cellular 
uptake of NP-PC8kFA6 by KB cells. The selective delivery of FITC-siRNA by NP-
PC8kFA6 to KB cells was also confirmed by confocal microscopic observations (Figure 4.10 
(D)). Collectively, NP-PC8kFA6 successfully delivered siRNA to FR+ KB cells specifically 
via FR-mediated endocytosis. 






Figure 4.10 Cellular uptake of FITC-siRNA/PC8kFA6 particles (NP-PC8kFA6) by FR+ KB 
and FR- A549 cells. Particles formed by host polymer (CD-SS-P) and siRNA (NP-Host) were 
used as positive controls. (A) Western blot analysis of folate receptor (-FR) expression in 
KB and A549 cells. I: cells with no pretreatment. II: the FR receptors of the cells were 
silenced by pretreating cells with Lipofectamine 2k/siRNA--FR. -actin expression was 
used as negative controls. (B) Flow cytometry analysis showed the relationships between 
cellular uptake of NP-PC8kFA6 targeted particles and the expressions of folate receptors on 
cells of KB and A549 cells. Cells were firstly treated with FITC-loaded nanoparticles for 4 h, 
then cells were fixed and stained using anti-rabbit a-FR as primary antibody and Alexa Fluor 
546 labelled goat anti-rabbit antibody as secondary antibody. (C) Flow cytometric histogram 
showed the effect of folate receptor silencing and blocking of folate receptor on cellular 
uptake of NP-PC8kFA6. I: cells with no pretreatment. II: the FR receptors of the cells were 
knocked down by pretreating cells with Lipofectamine 2k/siRNA-FR. III: Cells were firstly 
blocked with 600 M of free folic acids for 4 h. (D) Confocal laser scanning microscopic 
analysis of the cellular uptake of NP-PC8kFA6 particles by FR+ KB cells and FR- A549 cells. 
Green color indicated the FITC labeled siRNA, and nucleus staining with DAPI showed blue 
color. Scale bar = 20 m. 
4.3.5 GFP-siRNA delivered by NP-PC8kFA6 silenced gene expression.  
To evaluate whether siRNA transferred by NP-PC8kFA6 can specifically silence 
target gene expression, silencing efficiency of siRNA-GFP delivered by NP-PC8kFA was 
evaluated in both KB-GFP (FR+) and A549-GFP (FR-) cells, which stably express EGFP. 
siRNA-GFP delivered by NP-PC8kFA6 reduced GFP protein expression (Figure 4.11 (A)) 





and mRNA levels (Figure 4.11 (B)) in a dose-dependent manner only in FR+ KB-GFP cells. 
The reduction in GFP mRNA indicated that siRNA delivered by NP-PC8kFA silenced target 
gene expression via mRNA degradation. The silencing efficiency of NPs was summarized 
based on GFP expression measured by flow cytometry, as shown in Figure 4.11 (C). GFP 
expression of approximated 90% of KB-GFP cells were silenced when the siRNA dosage 
was 500 pmol, statistically higher than that of A549-GFP (p<0.001). It was proved that 
silencing by siRNA-GFP loaded NP-PC8kFA was specific as neglect reduction of GFP 
expression was detected in FA- A549 cells or with negative control siRNA. For the control 
sample NP-PC8k which bearing PEG shell but no targeting FA ligands, neglect silence effect 
was observed for both cell lines (data not shown). Moreover, no specific silencing was 
observed for NP-Host, as GFP silencing effects were observed for both FR+ and FR- cell 
lines. Collectively, siRNA-GFP delivered by NP-PC8kFA6 specifically knocked down gene 
expression of FR+ KB cells with high silencing efficiency. 
 





Figure 4.11 Knockdown effect of PC8kFA6/GFP-siRNA nanoparticles on GFP-KB and GFP-
A549 cells. Both GFP-KB and GFP-A549 cells were stably expression green fluorescence 
protein. The silencing effect was evaluated by expression of GFP protein expression and 
GFP-mRNA levels. Host/GFP-siRNA particles were used as the positive controls. Neg-
siRNA, the nonsilencing siRNA, was used as the baseline of silencing effect. (A) Flow 
cytometric histograms showed the expression of GFP. GFP-KB and GFP-A549 were 
incubated with GFP-siRNA/PC8kFA6 particles for 4 h, the GFP expression was evaluated 
after additional 48 h incubation. Black line: untreated cells; Red fill: Cells transfected with 
indicated particles. Neg-siRNA, the nonsilencing siRNA, was used as the baseline of 
silencing effect. (B) GFP-mRNA levels of FR+ and FR- cells after transfecting with various 
amounts of GFP-siRNA. (D) Silencing efficiency of PC8kFA6 in both FR+ and FR- cell line. 
Silencing efficiency (%) = Number of cells expressing GFP (after transfection) / Number of 
cells expressing GFP (before transfection) × 100%. Data were presented as mean ± S.D. 
(n=3).  
4.3.6 Suppression on Bcl-2 gene expression.  
The targeting siRNA delivery ability of optimized NP-PC8kFA6 was further 
evaluated in delivering a therapeutic Bcl-2 siRNA. The Bcl-2 gene is an important cell 
apoptosis regulator, which is overexpressed in cancer cells, preventing apoptosis of cancer 
cells [231, 232]. Inhibition of Bcl-2 expression is a critical strategy to recover apoptotic 
pathway of cancer cell. The Bcl-2 gene downregulation was assayed at both mRNA and 
protein levels 48 h post transfection. As shown in Figure 4.12 (A), RT-PCR analysis 
indicated that the Bcl-2 mRNA expression levels in of NP-PC8kFA6 transfected KB cells 
was significantly less than that of commercial reagent Lipofectamine 2k (p<0.05). On the 
other hand, neglect reduction of Bcl-2 mRNA levels was observed for the NP-PC8kFA6 
treated A549 cells. Similar downregulation trends of Bcl-2 protein level were observed by 
western blot (Figure 4.12 (B)). To further verify the downstream effects of delivery of Bcl-2 
siRNA, AnnexinV-FITC and PI co-staining analysis was conducted to quantify cell apoptosis 
(Figure 4.12 (C)). Clearly, flow cytometry results showed that NP-PC8kFA6/Bcl-2 treatment 
resulted in highest level of cell apoptosis in FR+ KB cells among all the tested groups, while 
neglect apoptosis level was observed for NP-PC8kFA6 treated FR- A549 cells, as shown in 
Figure 4.12 (D). The results indicated that Bcl-2 siRNA delivered by targeting nanoparticles 
NP-PC8kFA6 could specifically silence the Bcl-2 expression in FR+ KB cells and induce 
selective cell apoptosis. 






Figure 4.12 Intracellular pathway investigations. (A) Effect of endocytosis inhibitors on the 
cellular uptake of PC8kFA/FITC-siRNA particles. Filipin, geinistein, and methyl--
cyclodextrin are the endocytosis inhibitors of caveolae-meadiated pathway. Amantadine, and 
chlorpromazine inhibit the clathrin-mediated pathway. The cell associated mean fluorescence 
intensity (MFI) was measured by flow cytometry. Relative MFI (%) = MFIinhibitor-treated / 
MFInon-treated × 100%. (B) Effect of endocytosis inhibitors on the silencing efficiency of 
PC8kFA/GFP-siRNA particles. Relative silencing efficiency (%)= Silencing efficiencyinhibitor-
treated / Silencing efficiencynon-treated × 100%. All data shown were presented as mean ± S.D. 
(n=3). (C) Colocalization studies with PC8kFA6/FITC-siRNA nanoparticles and endocytosis 
markers for different pathway. Cells were analyzed by CLSM. Blue indicated DAPI-stained 
nuclei, green showed FITC labelled siRNA, and red displayed the endocytosis markers. 





 rows, Alexa Fluor-594 labeled cholera toxin B (1
st
) and Texas Red-Transferrin (2
nd
) 





 rows, KB cells were incubated with FITC-siRNA/PC8kFA6 nanoparticles for 2 h. 
Cells were fixed and inmmunostained against caveolin-1 (3
rd





 row, KB cells were treated with FITC-siRNA/PC8kFA6 and Lysotracker Red 
DND-99 for 2 h, and then examined by confocal microscopy. 
4.3.7 Endocytosis pathway of folate decorated NP-PC8kFA6.  
Knowledge about the intracellular localization of siRNA delivery vehicles is of great 
importance for further improvement of the system design [233]. The intracellular localization 
of folate targeting nanoparticles remains unclear. Moreover, though NP-PC8kFA6 showed 
higher cellular uptake levels on KB cells than NP-host which with no targeting ligands 
(p=0.046), it was worthy to note that the deviation of gene silencing efficiency between NP-





PC8kFA6 and NP-host was further enhanced (p=0.0009). It is possible that the distinct 
differences in silencing capacity for NP-PC8kFA6 and NP-PC-host could be also associated 
to different intracellular fate. Thus, intracellular routes for targeting NP-PC8kFA6 and non-
targeting NP-host were investigated on KB cells.  
Endocytic pathways were obtained by quantitatively monitoring the cellular uptake 
and gene silencing efficiency in the presence caveolae- and clathrin-mediated endocytosis 
inhibitors. Caveolae-dependent pathway was probably dominated in internalization of NP-
PC8FA7 (Figure 4.13 (A)). Inhibition of caveolae-dependent pathways led to approximated 
70-80% reduction in cellular uptake in comparison to that of control cells (p<0.05). A slight 
but not statistically significant reduction in cellular uptake was observed when clathrin-
mediated endocytosis was inhibited by adamantine (reduced by 13%, p=0.1655) and 
chlorpromazine (reduced by 17%, p=0.0522). On the other hand, unmodified NP-Host was 
reduced by both caveolae- (p<0.05) and clathrin- (p<0.01) mediated internalization, 
indicating that a combination intracellular routing was possibly involved in the cellular 
uptake of NP-Host. It seemed that the change of endocytosis pathway of NP-PC8kFA after 
folate modification was induced by folic acid, which is internalized by budding from 
membrane domains rich in caveolin protein [229]. There are also several reports showing that 
folate-modified particles were predominantly internalized by caveolae-manners [138, 223, 
234, 235]. 
Furthermore, gene silencing efficiencies were evaluated when the specific uptake 
routes were blocked (Figure 4.13 (B)). For NP-PC8kFA6, gene silencing efficiency was 
drastically reduced by 70%-85% when the caveolae-dependent endocytosis pathway was 
inhibited by filipin, geinistein and mCD, respectively, whereas inhibitors of clathrin-
dependent pathway did not negatively influence its silencing efficiency. It is suggested that 
caveolae is the major intracellular routing of folate modified NP-PC8kFA6. For non-modified 
NP-host, reduction in gene silencing efficiency by caveolae  inhibition (reduced 60%-70%, 
p<0.01) was observed. Surprisingly, inhibition of clathrin had no deleterious effects on 
knockdown effect of NP-host, though a large portion of the NP-Host particles cellular uptake 
in this pathway. It is possible that particles internalized by caveolae-mediated route 
contributed more in gene silencing [236].      
Aiming to get insight into the internalization fates of NP-PC8kFA, spatial bio-images 
were obtained to investigate the localization of particles with known endocytosis markers 
cholera toxin B (CTB) (Alexa fluor 594-labeled), a tracker for caveolae-mediated uptake 





[237], and transferrin (Texas red labeled), which is internalized by clathrin-mediated 
endocytosis [238]. As shown in Figure 4.13 (C) row 1 and 2, clear and high localization 
between NP-PC8kFA6 and caveolae tracker CTB was observed, as indicated by the presence 
of yellow particles, whereas only a low number of particles colocalized with clathrin markers 
transferrin, which was consistent with the above inhibition of cellular uptake results that NP-
PC8kFA6 entered cells predominantly by caveolae-pathway. On the contrary, non-targeted 
NP-Host showed higher colocalization with transferrin as compared to CTB. To further 
support the findings gained from the endocytotic marker co-incubation studies, colocalization 
of NP-PC8kFA6 with specific endocytotic compartment caveolae-1 protein and heavy 
clathrin chain, which was stained by immunofluoresence, was evaluated (Figure 4.13 (C), 
row 4 and 5). It was found that most of the NP-PC8kFA6 particles colocalized with caveolae-
1 but not clathrin-related protein after 2 h incubation. These results were essentially 
consistent with the findings in inhibition of uptake and colocalization experiments that the 
major intracellular route of NP-PC8kFA6 is caveolae-pathway. Though the fate of caveolae-
dependent pathway is less understood than the clathrin-mediated localization, most of the 
research admitted that caveosomes avoid trafficiking to lysosomes [239], which is a harsh 
barrier for gene delivery. Thus, to identify whether NP-PC8kFA nanoparticles would also 
bypass the lysosomes allocation, colocalization between NP-PC8FA7 and lysosomes was 
studied by labeling the late lysosomes with LysoTracker-Red, which stains the acidic cellular 
compartments. As shown in Figure 4.13 (C) row 5, a clear difference was noted between the 
folate-modifed NP-PC8FA7 and the non-modified control NP-Host in colocalization with 
lysosome. Large amount of NP-Host particles appeared to follow the classical route that 
trapped in lysosomes after 4 h incubation. In contrary, NP-PC8FA7 seemed to escape this 
route, colocalizing with lysosomes to a lower extend than NP-Host, indicating that NP-
PC8kFA6 might bypass the acidic environments.  
Taken together, our data demonstrated that cell targeting could influence the 
intracellular process of particles. Folate modified NP-PC8FA7 mainly utilized caveolae-route 
to enter cells, which was distinct from the uptake path of non-modified NP-Host. This 
characteristic might be caused by the cell targeting ligand folate. Avoidance of lysosomes 
trafficking for NP-PC8kFA6 might be the one of the properties that contributes to its supreme 
gene silencing efficiency. Until now, many of the gene delivery research focus on designing 
of carriers to break down the lysosome barriers by endosomal escape, but with our present 
results and other recent reports [138, 229, 234], we suggests that more emphasis should be 





placed on caveolae-pathway. Sorting out the obstacles of caveolae trafficking and designing 
carriers to intracellular-localize caveolae-route might be the directions for efficiency 
improvement.  
 





Figure 4.13 Delivery of Bcl-2 siRNA. (A) Downregulation of Bcl-2 mRNA levels as 
quantified by real-time RT-PCR (n=3). * p<0.05, **p<0.001. The relative level of mRNA 
expression levels was calculated  over the untreated control. (B) Suppression of Bcl-2 protein 
expression levels as evaluated by western blot. -actin was used as negative controls. (C) 
Quantitative analysis of the percentage of apoptotic cells using Annexin V-FITC/PI co-
staining assay (n=3) by flow cytometry. * p<0.05, *** p<0.0001. (D) Flow cytometry 
histogram of apoptotic cells analyzed by FITC-Annexin V/PI assay. 
4.4 Conclusion 
In order to concisely construct siRNA targeted delivery vehicle, we developed a “pegs 
into hole” multifunctional screening platform based on “LEGO® bricks” concepts to screen 
various architectures of siRNA system. The “hole” block is a cyclodextrin-functionalized 
siRNA binding fixed host, and the “pegs” are a series of defined adamantyl-bearing PEG or 
folate(s) conjugated PEG switchable guests, which could self-assemble into a supramolecule 
via host-guest interaction, like the “peg into hole” pattern, for siRNA targeted delivery 
screening. By using this strategy, the shells of siRNA delivery nanoparticles with different 
macromolecular architecture and targeting valency could be easily varied in a modular and 
non-covalent manner. This “LEGO®-like” robust platform can be advantageous over 
traditional covalent strategies for several reasons, e.g., the construction of candidates is 
markedly rapid and efficient. Moreover, the “hole” and “peg” blocks could be separately 
tuned, which would benefit the accuracy of complicated polymer designs.  
Taking the advantage of the “LEGO®-like” platform, our methodology for 
construction of siRNA targeting system is to firstly screen a series of PEG shielding shells 
with different shape and length to obtain minimizing non-specific binding, and follow by 
optimizing the density of folate ligands to achieve maximized targeting binding avidity. The 
logic of this approach could ensure no mix-up of electrostatic non-specific binding and 
ligand-mediated specific binding occurs, ensuring the latter one is dominated in nanoparticle 
binding. Based on the screening results, the comb-like PEG displayed better non-specific 
binding inhibition ability, as compared to linear PEG with equivalent molecular weights, 
indicating the dense architecture benefits to the steric and charge shielding. In addition, the 
use of multivalent folate ligands can increase nanoparticle affinity, but the binding avidity 
would decrease when the ligand density transcends the optimal levels, which might ascribe to 
the overcrowded effects of ligand.  
By using this versatile “LEGO®-like” screening platform, formulation NP-PC8kFA6 
bearing of a shielding corona of comb-shaped 8k pEGMA and multivalent folate ligands was 





obtained for siRNA targeting and cytosolic delivery. Nanoparticles NP-PC8kFA6 possessed a 
suitable size of approximately 130 nm, and showed high serum stability, low non-targeting 
cell binding and responsive cytosolic release of siRNA. NP-PC8kFA6 functionalized 
multivalent folate ligands could selectively and efficiently internalize in folate receptor 
overexpressed KB cells via folate receptor mediated endocytosis. High GFP silencing 
efficiency was observed in FR+ GFP-KB cells, but not FR- GFP-A549 cells. Moreover, this 
NP-8kFA6 was also applied in Bcl-2 therapeutic siRNA delivery. High and selective Bcl-2 
gene downregulating was observed only in FR+ KB cells, and resulting in sufficient cell 
apoptosis of KB cells, indicating this smart multifunctional nanoparticles could be applied in 
targeted cancer therapy.         
Lastly, cellular spatial--analysis showed that intracellular localization of NP-8kFA6 
was dominated by caveolae-pathway and seemed to bypass of acidic cellular compartment, 
which was regarded as another add-on to its supreme gene silencing capacity, This findings 
offer some biological hints for further architecture improvement of the system. The optimized 
multifunctional nanoparticles NP-PC8kFA6 possessed supreme ability in cytosolic a targeted 
delivery of siRNA. 
This highly versatile screening platform based on “LEGO®-like” self-assembly served 
as an example of rapid optimization of  the architecture of folate-based siRNA targeted 
system. It also can be extended to design/optimize other smart multifunctional nanoparticles 
with different targeting ligands like peptide and antibody or other surface properties. We are 
currently working along this line. 
  





CHAPTER 5. DUAL RESPONSIVE ASYMMETRIC 
VESICULAR NANOVECTOR BASED ON A 
SUPRAMOLECULAR TRIBLOCK COPOLYMER FOR 
DOXORUBICIN AND GENE SIMULTANEOUS DELIVERY  
5.1 Introduction 
Doxorubicin (DOX), as a cell-apoptosis inducer, is available in clinical use and 
widely studied in research studies [240, 241]. However, severe systemic toxicity and 
multidrug resistance (MDR) remain major obstacles to the successful DOX applications 
[242]. MDR is highly associated with drug efflux protein P-glycoprotein (P-gp), which would 
pump the intracellular released DOX out of the cells and result in the failure of DOX 
accumulation  in the P-gp overexpressed drug resistant cells. Commonly, P-gp is encoded by 
multidrug resistance gene 1 (MDR1) [243, 244].  RNA interference (RNAi) may be 
employed to suppress the expression of P-gp, led to reversal of the sensitization of cancer 
cells to conventional chemotherapeutics [245, 246]. Thus, co-delivery of siRNA encoded 
MDR1 and anti-cancer drug has been developed to conquer the multidrug resistance in 
chemotherapys [247-249]. In addition to mechanical considerations, spatially synergistic co-
delivery of anticancer drug and siRNA in a single carrier may further benefit in synchronized 
pharmacokinetics and delivery of both therapeutic payload to the same population of cells 
[247]. 
To date, various co-delivery carriers have been established to deliver both 
chemotherapeutic and siRNA to drug resistant cancer cells with the goal of overcoming MDR 
[26, 247, 250-253]. An ideal nano-carrier should compatibly encapsulate both anti-cancer 
drug and therapeutic nuclei acids, and have slow or neglect drug release during circulation 
while promptly release its payload when it reaches targeted cells. Liposomes have been 
widely investigated for chemotherapeutic drug delivery [254]. However, co-encapsulation of 
both drug and nucleic acids in the same liposome formulation have verified to be ‘leaky’ and 
instable, mainly associated with the thin and readily deformable hydrophobic core of 
liposome membrane [255, 256]. Moreover, lack of specificity leads the anticancer drug 
delivered by liposomal system fail to enrich and promptly release in the targeted tissue. 





Recently, synthetic macromolecular amphiphiles with appropriate compositions have 
been extended to self-assemble polymersomes (a.k.a. vesicles) [256-261]. Compared to 
conventional liposomes, polymersomes have more robust and thicker membranes, and offer 
possibilities to impart and tune various biological and physiochemical properties by simply 
varying the polymer structure. Previously, we have developed folate-functionalized comb-
shaped PEG coated nanoparticles with disulfide linkers (CD-SS-pDMAEMA/Ad-pEGMA-
FA) that were able to transfect siRNA to folate receptor overexpressing cells with high 
specificity and efficacy (Chapter 4). In this context, with the goal of developing an integrated 
nanomedicine approach for the therapy of multidrug resistant cancer by combining an 
chematherapeutic and siRNA silencer of cellular drug resistance within one multifunctional 
polymersome-based delivery system, we design a new class of supramolecular triblock 
pseudo-copolymer by introducing reactive poly(2-(diisopropyl-amino)ethyl methacrylate) 
(pDPA) blocks to the previously reported CD-SS-pDMAEMA/Ad-pEGMA-FA 
supramolecular diblock copolymer. pH-sensitive pDPA chains can be converted from 
hydrophilic in mild acidic solution into hydrophobic at neutral pH.  
This system comprised of star-shaped cycldoextrin-based host polymer CD-SS-
pDPA-pDMAEMA and comb-shaped adamantyl-functionalized guest polymer Ad-pEGMA-
FA. CD-SS-pDPA-pDMAEMA was synthesized using a sequential monomer addition atom 
transfer radical polymerization (ATRP) method [178, 179]. Ad-pEGMA-FA guest polymer 
was prepared as previously described (Chapter 4). These two polymers could form 
supramolecular pseudo triblock copolymer via host-guest recognition in mild acidic 
conditions, and further self-assembled into polymeric vesicles with asymmetric membranes 
by simply tuning the pH of aqueous solution from acidic to neutral (Figure 5.1 (A)). Given 
the inherent propensity, the central hydrophobic pDPA blocks can bridge across the 
membrane with hydrophilic pEGMA-FA and cationic pDMAEMA spatially segregated on 
the outer leaflet and interior, respectively. Hydrophobic doxorubicin could be encapsulated in 
this hydrophobic layer. The hydrophilic pEGMA-FA segment is preferentially segregated to 
the exterior of vesicles; The conjugated folic acids is for enhancing the targeting selectivity of 
polymersome to cancer cells overexpressing folate receptors. The cationic pDMAEMA 
chains should locate solely on the inner volume of polymersomes, which is suitable for 
siRNA complexation and protection (Figure 5.1 (B)). The disulfide linkers in the system are 
supposed to be beneficial to the intracellular release of DOX and siRNA payloads. 
Comparing to traditional vesicle preparation techniques which need to use organic solvent 





and are time-consuming, these pH-sensitive polymersomes are prepared in purely aqueous 
solution by simple pH-switch method. Another benefit of the pH-adjusting method is the 
generation of unilamelar vesicles with much narrower size distributions [261]. Moreover, the 
molecularly dissolved amphiphlic copolymer is nearly absent in aqueous solution under 
physiological conditions, implying that cytotoxic interaction between pure polymer and 
cellular membrane could be largely avoided. 
This vesicular carrier is structurally flexible enough to integrate multiple functions 
into one system (Figure 5.1 (C)), which is expected to be (i) recognized by folate receptors 
overexpressing cancer cells, and internalized selectively by cancer cells through receptor-
mediated active endocytosis, (ii) provide redox-trigger cytoplasmic release of DOX and 
siRNA, (iii) down-regulate the expression of drug efflux pump P-gp by siRNA-MDR1, (iv) 
increase DOX accumulation in the nucleic zone by resensitizaiton of multiple drug resistance 
cells to DOX, and induce apoptosis in MDR cancer cells. The effectiveness of this vesicular 
system was evaluated using a doxorubicin-resistant folate receptor overexpressing mouth 
epidermal carcinoma cell line (KB/DOX). To the best of our knowledge, this is the first 
report of supramolecular tri-block copolymers forming a dual-stimuli responsive vesicular 
system for integrating targeted delivery of anti-cancer drug and siRNA through redox-
triggered intracellular payloads release for overcoming drug resistance in cancer. 






Figure 5.1 (A) Structure of CD-SS-pP-pM/Ad-pE-FA triblock copolymer and effect of pH 
on the protonation of pDMAEMA and pDPA chains. Green: cationic pDMAEMA. Red: pH 
sensitive pDPA. pDPA was hydrophilic and protonanted as a weak polyelectrolyte when pH 
was low, whereas deprotonated and turn to hydrophobic at high pH. Blue: hydrophilic 
pEGMA. (B) (1) Formation of CD-SS-pP-pM/Ad-pE-FA triblock copolymer asymmetric 
vesicles. The pH sensitive vesicles were prepared by simply adjusting the pH of polymer 
aqueous solution from 2 to 7.4 by slowly adding aqueous NaOH. (2) Encapsulation of DOX 
and siRNA, also by the pH switch method. DOX was encapsulated in the central bridging 
pDPA layer; siRNA was compacted by pDMAEMA, locating in the inner volume of vesicle; 





Hydrophilic pEGMA-FA was segregated to the exterior of vesicles. (C) Schematic diagram 
of dual responsive vesicleplexes for DOX and siRNA co-delivery to multidrug resistant cells. 
(a) Free DOX entered MDR cells by passive diffusion. Free DOX failed to accumulate in the 
cells as most of the intracellular free DOX would be pumped out by the drug efflux pump P-
gp. (b) The vesicular co-delivery system demonstrated potentials in the simultaneous 
transportation of DOX and siRNA to MDR cells, to inhibit the expression of P-gp and induce 
apoptosis of the cells. The system (i) was internalized selectively by cancer cells through 
receptor-mediated active endocytosis, (ii) provided redox-trigger cytoplasmic release of DOX 
and siRNA, (iii) down-regulated the expression of drug efflux pump P-gp by siRNA-MDR1, 
(iv) increased DOX accumulation in the nucleic zone by resensitizaiton of MDR cells to 
DOX, and induced apoptosis in MDR cancer cells. 
5.2 Materials and Methods 
Synthesis of βCD-SS-pDPA. Generally, βCD-SS-Br (104 mg, 0.04 mmol) (Synthesis 
methods as shown in Chapter 3) and monomer (2-(diisopropyl-amino)ethyl methacrylate) 
(DPA) (1.706 g, 8 mmol), and Me6-TREN (55 mg, 0.24 mmol) was dissolved in 3 mL of 
DMSO/methanol (V/V 1:2). After de-gassing, CuBr (22 mg, 0.16 mmol) was added to the 
mixture solution. The [DPA]:[CD-Br]:[CuBr]:[Me6-TREN] relative molar ratios were 
200:1:1:1.5. The mixture was stirred for 24 h at 70 °C. Subsequently, final solution was 
passed through a short Al2O3 column to remove the catalyst copper. Resulting solution was 
then precipitated in hexane. The crude product was collected by centrifugation and dried 
under vacuum. The product was further purified by dialysis against HCl solution (0.01 M) for 
a week (MWCO 2000), follow by freeze-dried. Yield:  1.2711 g, 68.7%. 
Synthesis of βCD-SS-pDPA-pDMAEMA. Typically, when the monomer conversion 
of the above reaction (ATRP of CD-SS-pDPA) achived 99%, as justified by 1H NMR, de-
gassed monomer (2-(dimethyl-amino)ethyl methacrylate) (DMAEMA) (440 mg, 2.8 mmol), 
Me6-TREN (55 mg, 0.24 mmol) and CuBr (22 mg, 0.16 mmol) was added to the mixture 
solution. The [DMAEMA]:[βCD-SS-pDPA-Br]:[CuBr]:[Me6-TREN] relative molar ratios 
were 15:1:1:1.5. The mixture was stirred at 40 °C for 48 h before passing through an Al2O3 
column to remove the copper catalyst. The resulting solution was precipitated in ether, and 
was collected by centrifugation. The white product was further purified by dialysis against 
HCl solution (0.01 M) for a week (MWCO 2000), follow by lyophilized. Yield:  1.5733 g, 
91.8%. 
Synthesis of guest polymer Ad-pEGMA22-FA6. Synthesis methods were shown in 
Chapter 4 





pH titration of polymers. The polymers were firstly dissolved in 0.1 N HCl at a 
concentration of 10 mg/mL, respectively. 0.1 N NaOH solution (80 L increments) was 
added to polymer solutions  under stirring. The pH increase from 3 to 10 was measured as a 
function of added volume of 0.1N NaOH (VNaOH). The pH values were monitored using a pH 
meter (Sartorius).  
In vitro drug release study. In vitro drug release from 20%DOX-loaded naoparticles 
was performed in buffers (PBS, pH 5.0 and pH 7.4), and with DTT (30 mM in PBS, pH 7.4) 




 G2 tube (0.5 – 1 kD). The PBS of pH 7.4 
without DTT simulated the extracellular environment which nanoparticles would circulate in 
after i.v. administration, while the PBS of pH 7.4 with 30 mM of DTT mimics the 
intracellular environment. The nanoparticle solution (equivalent to 40 g of DOX) or pure 
DOX solution was placed into a dialysis tube in indicated buffer. At a pre-determined time, 7 
mL of buffer was changed and same amount of fresh buffer was added. The samples taken 
out were freeze-dried and re-dissolved in DMSO/H2O (v/v, 1:1), and the fluorescence of the 
solution was measured by a a fluorescence spectroscopy (excitation at 485 nm and emission 
at 520 nm) to determine the amount of released DOX.  
Determination of critical micelle concentrations (CMC).  The CMC value of 
vesicles was measured by pyrene-based fluorescence measurement. The stock solution of 
vesicles was freshly prepared and diluted to a series of concentrations. Pyrene solution (0.1 
mg/L) was slowly added to each sample solutions with pyrene final concentration of 1.0 × 10
-
7
 mol/L. The fluorescence spectra was recorded on fluorescent spectroscopy (Infinitie pro 
200M, TECAN). The excitation wavelength was set at 345 nm and the emission wavelength 
was set at 390 nm.  The CMC was calculated by plotting I3 (385 nm) / I1 (374 nm) vs 
concentrations.  
Drug encapsulation. Various amounts of Dox·HCl was dissoved in 1 mL of 
deionized water and added to 10 mg of CD-SS-pDPA-pDMAEMA/AdPEGMAFA inclusion 
complex. The solution was stirred for 72 h at R.T. 1 mM of NaOH was added to the solution 
to adjust the pH to 7.4 slowly, and stirred for 24 h. The unloaded DOX molecules were 
precipitated and removed by centrifugation and filtration.  The drug loaded particles were 
obtained by freeze drying. 
Drug loading level and encapsulation efficiency. To determine DOX loading level 
and encapsulation efficiency, 1 mg of DOX-loaded micelle was dissolved in 1 mL 
DMSO/H2O (v/v 1:1). The DOX concentration was estimated with a fluorescence 





spectroscopy (excitation at 485 nm and emission at 520 nm). The drug content in the solution 
was determined based on the standard curve obtained from DOX in DMSO. The loading 
level (LL) and encapsulation efficiency (EE) of DOX were calculated based on the following 
formulas:  
                                              
          
                
                                      (1) 
                                           
                   
                 
                   (2) 
Particle size and zeta potentials. DOX-free, DOX-loaded, siRNA-loaded 
nanoparticles were prepared as above indicated. Particle size and zeta potentials of 
nanoparticles were measured by dynamic light scattering using a Zetasizer Nano ZS 
instrument (Malvern).  
siRNA binding ability. The siRNA binding ability of blank vesicle and 20%DOX-
vesicle were evaluated by agarose gel electrophoresis. The blank vesicle and 20%DOX-
vesicle were prepared as indicated in supporting information. 20%DOX-vesicle/siRNA 
vesicleplexes were prepared by mixing equal volumes of siRNA (containing 2 pmol siRNA) 
and serially diluted concentration of DOX-loaded or DOX-free vesicles, and incubated for 30 
min at R.T. Complexes were loaded onto a 2% agarose gel containing SYBR safe dye. 
Electrophoresis was performed at 100 mV for 30 min. The results were imaged under UV 
illumination of gel imaging system (Syngene). 
Morphological observation. Morphologies of various nanoparticles (DOX-free, 
DOX-loaded, siRNA-compacted) formed at pH 5.0 and pH 7.4 were observed by 
transmission electron microscopy (TEM), respectively. A small volume (10 L) of freshly 
prepared nanoparticles was added to a 200 Mesh Copper/Carbon Film (Agar Scientific) and 
allowed to absorb for 60 s. The film was then dried and stained by a droplet of 1% 
phosphotungstic acid (PTA) for 10 s. Afterwards, the film was dried by air. Imaging was 
conducted by a JEOL-JEM 3010 transmission electron microscopy.  
Construction of multiple drug resistant KB cells. KB, oral carcinoma cell line, was 
purchased from ATCC. KB/DOX cells (DOX induced multidrug resistant cells) were 
established by selection of parental KB cells exposed to increasing concentrations of DOX to 
10 g/mL and were maintained in 1 g/mL of DOX, as described previously [1-2]. After a 1-
year period of cell culturing, these KB/DOX cells were tested for expression of MDR1 protein 
by western blots. Dox were removed from the KB/DOX cell lines 1 week before assays. 





Western blotting. Western blot analysis was performed to verify the construction of 
KB/DOX cells and the silencing effect of siRNA-MDR1 loaded nanoparticles. Briefly, 30 g 
protein was separated by 10% SDS-PAGE gel, and blotted onto a PVDF membrane. The 
membrane was incubated with MDR-1 primary antibody (1:1000 v/v, Santa Cruz 
Biotechonology, Inc.), and horseradish peroxidase conjugated goat anti-rabbit IgG (1:5000 
v/v, Life Technologies), as described by the manufacturer. Image of protein band was 
recorded by ChemiDox MP (Bio-Rad Laboratories). GADPH was used as the negative control 
protein. 
Assessment of silencing effects on multidrug resistance protein (P-glycolprotein). 
KB/DOX cells or KB cells were seeded into 24-well plate with a density of 8 × 10
4
 cells/well 
and cultured for 24 h. The medium was replaced by fresh medium containing various siRNA 
loaded samples. After incubated for predetermined time, cells were washed with cold PBS for 
three times. Cells were then lysed for western blot analysis, as outlined in the Supporting 
information. A commercially available transfection reagent Lipofectamine 2k was used as 
positive control. Scrambled siRNA (siRNA-NEG) was used as negative control.  
Cellular uptake study. Two-color flow cytometry was employed to determine the 
cellular uptake of nanoparticels co-encapsulating FITC-siRNA-MDR1 and DOX in normal 
KB cells and multiple drug resistant KB/DOX cells. FITC-siRNA-NEG, free DOX, and 
physical mixture of free DOX and FITC-siRNA-MDR1 formulated nanoparticles were used 
as negative controls. To determine the cellular uptake, both KB and KB/DOX cells were 
seeded into 24-well plates and incubated at 37 °C for 24 h until cells reached 70% confluency. 
Nanoparticles containing DOX (10 g/mL equivalent DOX) and FITC-siRNA (N/P ratio of 
20) were incubated with cells for 4 h, 24 h and 48 h, respectively. After incubations, cells 
were washed with cold PBS for three times, then the cells were trypsinized, and finally 
analyzed on a FACsort flow cytometer (Beckman). Flow cytometric data were measured 
using a 488 nm laser and FL1 band-pass emission for the green FITC-siRNA (520 nm) and 
FL3 band pass emission (610 nm) for red DOX. Flow cytometric dot plots and fluorescence 
histograms were created by FCS Expression Flow Research Edition.  
Observation of cellular uptake of DOX-loaded nanoparticles. Fluorescence 
microscopy was employed to examine the cellular uptake of DOX. KB/DOX and KB cells 
were seeded in the 24-well plates at a density of 8 × 10
5
 cells/well and cultured for 24 h. Then 
cells were exposed to DOX- and siRNA-MDR1- co-loaded nanoparticles (with equivalent 10 
g/mL of DOX) for further incubations. Free DOX was used as controls. At the 





predetermined incubation time (1 h, 2 h, 3 h, 4 h, 12 h, and 24 h), the cells were washed with 
cold PBS for three times, and fixed with 4% of parafomaldehyde in PBS at room temperature 
for 30 min. After fixation, cells were rinsed by PBS for three times and observed by 
fluorescence microscopy. 
Intracellular trafficking of DOX. Intracellular distributions of free DOX or DOX 
encapsulated nanoparticles were observed by confocal laser scanning microscopy. KB/DOX 
or KB cells were seeded into 8-chambered borosilicate coverglass system (Lab-Tek), at a 
density of 1.2 × 10
4
 cells/chamber, and cultured until they reach 70% confluency. The 
medium was replaced with 300 L of fresh medium containing free DOX or 20%DOX-
vesicle/FITC-siRNA-MDR1 (equivalent to 10 g/mL DOX) and incubated for predetermined 
time (12 h, 24 h, and 48 h) at 37 °C. Then cells were fixed with 4% paraformaldehyde for 3 
min, and the nucleus were stained with DAPI (final concentration 2 g/mL) for 2 min. Finally, 
cells were washed with PBS for 3 times and observed under a confocal laser scanning 
microscope. Images were analyzed by ImageJ software. KB cells were treated with free DOX. 
KB/DOX cells were treated with DOX or 20%-DOX-NP/FITC-siRNA-MDR1, and KB/DOX 
cells for GSH inhibition treatment was firstly incubated with buthionine sulphoximine  (BSO) 
(300 nM) for 10 h.  
Evaluation of apoptosis level on KB/DOX cells. The apoptosis level induced by 
vescleplexes co-encapsulating DOX and siRNA-MDR1 after 48 h incubation was assessed by 
Anexin V/propidium idodie (PI) co-staining assay. The apoptosis level induced by DOX 
loading nanoparticles in the presence or absence of siRNA-MDR1 were compared with the 
levels induced by free DOX and physical mixture of free DOX and siRNA-MDR1 loaded 
nanoparticles. Treated and untreated KB cells or KB/DOX cells were harvested with samples 
for 48 h. Prior to analysis via flow cytometry, cells were stained with FITC-Annexin V at R.T. 
for 10 min, and followed by PI staining on ice for 15 min.  
Evaluation of anti-tumor effects on KB/DOX cells. The anti-cancer activities on 
KB/DOX or KB cells were evaluated using MTT assays. The cytotoxicities induced by DOX 
loading vesicles in the presence or absence of siRNA-MDR1 were determined and compared 
with the anti-tumor levels induced by free DOX and physical mixture of free DOX and 
siRNA-MDR1 loaded nanoparticles. Untreated KB/DOX or KB cells served as negative 
controls. Generally, KB/DOX or KB cells were seeded into 96-well plate at a density of 
10,000 cells/well. The growth medium was replaced with fresh medium with DOX and 
siRNA-MDR1 co-loaded  samples containing various amounts of DOX and with various drug 





loading contents. Cells were incubated at predetermined times. After that, 15 L of MTT 
solution (5 mg/mL) was added to each well and cells were further incubated for additional 4 h. 
The medium was removed and washed with cold PBS. 200 L of DMSO were added into 
each well to dissolve the fomazan crystal. The absorbance of each well was measured at 570 
nm. The cell viabilities were calculated as, 
Cell viabilities (%) = (Isample – Iblank) / (Icontrol - Iblank ) × 100%               (3) 
where Isample, Icontrol, and Ibalnk represents for cells treated with samples, for control cells 
(untreated cells), and for blank wells with no cells, respectively. 
In this study, effects of DOX concentrations (1 g/mL, 2g/mL, 5 g/mL, 10 g/mL 
and 20 g/mL), drug loading contents (5 wt%, 10 wt%, 15 wt%, and 20 wt%), incubation 
time (12 h, 24 h, 48 h, and 72 h), and N/P ratios (N/P 10, N/P 20, and N/P 30) on the anti-
tumor effects were evaluated, respectively.  
Statistical analysis. Statistical analysis was performed using variance test by 
Microsoft Excel 2007. Data sets were compared using two-tailed un-paired t-test. p < 0.05 
was defined as statistically significant. 
5.3 Results and Discussion 
5.3.1 Synthesis and characterization of supramolecular triblock copolymer 
Star-shaped host copolymer CD-SS-pDPA-pDMAEMA was synthesized by 
sequential monomer addition atom transfer radical polymerization (ATRP) method. Starting 
from ATRP macroinitiator CD-SS-Br, monomer DPA was firstly added. Monomer 
DMAEMA was added after the conversion of pDPA exceeded > 99% as judged by 
1
H NMR 
spectrum. The polymer synthesis scheme and typical 
1
H NMR spectra of host polymer were 
shown in Figure 5.2 (A) and Figure 5.2 (B) in the supporting information, respectively. The 
compositions of star-shaped copolymers were determined by 
1
H NMR spectra in CDCl3 by 
comparing the integration of peaks c (pDPA) and h (pDMAEMA). Molecular weight of 
copolymers were measured by GPC (Table 5.1). It was determined that there were 4 arms of 
pDPA--pDMAEMA attached to the -CD core, and the degree of polymerization (DP) of 
total 4 arms of pDPA and pDMAEMA were 163 and 57. Other host polymer CD-SS-pDPA 
and CD-SS-pDMA were also synthesized by using a similar protocol as various controls. 
Guest polymer Ad-pEGMA-FA was synthesized and characterized as previously described in 





Chapter 4. The DP of Ad-pEGMA was determined to be 22 and the number of folic acids 
conjugated to pEGMA chain was 6. The CD-SS-pDPA-pDMAEMA/Ad-pEGMA-FA 
supramolecular pseudo-triblock copolymer was formed by mixing the host and guest 
polymers at 1:1 molar ratio in 0.01 M HCl solution (pH = 2). For brevity, the above polymers 
were abbreviated as follows: pE denoted a poly(ethylene glycol) monomethyl ether 
methacylate block, FA denoted folic acid, pP denoted a poly(2-(diisopropyl-amino)ethyl 
methacrylate) (pDPA) chain and pM denoted a poly(2-(dimethyl-amino)ethyl methacrylate) 
(pDMAEMA) block, with the supromolecular pseudo-triblock copolymer having the formula 
of CD-SS-pP-pM/Ad-pE-FA. 
 
Figure 5.2 (A) Synthesis scheme of supramolceular triblock polymer CD-SS-pDPA-
pDMAEMA. (B) 
1
H NMR (CDCl3) of  CD-SS-pDPA (upper) and CD-SS-pDPA-
pDMAEMA (bottom).  
Table 5.1 Molecular weight of polymers synthesized by ATRP, determined by GPC. 
Sample Abbreviation Mn, GPC Mw/Mn 
CD-SS-pDPA-pDMAEMA CD-SS-pP-pM 44500 1.23 
CD-SS-pDPA CD-SS-pP 34800 1.15 
CD-SS-pDMAEMA CD-SS-pM 9000 1.18 
Ad-pEGMA Ad-pE 8200 1.20 
Ad-pEGMA-FA Ad-pE-FA 11000 1.21 
 
 





5.3.2 Physicochemical properties of polymers, vesicles, vesicleplexes 
Preparation of DOX encapsulated vesicles. Vesicle type nanoparticles of CD-SS-pP-
pM/Ad-pE-FA with/without DOX were prepared by pH gradient methods (simply adjusting 
the pH of CD-SS-pDPA-pDMA/Ad-pEGMA-FA solution from 2 to 7.4). The triblock 
copolymers were colorless and molecularly dissolved in aqueous solution with pDPA block 
as a weak cationic polyelectrolyte when the pH was below 5. When pH increased above 6, 
the solution changed to milky white, implying the self-assembly of triblock copolymer was 
formed (Figure 5.3). This was because the deprotonation of pDPA segments led it to be 
insoluble. The critical micelle concentration (cmc) was calculated to be  2.2 × 10-3 mg/mL 
by fluorescent probes pyrene-based technique (Figure 5.4). For DOX encapsulation, the 
amounts of DOX feed were optimized to 20 wt%, among the feeding ratio from 5 wt% to 30 
wt%. The vesicles can have loading levels of 17.1 ± 0.8%, with encapsulation efficiency of 
73.1 ± 5.7 % (Figure 5.5). The particle size and zeta potentials of the DOX-loaded 
polymersomes were measured by DLS (Figure 5.6 (A)). The polymersomes with 20 wt%  
DOX loading were ca. 30 nm larger than the DOX-free ones. This phenomenon agreed with 
the observations of other polymeric nanoparticles that encapsulating of hydrophobic drug led 
to increase of particle size [262]. The zeta potentials of vesicles with various DOX loading 
densities were maintained at approximately +13 mV, suggesting that loading of DOX had 
neglect effect on the zeta potentials of the particles. 
 
Figure 5.3 Digital photographs of aqueous solutions of supramolceular triblock pseudo-
copolymer at the concentration of 5 mg/mL. (Left pH = 2, right pH = 7.4). 






Figure 5.4 Critical micelle concentration (CMC) of CD-SS-pDPA-pDMAEMA self-
assembles determined by the pyrene-technology. 
 
 
Figure 5.5 (A) Standard curve of doxorubicin (DOX) detected with a fluorescence 
spectroscopy (excitation at 485 nm and emission at 520 nm). (B) Fluorescence spectra 
determined DOX-loading contents and encapsulation efficiency. Encapsulation efficiency 
and loading level in vesicels (n=2 independent batches), based on 10 mg of CD-SS-pDPA-
pDMAEMA/Ad-pEGMA-FA polymer. 






Figure 5.6 (A) Particle size and zeta-potential of DOX-loaded CD-SS-pDPA-
pDMAEMA/Ad-pEGMAFA polymersomes. Particle size (B) and zeta potential (C) of DOX-
vesicle/siRNA vescileplexes at different N/P ratios and DNA loading densities. 
Physicochemical properties of polymer. The pH titration curve of supramolecular 
triblock copolymer CD-SS-pP-pM/Ad-pE-FA (blue line) was compared with the control 
pseudo diblock copolymers CD-SS-pP/Ad-pE-FA (red line) and CD-SS-pM/Ad-pE-FA 
(orange line) (Figure 5.7 (A)). The pKa of diblock copolymer CD-SS-pP/Ad-pE-FA and 
CD-SS-pM/Ad-pE-FA were determined to be 6.41 and 7.34, respectively. As the pKa(s) of 
CD-SS-pP-pM/Ad-pE-FA with dual functional groups may overlap, the pKa of triblock 
copolymer CD-SS-pP-pM/Ad-pE-FA was re-calculated using interation method [263], 
starting from the pKa value determined at the half-way neutralization point (pKa = 6.96 half-
way neutralization point). After correction, dual pKa values of CD-SS-pP-pM/Ad-pE-FA 
were calculated to be 6.33 and 7.05, which corresponded to pDPA and pDMAEMA segments, 
-SS-pP-
pM/Ad-pE-FA and diblock CD-SS-pP/Ad-pE-FA, probably correlated to the deprotonation 
of the tertiary ammonium groups of pDPA chains. This observation was in agreement with 





the previous [264]. More specifically, change of pH unit verse degree of deionization ( is 
defined as mole portion of neutrally charged amines,  = [R3N]/([R3N]+[R3NH+]))was 
calculated. For pH sensitive CD-SS-pP-pM/Ad-pE-FA, amines deionized from 20% to 80% 
within 0.24 pH units, as compared to 1.67 and 0.67 pH units and for diblcok copolymer CD-
SS-pM/Ad-pE-FA and CD-SS-pP/Ad-pE-FA. These data indicated supramolecular triblock 
copolymer CD-SS-pP-pM/Ad-pE-FA had a strong buffering capacity. 
Release of DOX under various conditions. In vitro drug release from DOX-loaded 
vesicles were evaluated in PBS (pH 5 and pH 7.4), with and without dithiothreitol (DTT) (30 
mM). The drug release kinetics profiles were shown in Figure 5.7 (B). The release of DOX in 
PBS (pH 7.4) was slow. Only 10% of DOX was released from the nanoparticles in the first 
48 hours and achieved 50% of release 6 days incubation. The slow release of DOX from 
CD-SS-pP-pM/Ad-pE-FA nanoparticles at physiological conditions may ensure minimum 
drug release during blood circulation and minimize the side effect of DOX. As expected, 
release of DOX  from nanoparticles at pH 5 was much faster than that in pH 7, due to the 
protonation of pDPA blocks and disassemble of the nanoparticles. The results were in good 
agreement with the TEM observations (discussed in latter section). Furthermore, DOX 
release from CD-SS-pP-pM/Ad-pE-FA nanoparticles in redox environment was found to be 
much faster and the amount of DOX released from the particles was promptly increased, as 
compared to the release in physiological environment (no DTT treatment). ~40% and ~90% 
of DOX was released from particles when they were incubated in the PBS supplemented with 
30 mM DTT for 48 hours and 6 days, respectively. It was worth mentioning that the DOX 
release kinetics in high redox potential medium was a two-phase pattern, an initial fast 
release phase followed by a slow release phase. The appearance of beginning fast release of 
DOX was due to the cleavage of disulfide bonds under reductive environment. The relative 
slow release phase was ascribed to the declined wettability of vesicles resulting from the 
detachment of Ad-pEGMA-FA hydrophilic corona. Moreover, this “fast-slow” two-phase 
pattern was different from the unwanted pattern that a burst release followed by a controlled 
release phase, as it only occurred in intracellular high redox environment. It was supposed 
that this “fast-slow” two phase release pattern would benefit to the delivery of DOX [241]. 
The initial fast release of DOX would offer maximum therapeutic effects on the cancer cells, 
while the slow release of DOX could provide a maintenance dose to inhibit the revival of 
cancer cells after initial high dose treatment. 





Physicochemical properties of vesicle/siRNA particles. The siRNA binding 
abilities of DOX-free and DOX-loaded vesicle-CD-SS-pP-pD/Ad-pE-FA were examined by 
gel retardation assay (Figure 5.7 (C)). At N/P ratio of 3 and above, blank vesicle was able to 
completely retard the shift of siRNA, suggesting siRNA binding affinity by pDMAEMA 
located in the inner volume of vesicle was strong. After loading with 20% of DOX, siRNA 
band was completely retarded by 20%DOX-vesicles at N/P ratio of 4, indicating that siRNA 
binding ability was slightly decreased after loading with DOX. After siRNA complexation, 
particle size of vesicleplexes at N/P ratio of 10 to 30 were found to be comparable to that of 
the corresponding DOX-loaded micelles at various loading levels (Figure 5.6 (B)). The 
surface charges of DOX- and siRNA- co-encapsulated nanoparticles decreased with increase 
of N/P ratios (Figure 5.6 (C)). These trends were observed at all nanoparticles with various 
DOX loading levels.  
Morphologies of particles. Morphology of the self-assemblies were further 
characterized by transmission electron microscopy (TEM). At pH 5 (the pKa of the pDPA 
segment of polymer CD-SS-pDPA-pDMA/Ad-pEGMA-FA was 6.33), no DOX-free or 
DOX-loaded nanoparticles were observed by TEM (Figure 5.7 (D)). Only unimers of CD-
SS-pDPA-pDMA were present in TEM images, which was related to the protonation of the 
pDPA segment and dissociation of the nanoparticles (Figure 5.7 (E)-a). DLS studies (data not 
shown) also revealed that below pH 5, the pseudo polymer CD-SS-pP-pM/Ad-pE-FA was 
molecularly dissolved in water. At pH 7.4, generating polymersomes of CD-SS-pP-pM/Ad-
pE-FA was confirmed by TEM. The DOX-free and 20%-DOX-loaded nanoparticles (Figure 
5.7 (D)-b) both showed vesicular morphology with well-defined unilamellar membranes, due 
to the deprotonation of the tertiary amine groups of pDPA chains at neutral pH. The particle 
sizes were reasonably consistent with the diameter determined by DLS. Based on the TEM 
images and the inherent propensity of triblock cpolymer CD-SS-pP-pM/Ad-pE-FA, it was 
predicted that deprontanated pDPA blocks formed the vesicle membrane, pEGMA-FA 
formed the corona of membrane and pDMAEMA chains were preferentially located in the 
interior of vesicles (Figure 5.7 (E)-b). The average of pDPA membrane thickness of DOX-
free and DOX-loaded nanoparticles was ~10 nm and ~20 nm, respectively. After 
complexation with siRNA, the representative TEM images showed that the particles formed 
at pH 5 were all spherical and compacted particles, in both cases of DOX free and DOX-
loaded (Figure 5.7 (D)-c). This was because the pDPA block became weak cationic 
polyelectrolyte at low pH and was able to bind to negatively charged siRNA. This acidic pH 





triggered the transition from DOX free or DOX-loaded- vesicle/siRNA vesicleplexes to 
siRNA-copolymer complex (Figure 5.7 (E)-c). At pH 7.4, the DOX- and siRNA- co-
encapsulated nanoparticles demonstrated vesicular type (Figure 5.7 (D)-d). It was considered 
that the pDPA chain of pseudo-polymer was deprotonated and resulted in the formation of 
non-hydrated vesicle membrane. Hydrophobic DOX was encapsulated in this membrane 
layer. The cationic pDMA block interacted with siRNA to be the cationic inner volume of 
vesicle, whereas pEGMA-FA acted as the outer leaflet of vesicle (Figure 5.7 (E)-d). 
Moreover, pseudo-polymer CD-SS-pM/Ad-pE-FA was used as a control to form siRNA 
complexes at both pH 5 (Figure 5.7 (D)-e) and 7.4 (Figure 5.7 (D)-f). Only spherical and 
compact particles were observed and no vesicular type particles were found,  indicating that 
the morphologies of self-assemblies were significantly affected by the composition of 
copolymer. Triblock copolymer with pDPA and pDMAEMA chains formed vesicles whereas 
diblock copolymer with only pDMA block while without pDPA chains led to simple 
complexes with compact cores.  
In this study, we refer the x wt% DOX loaded polymersome (vesicle) as x%DOX-
vesicle, and refer vesicle-mediated formation of siRNA complex to “vesicleplex”. The x wt% 
DOX- and siRNA co-loaded vesicles were denoted as x%DOX-vesicle/siRNA (x%DOX-
vesicleplex). 






Figure 5.7 (A) Titration curves of supramolecular triblock copolymer CD-SS-pDPA-
pDMAEMA/Ad-pEGMA-FA (CD-SS-pP-pM/Ad-pE-FA). Diblock pseudo-copolymer 
CD-SS-pDPA/Ad-pEGMA-FA (CD-SS-pP/Ad-pE-FA) and CD-SS-pDMAEMA/Ad-
pEGMA-FA (CD-SS-pM/Ad-pE-FA) were used as references. (B) Drug release profile of 
20%DOX-vesicles under different conditions, including in pH 5 and pH 7.4 PBS, and in PBS 
with 30 mM DTT. Free DOX was used as controls. (C) Gel retardation assay showed the 
siRNA bindiding ability by DOX-free or DOX-loaded  nanoparticles formed by self-
assembles of CD-SS-pP-pM/Ad-pE-FA pseudo copolymers. (D) TEM images of (a) and (b) 
DOX-free or 20% wt DOX-loaded nanoparticles at pH 5 and 7.4. (c) and (d) DOX-free or 20% 
wt DOX-loaded vesicle/siRNA vesicleplexes at pH 5 and pH 7.4. (e) and (f) Polyplexes 
formed by CD-SS-pDMAEMA and siRNA were used as controls. Small spheres (~10 nm) 
were artifacts from the staining reagent. (E) The possible structure of self-assembly 
depending the morphology obtained by TEM and  copolymer inherent properties. (a) 
Supramolceular triblock copolymer CD-SS-pP-pM/Ad-pE-FA was moleclularly dissolved 
in pH 5 aqueous solution, due to the protonation of pDPA and pDMAEMA segments. (b) 
CD-SS-pP-pM/Ad-pE-FA self-assembled to asymmetric polymersomes when the pH was 
adjusted to 7.4, where the central hydrophobic pDPA bridging the membrane with segregated 
hydrophilic pEGMA-FA and cationic pDMAEMA locating in the exterior and interior of 





vesicles, respectively. (c) siRNA were complexed by pDPA and pDMAEMA and solid 
copolymer-siRNA complexes was formed, due to the protonation of pDPA and pDMAEMA 
segments at pH 5. (d) CD-SS-pP-pM/Ad-pE-FA self-assembled to asymmetric vesicles with 
DOX loaded into pDPA layer and siRNA compacted in the pDMAEMA inner volume at pH 
7.4. 
5.3.3 Reversal of multidrug resistance of KB/DOX cells 
Prior to evaluate the ability of CD-SS-pP-pM/Ad-pE-FA/siRNA vesicleplex of 
silencing the P-glycoprotein (P-gp) encoded with MDR1 gene, a DOX-resistant cell line 
(KB/DOX) was established. It was confirmed by western blotting that the P-gp expression 
levels of KB/DOX were markedly raised compared to the original KB cells (Figure 5.8 (A)). 
The DOX sensitivity of the KB/DOX cells (IC50 = 8.25 g/mL after 24 h incubation) 
decreased 10-fold compared to the parental KB cells  (IC50 = 870 g/mL after 24 h 
incubation). The efficacy of silencing the MDR1 gene with vesicle/siRNA in KB/DOX cells 
was evaluated at MDR1 protein expression level, and compared to commercial transfection 
reagents Lipofectamine 2k. As shown in Figure 5.8 (A), both DOX-free and 20%DOX-
loaded vesicleplexes (N/P ratio of 20) effectively delivered siRNA-MDR1, which resulted in 
significant suppression of drug efflux protein expression in KB/DOX cells. The MDR1 
silencing level of 20%DOX-vesicle/siRNA was even higher than that of commercially 
available transfection reagent Lipofectamine 2k. In addition, loading with DOX increased the 
down-regulation levels of MDR1 genes, but the DOX loading contents ranging from 5 wt% 
to 20 wt% had no influence on the gene transfection efficacy (Figure 5.8 (B)). It was 
indicated that the delivery of DOX did not affect the ability of the siRNA-MDR1 to suppress 
the P-gp in cancer cells, which was beneficial to the synergistic delivery of DOX and siRNA. 
Furthermore, it was observed that increase of N/P ratio exhibited positive effects on the 
MDR1 knockdown levels (Figure 5.8 (C)). Vesicleplexes formed at N/P ratio of 20 and 30 
were more efficient in silencing than particles prepared at N/P ratio of 10. As demonstrated in 
Figure 5.8 (D), 48-hour incubation period was the optimized time for silencing. Either shorter 
or longer incubation time decreased the knockdown efficiencies. 






Figure 5.8 MDR1 protein expression measured by western-blotting. GADPH protein was 
used as negative controls. (A) Lane 1-2: Verification of DOX-resistant property of KB/DOX 
cells. Lane 3-8: Comparisons of the silencing effect Lipofectamine 2k, DOX free and 20% 
DOX loaded vesicleplexes. (B) Effect of DOX loading contents on the silencing of MDR1 
protein. (C) Effect of N/P ratios on the downregulation of MDR1 protein. (D) Effect of 
incubation time on the silencing of MDR1 protein. 
5.3.4 Cellular uptake of DOX and siRNA  
Two-color flow cytometry was employed to quantify the cellular uptake of DOX- and 
FITC-siRNA- co-loaded vesicleplexes by both normal KB cells and DOX-resistant KB/DOX 
cells. As shown in Figure 5.9 (A), (a) free DOX demonstrated weak accumulation in 
KB/DOX cells, due to the subtraction of P-gp. However, delivery of DOX by (b) CD-SS-
pP-pM/Ad-pE-FA vesicles led to elevated intracellular levels of DOX in KB/DOX cells, 
presumably attributed to the bypass of P-gp recognition with the aid of vesicles via the folate 
receptor mediated endocytosis. Treatment of resistant KB/DOX cells with (d) 20%DOX-
vesicle/siRNA-MDR1 led to further increase in intracellular accumulation of DOX, which 
was associated with siRNA-MDR1 mediated suppression of P-gp drug efflux pump. 
Importantly, the amount of DOX transported by (d2) vesicleplex co-encapsulated with DOX 
and siRNA-MDR1 were significantly more than (c2) vesicleplexes with DOX and siRNA-
NEG (scrambled siRNA), which further verified the down-regulation effect of P-gp mediated 
by siRNA-MDR1 transfection. It was confirmed that delivery of siRNA-MDR1 induced the 
re-sensitization of MDR cells to DOX. In addition, it was worth noting that cellular uptake of 
DOX delivered by (d) vesicleplexes co-encapsulated with DOX and siRNA-MDR1 were 
more efficient than (f) free DOX, which was physically mixed with vesicleplexes loaded only 





with siRNA-MDR1. These observations confirmed that DOX and siRNA-MDR1 co-delivery 
system performed better than separate vesicle populations. In summary, vesicular 
nanoparticles containing dual therapeutic reagents DOX and siRNA-MDR1 demonstrated the 
highest levels of DOX resistance reversal and highest DOX internalization.  
The efficiency of delivering DOX to KB and KB/DOX cells by vesicleplexes and 
other control systems were further summarized as DOX positive cell population in bar graphs 
(Figure 5.9 (B)). Generally, the DOX-positive cell population increased with the prolongation 
of the incubation period. In the case of delivering DOX to KB/DOX cells with a 48 h 
incubation time, the DOX positive cell percentage increased from 3.9 ± 0.6% for free DOX to 
31.3 ± 0.6% for 20%DOX-vesicles. After siRNA-MDR1 transfection, the DOX uptake 
percentages increased to 87.3 ± 3.5% for physical mixture of free DOX and siRNA-MDR1 
loaded vesicleplexes and 99.2 ± 0.6% for vesicleplexes containing 20 wt% DOX and siRNA-
MDR1. DOX accumulation in DOX resistant KB/DOX cells was elevated approximately 8-
fold with vesicle transportation and achieved 22-25 folds increase when combined with 
MDR1 for P-gp silencing relative to free DOX. 
 





Figure 5.9 Cellular uptake vesicleplexes containing DOX and FITC-siRNA-MDR1 in KB 
cells and KB/DOX cells. (A) Flow cytometry dot plots showing the distribution of DOX and 
FITC-siRNA on KB and KB/DOX cells. KB and KB/DOX cells were incubated with 
determined samples for 4 h. Upper panel: KB cells. Bottom panel: KB/DOX cells. (a) 
untreated; (b) free DOX; (c) 20%DOX-vesicle/siRNA-NEG vesicleplexes; (d) 20%DOX-
vesicle/siRNA-MDR1 vesicleplexes; (e) physical mixture of DOX and vesicle/siRNA-NEG; 
(f) DOX physical mixture of DOX and vesicle/siRNA-MDR1. (B) Percentage of cells 
containing internalized DOX, which were quantified by flow cytometry. Results were 
reported as mean ± S.D., (n=3). 
The cellular uptake of DOX by KB and KB/DOX cells was further studied by 
fluorescence microscopy (Figure 5.10). The red fluorescence in the cells treated with 
20%DOX-vesicle/siRNA-MDR1 was significantly more and brighter than the cells treated 
with free DOX at the same incubation time, indicating that intracellular accumulation of 
DOX was remarkably enhanced by the dual-delivery system in DOX resistant cells. This 
observation was consistent with the data of flow cytometry studies (Figure 5.9 (B)). Thus, use 
of CD-SS-pP-pD/Ad-pE-FA vesicular particles as co-delivery platforms could enhance 
DOX accumulation in DOX resistant cells by bypassing the P-gp drug efflux pump and 
down-regulating the expression levels of P-gp via siRNA-MDR1 gene silencing. 
 
 
Figure 5.10 Fluorescence microscopic images of free DOX at 10 g/mL and 20%DOX-
vesicle/siRNA-MDR1 vesicleplexes internalized by (A) KB cells and (B) KB/DOX cells at 
various incubation time points. Magnification: 10×. 





5.3.5 Intracellular distribution of DOX  
    Confocal microscopy was used to evaluate the intracellular distribution of DOX in 
drug resistant KB cells after treatment with vesicular co-delivery system. Similar to the flow 
cytometry study, free DOX, exhibited un-detectable red fluorescence inside the resistant 
KB/DOX cells. Thus, only DOX sensitive KB cells could be used to evaluate the intracellular 
localizations of DOX. The representative confocal images of KB cells treated with free DOX 
(Figure 5.11 (A)) and KB/DOX cells incubated with vesicular nanoparticles containing DOX 
and FITC-labeled siRNA-MDR1 (Figure 5.11 (B)) were shown. Strong DOX fluorescence 
(red) and FITC-siRNA fluorescence (green) were observed in KB/DOX cells, which were 
treated with 20%DOX-vesicle/FITC-siRNA-MDR1. At the same incubation time, the red 
fluorescence intensity (DOX) was even higher in the KB/DOX cells treated with 20%DOX-
vesicle/FITC-siRNA-MDR1 than that of free DOX treated KB cells. The speed of 
internalization of DOX loaded in the dual delivery system by DOX-resistant KB cells were 
also faster than that of free DOX by DOX-sensitive KB cells. The higher DOX fluorescence 
intensity in the cells treated with dual-delivery vesicleplex was probably ascribed to the 
enhanced cellular uptake through folate receptor mediated active endocytosis, whereas DOX 
entered cells by slow passive diffusion. These observations were in line with the cellular 
uptake results determined by flow cytometry. 
It was known that the mechanism of DOX-induced killing cancer cells was to 
intercalate with DNA to cease its replication [265]. DNA molecules were mainly located in 
the nucleus. Hence, designing a nuclear targeted DOX delivery system was crucial to DOX-
based cancer therapy. In order to evaluate whether our co-delivery vesicleplexes were able to 
achieve DOX accumulation in nucleus, the intracellular distributions of DOX were observed 
and analyzed. Figure 5.11 (C) showed the line-scale profiles suggesting the overlaps of DOX 
fluorescence  (red colored line) and DAPI fluorescence (blue colored line). For free DOX 
(Figure 5.11 (C)-a), as expected, the majority of red signals of DOX was concentrated in 
nuclear zone of KB cells stained with DAPI, showing magenta color in the merge image. 
This was because the free DOX could diffuse into nuclei and further intercalate with DNA 
after it entered into cells. However, to our surprise, high nuclear accumulation was also 
observed for DOX co-delivered with siRNA-MDR1 by the vesicular system. As qualitatively 
indicated in the line profiles, the majority of red fluorescence clearly overlapped with the 
region of nucleus (Figure 5.11 (C)-b), which was similar to that of free DOX (Figure 5.11 
(C)-a). We had already verified that DOX released from the vesicular nanoparticles in a “fast-





slow” two phase release pattern under redox conditions (Figure 5.7 (B)). It was highly 
possible that the fast and complete release of DOX from the system in the cytoplasm 
triggered by degradation of disulfide linkages of system led to the nuclear accumulation of 
DOX. To validate whether the degradation of disulfide linkages facilitated the nucleus 
targeting of DOX, we inhibited the activity of glutathione (GSH) of KB/DOX cells, which 
was the major redox for intracellular disulfide linkage degradation, by treating cells with 
buthionine sulphoximine (BSO) prior to incubation with DOX-loaded vesicleplex. Once the 
cells were treated with BSO, the disulfide linkers were supposed not to be degraded inside the 
cells. Figure 5.11 (C)-c showed that with BSO treatment, DOX fluorescence signals 
dominantly appeared in the region adjacent to nucleus for the cells incubated with 20%DOX-
vesicle/FITC-siRNA-MDR1 for 24 hours. The red fluorescence intensity in the nuclear zone 
was much weaker than that from BSO untreated cells, indicating that DOX failed to achieve 
nuclear accumulation once the disulfide bonds were not degraded. It was worth pointing out 
that most of the red fluorescence (DOX) were colocalized with green fluorescence (FITC-
siRNA-MDR1), implying that the majority of DOX and FITC-siRNA-MDR1 were still 
encapsulated in the vesicles and not released. These observations were in good agreement 
with the drug release profile of the system under normal physiological conditions that less 
than 5% of DOX were released from the particles (Figure 5.7 (B)). Thus, it was proved that 
the degradation of disulfide linkers followed by fast release of DOX was the major cause to 
the nuclear targeting delivery of DOX. Moreover, much lesser extent of DOX accumulation 
was observed after incubation with vesicleplex containing DOX and scrambled FITC-siRNA 
(data not shown). The reason for that was presumably because once the drug efflux pump was 
not de-activated, the released DOX in the cytosol was pumped out of the cells by the P-gp 
and failed to accumulate in the nucleus of MDR cells. Based on the above results, it was 
considered that enhanced cellular uptake by the folate receptor mediated endocytosis, 
suppression of the drug efflux pump on the cell membrane, and fast release of DOX induced 
by the degradation of disulfide bonds of the nanoparticles were three major elements 
contributing to the nuclear zone enrichment of DOX. 






Figure 5.11 Confocal microscopic observation of intracellular trafficking of DOX and FITC-
siRNA-MDR1 delivered by CD-SS-pP-pM/Ad-pE-FA vesicleplexes at various incubation 





times. (A) Intracellular distributions of DOX in KB cells. (B) Intracellular distributions of 
DOX and FITC-siRNA-MDR1 in KB/DOX cells, which were treated with 300 nM of BSO or 
with no pre-treatment. (C) Comparison of the nucleus localization of DOX in indicated cells. 
(a) Free DOX in KB cells. (b) DOX delivered by 20%DOX-vesicle/FITC-siRNA-MDR1 
vesicleplexes in KB/DOX cells. (c) DOX delivered by 20%DOX-vesicle/FITC-siRNA-
MDR1 vesicleplexes in BSO pre-treated KB/DOX cells. Upper panel: Confocal images of 
intracellular distribution of DOX. Bottom panel: Analysis of the colocalization of DOX (red) 
and nucleus stained by DAPI, by establishing the line-scale profiles of cell fluorescence 
intensity. the cells. Red line, intensity of DOX; Blue line, intensity of nucleus. 
5.3.6 Evaluation of anti-cancer efficacies 
Based on the above results, we found that the vesicular co-delivery system not only 
enhanced the cellular uptake of DOX by avoiding the P-gp efflux pump recognition and 
resensatiting the MDR cells, but also facilitated the nuclear localization of DOX via 
intracellular fast release of DOX. To validate whether these advantages could be translated to 
anti-cancer effects in MDR cells, the apoptotic efficiency and cytotoxicity of the DOX 
encapsulated vesicleplexes were evaluated. To evaluate the apoptotic efficacy of DOX in 
different delivery varieties, FITC-Annexin V and Propidium Iodide (PI) apoptosis detection 
kits were used to co-stain the KB and KB/DOX cells. Live cells would show no staining. 
Cells, which were in the early apoptotic process, would be stained with the FITC-Annexin V 
alone. Necrotic cells would be stained by both Annexin V and PI. In this study, DOX 
concentration was set to be 2 g/mL. The red fluorescence emitted by DOX at this low 
concentration would not affect the determination of PI fluorescence. The cell status was 
analyzed by flow cytometry (Figure 5.12 (A)) and summarized in bar graph (Figure 5.12 (B) 
and Figure 5.12 (C)). The rank order in efficacy in induction of KB/DOX cell apoptosis and 
necrosis were shown as follows (from most effective to least): 20%DOX-vesicle/siRNA-
MDR1 >  physical mixture of free DOX and vesicle/siRNA-MDR1 > 20%DOX-
vesicle/siRNA-NEG > physical mixture of free DOX and vesicle/siRNA-NEG ≈ free DOX. 
Interestingly, this ranking was the same as that of cellular uptake efficiency (Figure 5.9 (B)). 
As expected, neglect apoptotic KB/DOX cells were detected for free DOX treatment as most 
of the drug were pumped out by P-gp. Encapsulated DOX successfully increased the number 
of apoptoic and necrotic cells as compared to free DOX by elevating the intracellular 
accumulation via bypassing of the P-gp recognition. In addition, there was a significant 
increase in both apoptoic cells and dead cells when treated with dual-delivery vesicleplexes 
containing both DOX and siRNA-MDR1, in comparison with the single DOX-loaded 
vesicles and vesicleplexes co-loaded with DOX and scrambled siRNA. It was suggested that 





transfection of siRNA-MDR1 down-regulated of P-gp efflux pump and highly restored the 
drug sensitivity of DOX resistant KB/DOX cells. The apoptosis efficacy of  20%DOX-
vesicle/siRNA-MDR1 was even higher than the physical mixture of free DOX- and siRNA-
MDR1- co-loaded vesicleplex, which validated that DOX and siRNA-MDR1 were co-
encapsulated in one particle and confirmed their synergistic effects for anti-cancer. It was 
worthy to mention that, physical mixture form of free DOX and siRNA-MDR1-encapsulate 
vesicplex were not suitable for in vivo application, as their discrepant pharmacokinetics might 
lead the DOX an siRNA-MDR1 to distribute in different cell population. 
 
Figure 5.12 Anti-tumor effect of 20%DOX-vesicle/siRNA-MDR1 vesicleplexes. (A) Flow 
cytometric histogram showing the apoptosis of KB and KB/DOX cells treated with various 
samples, which were assessed using Annexin V/PI staining. Both KB (upper panel) and 
KB/DOX cells (bottom panel) were incubated with indicated samples (a) untreated; (b) free 
DOX; (c) 20%DOX-vesicle/siRNA-NEG vesicleplexes; (d) 20%DOX-vesicle/siRNA-MDR1 
vesicleplexes; (e) physical mixture of DOX and vesicle/siRNA-NEG; (f) DOX physical 
mixture of DOX and vesicle/siRNA-MDR1.  Live cells: no staining; Apoptotic cells: FITC-
Annexin V staining alone; Necrotic cells: Annexin V and PI co-staining. The percentage of 
early apoptosis cells and necrotic cells of (B) KB cells and (C) KB/DOX cells were 
summarized in bar graph. (D) Cell proliferation profile KB and KB/DOX cells incubated with 
different samples. Results were reported as mean ± S.D., (n=3). ** p<0.01, *** p<0.001. 





Furthermore, cell viability of all modalities of DOX delivered was quantified by MTT 
assay. Toxicity of DOX-free vesicles and DOX-free vesicleplexes with siRNA-MDR1 (N/P 
ratio of 20) were firstly evaluated in parallel. The control experiments demonstrated that 
neglect cytotoxicity related to pseudo-polymer itself and empty vesicleplex was detected (cell 
viability was over 90% when the concentration of vescicle or vesiclesplexes was lower than 
400 g/mL) even at the concentration 5-fold higher than its corresponding amount in the 
DOX-encapsulated formulation tested in this anti-cancer treatment (data not shown). In 
addition, supramolecular triblock pseudo-copolymer CD-SS-pP-pM/Ad-pE-FA was 
insoluble in cell culture medium under physiological pH, thus its cytotoxcity was neglect 
owing to limited interaction between pure polymer and cellular membrane [260, 266]. Prior 
to the overall evaluation of the anti-cancer ability of the dual-delivery system, the 
formulations of including concentration of DOX, drug loading levels, incubation time and 
N/P ratios were optimized. As shown in Figure 5.13, better therapeutic effect was found with 
the increase of DOX concentration. The DOX concentration was optimized to be 20 g/mL 
to obtain the best therapeutic effect (Figure 5.13 (A)). Neglect differences among various of 
drug loading content with same DOX concentration were observed (Figure 5.13 (B)). The 
viabilities of KB/DOX cells treated with 20%DOX-vesicle/siRNA-MDR1 at 48 h and 72 h 
were significantly decreased as compared to 12 h and 24 h (Figure 5.13 (C)). Cell viability of 
KB/DOX cells reached minimal levels when treated with vesicleplexes prepare at the N/P 
ratio 20 (Figure 5.13 (D)). Based on the above screening results, the optimized therapeutic 
condition was set as follows: KB/DOX cells were incubated with vesciclplexes containing 20 
wt% of DOX (equivalent DOX concentration was 20 g/mL) and siRNA-MDR1 (N/P ratio 
of 20) for 48 h. The overall cytotoxicities of DOX delivered by various systems as indicated 
as cell viability were shown in Figure 5.12 (D). Similar to the results of apoptotic efficiency, 
targeted vesicular co-delivery system with DOX and siRNA-MDR1 were significantly more 
toxic than free DOX, 20%DOX-vesicles, 20%DOX-vesicle/scrabled-siRNA, physical 
mixture of free DOX and vesicle/siRNA-MDR1 in KB/DOX cells. Vesicular nanoparticles 
20%DOX-vesicle/siRNA-MDR1 enhanced the effect of DOX-based chemotherapy to a level 
that cannot be achieved by applying its components separately. Collectively, due to the 
synergistic effects of folate receptor mediated transportation for DOX to bypass the P-gp 
pump, MDR1 gene silencing for increasing the intracellular accumulation of DOX, and 
degradation of disulfide bonds allowed DOX for nuclear targeting, 20%DOX-vesicle/siRNA-





MDR1 co-delivery system induced higher the percentage of cell apoptosis and cell death, 
displaying significant better MDR cell killing effects than all other controls.  
 
Figure 5.13 Optimization of anti-tumor formulation and conditions. Effects of (A) DOX 
concentration, (B) DOX loading contents, (C) incubation time, and (D) N/P ratio on anti-
tumor effect of DOX- and siRNA-MDR1-loaded CD-SS-pDPA-pDMAEMA nano-
assemblies. Samples were incubated with KB/DOX cells under indicated conditions, and then 
the cell viabilities of cells were evaluated by MTT to determine the cell viability. 
5.4 Conclusion 
In order to achieve simultaneous transport of DOX and siRNA-MDR1, we developed 
a novel supramolecular triblock pseudo-copolymer, which was self-assembled via host-guest 
recognition from star-shaped host polymer consisting of multiple-arm pH sensitive diblock 
copolymers pDPA-pDMAEMA linked to a CD core with bioreducible disulfide linkers, and 
the guest polymer being an adamantyl-capped comb-shaped pEGMA with conjugated folate 
ligands. This triblock copolymer was able to form unilamellar polymersome in aqueous 
solution by simple pH-switch method. DLS, TEM and two-color flow cytometry 





measurements proved that anticancer drug DOX and siRNA could be co-encapsulated within 
one vesicle. Dox was physically encapsulated into the central pDPA layer, siRNA was 
selectively bound by pDMAEMA within the inner vesicle volume, coupled with a folate-
receptor targeting exterior. These resulting asymmetric polymersome were dual-responsive 
that could stimuli release intact DOX by a pH- or redox- triggered mechanism. This folate-
functionalized vesicleplexes demonstrated integrated properties including targeted selectivity 
to folate receptor overexpressing cells, improved cellular internalization, suppression of the 
drug efflux pump and re-sensitization of MDR cells, enhanced nuclear accumulation of DOX, 
and capability of inducing cell apoptosis and elevated DOX toxicity in DOX-resistant cells. 
The co-delivery system showed synergistic effects of DOX and siRNA-MDR1, and its anti-
cancer efficacy was remarkably higher than those applying its active components separately. 
Collectively, this DOX and siRNA-MDR1 co-delivery vesicular system showed potential to 
be a promising nano-chemotherapy for targeted treatment of multidrug resistant tumors. 
  





CHAPTER 6. CONCLUSION AND FUTURE WORK 
6.1 Summary of Results 
Over the past decades, chemotherapeutic therapeutic drug, genetic materials such as 
plasmid DNA (pDNA), and small interfering RNA (siRNA) etc. have demonstrated promise 
effects in cancer therapy. However, the major obstacle  of cancer therapy is lack of safe, 
smart, multifunctional, efficient carriers to deliver the therapeutic payload to targeted sites. In 
this thesis, a supramolecular block building approach based on “Molecular LEGO®” strategy 
was developed to construct and optimize efficient gene and drug delivery systems for cancer 
therapy. This supramolecular approach was based on the host-guest interaction between 
cyclodextrin and adamantyl moieties in the host and guest. Compared to traditional 
covalent conjugation block building approaches, this supramolecular approach, like the 
assembly of LEGO
®
 bricks, is much more convenient in building complicated architectures 
with multiple functionalities integrated within one system, as the respective components can 
be produced and modified separately, allowing the target system to be readily customized and 
fine-tuned to optimize the overall performance.  
Firstly, we demonstrate a prototype of “Molecular LEGO®” strategy for building a 
smart DNA carrier system with the functions of reduction-responsiveness and biomimetic 
switchable shielding for DNA delivery with significantly enhanced gene transfection 
efficiency. This delivery system is composed of two modular molecular building blocks: one 
host polymer and one guest polymer that can self-assemble to integrate multiple functions 
into one carrier system, based on the host-guest interaction between β-cyclodextrin (β-CD) 
and adamantyl (Ad) moieties in the host and guest, respectively. The host polymer is a star-
shaped multiple-arm pDMAEMA with β-CD as a core and bioreducible disulfide bonds as 
linkers (βCD-SS-P). The guest polymer is an adamantyl-end capped pMPC (Ad-pMPC). Like 
the assembly of LEGO
®
 bricks, βCD-SS-P and Ad-pMPC could be assembled to form a 
supramolecular pseudo-diblock copolymer (βCD-SS-P/Ad-pMPC), which can further 





and 2D NMR data showed that the supramolecular copolymer formation was based on the 
host-guest interaction between the β-CD core of the host polymer and the Ad moiety of the 
guest polymer. The βCD-SS-P/Ad-pMPC carrier had good DNA binding ability to form 
DNA polyplex nanoparticles with size ranging from 110 to 150 nm and zeta potential ranging 





from 18 to 25 mV at N/P ratio from 10 to 40. The βCD-SS-P/Ad-pMPC/DNA polyplex 
nanoparticles have been proved to have excellent serum stability and protein resistance due to 
the shielding effect of pMPC, and in the meantime showed high cellular uptake efficiency 
due to the membrane-mimic structure of pMPC. After the efficient cellular uptake into the 
cytoplasm, the polyplex nanoparticles readily released the DNA payload due to the cleavage 
of the disulfide bonds in the intracellular reductive environment. In addition, the βCD-SS-
P/Ad-pMPC gene carrier also showed very low cytotoxicity. Therefore, the excellent protein 
stability, serum tolerance, cellular uptake and intracellular DNA release properties, and low 
cytotoxicity worked collectively to result in a highly efficient gene delivery system. Finally, 
the βCD-SS-P/Ad-pMPC “Molecular LEGO®” assembly gene carrier was applied to deliver 
the therapeutic p53 anti-cancer gene in MCF-7 cells, and have achieved high efficiency in 
cell apoptosis and death, showing great potential for cancer gene therapy. 
Secondly, with the aim of precise construction of multifunctional siRNA targeted 
delivery vehicle for cancer gene therapy, we applied this supramolecular block building 
“LEGO® bricks” concept to develop a “pegs into hole” multifunctional screening platform to 
screen various architectures of siRNA targeting delivery system. The “hole” block is a 
cyclodextrin-functionalized siRNA binding fixed host, and the “pegs” are a series of defined 
adamantyl-bearing PEG or folate(s) conjugated PEG switchable guests, which could self-
assemble into a supramolecular via host-guest interaction, like the “peg into hole” pattern, for 
siRNA targeted delivery screening. By using this strategy, the shells of siRNA delivery 
nanoparticles with different macromolecular architecture and targeting valency could be 
easily varied in a modular and non-covalent manner. Taking the advantage of the “LEGO®-
like” platform, a series of PEG shielding shells with different shape and length to obtain 
minimizing non-specific binding were screened, and followed by optimizing the density of 
folate ligands to achieve maximized targeting binding avidity. Based on the screening results, 
we found that the comb-like PEG displayed better non-specific binding inhibition ability, as 
compared to linear PEG with equivalent molecular weights, indicating the dense architecture 
benefits to the steric and charge shielding. In addition, the use of multivalent folate ligands 
can increase affinity of nanoparticles, but the binding avidity would decrease when the ligand 
density transcends the optimal levels, which might ascribe to the overcrowded effects of 
ligand. Based on the optimization results, formulation NP-PC8kFA6 bearing of a shielding 
corona of comb-shaped 8k pEGMA and multivalent folate ligands were obtained for siRNA 
targeting and cytosolic delivery. Nanoparticles NP-PC8kFA6 possessed a suitable size of 





approximately 130 nm, and showed high serum stability, low non-targeting cell binding and 
responsive cytosolic release of siRNA. NP-PC8kFA6 functionalized multivalent folate 
ligands could selectively and efficiently internalize in folate receptor overexpressed KB cells 
via folate receptor mediated endocytosis. High GFP silencing efficiency was observed in FR+ 
GFP-KB cells, but not FR- GFP-A549 cells. Cellular spatial--analysis showed that 
intracellular localization of NP-8kFA6 was dominated by caveolae-pathway and seemed to 
bypass of acidic cellular compartment, which was regarded as another add-on to its supreme 
gene silencing capacity. Moreover, this NP-8kFA6 was also applied in Bcl-2 therapeutic 
siRNA delivery. High and selective Bcl-2 gene downregulating was observed only in FR+ 
KB cells, and resulting in sufficient cell apoptosis of KB cells, indicating these smart 
multifunctional nanoparticles could be applied in targeted cancer therapy.         
Thirdly, with the aim of simultaneous combine chemotherapy and gene therapy 
technology for the treatment of multidrug resistant cancer, we applied the “Molecular 
LEGO
®” block building strategy to develop a novel vesicular system basd on supramolecular 
triblock pseudo-copolymer for doxorubicin and siRNA-MDR1 simultaneous delivery. The 
supramolecular triblock copolymer was self-assembled via host-guest recognition from star-
shaped host polymer consisting of multiple-arm pH sensitive diblock copolymers poly(2-
(diisopropyl-amino)ethyl methacrylate)-poly(2-(dimethyl-amino)ethyl methacrylate)  (pDPA-
pDMAEMA) linked to a CD core with bioreducible disulfide linkers, and the guest polymer 
being an adamantyl-capped comb-shaped pEGMA with conjugated folate ligands. This 
triblock copolymer was able to form unilamellar polymersome in aqueous solution by simple 
pH-switch method. DLS, TEM and two-color flow cytometry measurements proved that 
anticancer drug DOX and siRNA could be co-encapsulated within one vesicle. DOX was 
physically encapsulated into the central pDPA layer, siRNA was selectively binded by 
pDMAEMA within the inner vesicle volume, coupled with a folate-receptor targeting exterior. 
These resulting asymmetric polymersome were dual-responsive that could stimuli release 
intact DOX by a pH- or redox- triggered mechanism. The DOX-loaded vesicles were stable 
under physiological conditions, compliance with the in vivo therapeutic requirements that no 
or low drug release. It showed a “fast-slow” two-phase DOX intracellular release kinetics, 
which mimic the clinic administratering pattern that initially medicating a high effective dose 
and followed by a low maitance dose. This folate-functionalized vesicleplexes demonstrated 
integrated properties including targeted selectivity to folate receptor overexpressing cells, 
improved cellular internalization, suppression of the drug efflux pump and re-sensitization of 





MDR cells, enhanced nuclear accumulation of DOX, and capability of inducing cell 
apoptosis and elevated DOX toxicity in DOX-resistant cells. The co-delivery system showed 
synergistic effects of DOX and siRNA-MDR1, and its anti-cancer efficacy was remarkably 
higher than those applying its active components separately. Due to the synergistic effects of 
(1) folate receptor mediated transportation for DOX to bypass the drug efflux pump, (2) 
MDR1 gene silencing for inhibiting the expression of drug efflux pump, which led to 
increased  intracellular accumulation of DOX, and (3) nuclear distribution of DOX triggered 
by degradation of bioreducible disulfide linkers, this co-delivery vesicleplexes induced 
supreme effect on cell apoptosis and cell death. Collectively, this DOX and siRNA-MDR1 
co-delivery vesicular system showed potential to be a promising nano-chemotherapy for 
targeted treatment of multidrug resistant tumors. 
6.2 Recommendations for future work 
To provide a better justification of the biomaterials and gene/drug delivery systems 
being designed in this thesis, the author would like to make several recommendations for 
future work. 
6.2.1 In vivo evaluation 
With the promising results obtained from in vitro evaluation of the systems in this 
thesis including CD-SS-P/Ad-pMPC for anti-cancer p53 plasmid DNA delivery, NP-
PC8kFA6 for anti-cancer siRNA-Bcl2 delivery, and 20%DOX-vesicle/siRNA-MDR1 for 
DOX and siRNA-MDR1 co-delivery, research efforts should be further extended to in vivo 
investigation. The in vivo evaluations were recommended to divide into the following stages:  
(1) The initial stage of in vivo studies would be the evaluation of the biodistribution of 
the system. A folate receptor positive tumor bearing nude mice model needs to be established 
for the evaluation NP-PC8kFA6/siRNA-Bcl2 folate receptor mediated siRNA targeting 
delivery system (the system discussed in Chapter 4), whereas a FR+ and multidrug resistant 
tumor bearing nude mice models will be constructed for the justification of 20%DOX-
vesicle/siRNA-MDR1 gene and drug co-delivery system (the system discussed in Chapter 5). 
Different routes of injections (via tail vein and intratumoral injection) should be performed. 
To better understand the biodistribution and targeting efficacy of the systems, non-invasive 
fluorescent imaging was conducted at various time points up to 5 days. After that, the nude 





mice are sacrificed at the end of the experiments. The concentration of drug in blood 
circulation would be measured at various time points up to 24 h. The distribution of 
nanoparticles in individual tissues, including liver, kidney, heart, tumor would be determined. 
(2) The in vivo cytotoxicity of the delivery systems, including immunity and 
hemoglobin neurotoxicity would be evaluated. 
(3) The third stage of in vivo studies would be the evaluation of anti-tumor efficacy.  
The above mentioned tumor-bearing nude mice model would be used. The anti-tumor 
efficacy of NP-PC8kFA6/siRNA-Bcl2 system and 20%DOX-vesicle/siRNA-MDR1 system 
would be determined by evaluating the mean relative tumor size, and compared with other 
control groups.  
6.2.2 Construction of new targeting system via the supramolecular screening platform 
In the chapter 4 of the thesis, a switchable screening platform of precise architectural 
control of siRNA targeted delivery vehicle was established. By using this “LEGO®-like” 
screening platform, formulation NP-PC8kFA6 bearing a shielding corona of comb-shaped 8k 
pEGMA and multivalent folate ligands was obtained for siRNA targeting delivery. In future 
work, application of this screening system could be extended to design/optimize other smart 
multifunctional nanoparticles with different targeting ligands like peptide and antibody or 
other surface properties. The work on optimizing a siRNA delivery system with antibody 
8G12k as targeting ligand for leukemia cancer therapy using this supramolecular screening 
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